I Mina'trentai Sais Na Liheslaturan Guåhan BILL STATUS

BILL NO.	SPONSOR	TITLE	DATE INTRODUCED	DATE REFERRED	CMTE REFERRED	PUBLIC HEARING DATE	DATE COMMITTEE REPORT FILED	FISCAL NOTES	NOTES
169-36 (LS)	Telena Cruz Nelson	AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.	1:35 p.m.	8/9/21	Committee on Health, Land, Justice, and Culture	1/19/22 9:00 a.m.	3/21/22 11:41 a.m. As amended by the Committee on Committee on Health, Land,	Request: 8/10/21 Waiver: 8/16/21	APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E
							Committee on Health, Land, Justice, and Culture.		

CLERKS OFFICE Page 1



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

March 16, 2022

The Honorable Tina Rose Muña Barnes

Chairperson, Committee on Rules

I Mina'trentai Sais na Liheslaturan Guåhan

163 Chalan Santo Papa

Hagåtña Guam, 96910

RE: Committee Report on Bill No. 169-36 (LS)- As Amended

Håfa Adai Chairperson Muña Barnes:

Transmitted herewith is the Committee Report on the Bill No. 169-36 (LS)- As Amended by the Committee on Health, Land, Justice and Culture- Introduced by Senator Telena Cruz Nelson- "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

Committee votes are as follows:

5 TO DO PASS
0 TO NOT PASS
3 TO REPORT OUT ONLY

0 TO ABSTAIN

0 TO PLACE IN INACTIVE FILE

COMMITTEE ON RULES RECEIVED:

March 16, 2022 2:58 P.M.

Sincerely,

Therese M. Terlaje



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

COMMITTEE REPORT

Bill No. 169-36 (LS),

As Amended by the Committee on Health, Land, Justice, and Culture

Introduced by: Senator Telena Cruz Nelson

"AN ACT TO AMEND APPENDIX A, APPENDIX B,
APPENDIX C, APPENDIX D, AND APPENDIX E ALL
OF CHAPTER 67, TITLE 9, GUAM CODE
ANNOTATED, RELATIVE TO UPDATING THE LIST
OF SCHEDULED CONTROLLED SUBSTANCES
PROVIDED IN THE GUAM UNIFORM
CONTROLLED SUBSTANCES ACT."



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

March 16, 2022

MEMORANDUM

To: All Members

Committee on Health, Land, Justice and Culture

From: Speaker Therese M. Terlaje

Committee Chairperson

Subject: Committee Report on Bill No. 169-36 (LS), As Amended

Transmitted herewith for your consideration is the Committee Report on Bill No. 169-36 (LS)- As Amended by the Committee on Health, Land, Justice and Culture- Introduced by Senator Telena Cruz Nelson- "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

This report includes the following:

- Copy of COR Referral of Bill No. 169-36 (LS)
- Notices of Public Hearing & Other Correspondence
- Public Hearing Agenda
- · Public Hearing Sign-in Sheet
- Submitted Written Testimonies & Supporting Documents
- Committee Report Digest
- Copy of Bill No. 169-36 (LS), As Introduced
- Copy of Bill No. 169-36 (LS), As Amended
- Amended Mark-up Version
- Copy of Fiscal Note from the Bureau of Budget & Management Research
- Committee Vote Sheet

Please take the appropriate action on the attached vote sheet. Your attention to this matter is greatly appreciated. Should you have any questions or concerns, please do not hesitate to contact me. Si Yu'os Ma'åse'!

Guam Congress Building 163 Chalan Santo Papa Hagåtña, Guam 96910 Tel 671-472-2461 Cor@guamlegislature.org

August 9, 2021

MEMO

To: Rennae Meno

Clerk of the Legislature

Attorney Ana Won Pat-Borja Legislative Legal Counsel

From: Senator Amanda L. Shelton

Acting Chairperson, Committee on Rules

Re: Referral of Bill No. 169-36 (LS)

Håfa Adai,

As per my authority as Acting Chairperson of the Committee on Rules and subject to §6.01(d), Rule VI of our Standing Rules, I am forwarding the referral of Bill No. 169-36 (LS) – Telena Cruz Nelson – "AN ACT TO *AMEND* APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

Please ensure that the subject bill is referred to the Committee on Health, Land, Justice, and Culture, chaired by Speaker Therese M. Terlaje.

I also request that the same be forwarded to the prime sponsor of the subject bill.

If you have any questions or concerns, please feel free to contact Mary Maravilla, Committee on Rules Director at 472-2461.

Thank you for your attention to this important matter.

Respectfully,

Senator Amanda L. Shelton

Acting Chairperson, Committee on Rules



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

FIRST NOTICE of Virtual Public Hearing – Wednesday, January 19, 2022 beginning at 9:00AM

2 messages

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> Tue, Jan 11, 2022 at 8:42 AM To: phnotice@guamlegislature.org Cc: Audio / Video <av@guamlegislature.org>, Guam MIS <mis@guamlegislature.org>, Ibarra Hernandez <ihernandez@quamleqislature.org>, Tom Unsioq <sqtarms@quamleqislature.org> Bcc: mindy@postguam.com, The Post Editor in Chief <editor@postguam.com>, Oyaol Ngirairikl <managingeditor@postguam.com>, haidee@postguam.com, John Oconnor <john@postguam.com>, reporters@postguam.com, rlimtiaco@guampdn.com, Rindraty Limtiaco <slimtiaco@guampdn.com>, Guam PDN <news@guampdn.com>, Jerick Sablan <jpsablan@guampdn.com>, life@guampdn.com, dmgeorge@guampdn.com, Mar-Vic Cagurangan <publisher@pacificislandtimes.com>, Pacific Island Times <pacificislandtimes@gmail.com>, Maureen Maratita <publisher@glimpsesofquam.com>, bryan@mvariety.com, emmanuel@mvariety.com, <jason@kuam.com>, Sabrina Salas Matanane <sabrina@kuam.com>, Chris Malafunkshun Barnett <Chris@kuam.com>, Nestor Licanto <nestor@kuam.com>, reporters@kuam.com, K57 <news@k57.com>, Patti Rodriguez <parroyo@spbguam.com>, pattiontheradio@yahoo.com, Sorensen Pacific Broadcasting <news@spbguam.com>, raygibsonshow@gmail.com, manasilva626@yahoo.com, KISH <kstokish@gmail.com>, Manuel Cruz <cruzma812@gmail.com>, Troy Torres <troy@kanditnews.com>, Maria Louella Losinio <louella.losinio@gmail.com>, "Mayors' Council of Guam - Admin." <mcogadmin@teleguam.net>, "Mayor Paul M. McDonald" <mayor.mcdonald671@gmail.com>, agatmayor@yahoo.com, agatvice.chrisfejeran@yahoo.com, "Mayor Frankie A. Salas" <asanmainamayor@gmail.com>, June Blas <mayorbarrigada@gmail.com>, Jessie Bautista <jessie.bautista007@gmail.com>, Jessy Gogue <ocp.mayor@gmail.com>, MELISSA SAVARES <melissa.savares@gmail.com>, "Vice Mayor Peter John S. Benavente" <onedededo@gmail.com>, hagatnamayor@hotmail.com, Mayor Anthony Chargualaf <inalahanmayor@gmail.com>, Allan Ungacta <mayorallan.ungacta@yahoo.com>, Vice Mayor Kevin AN Delgado <mangilao.vicemayor@gmail.com>, mayorernestc@yahoo.com, mtmmayorpaco17@gmail.com, Jesse Alig <jesse.alig@pitiguam.com>, Dale Alvarez <daleealvarez@gmail.com>, Robert Hofmann <guammayor@gmail.com>, rudy iriarte <rudyiriarte@gmail.com>, Mayor Taitague <talofofomayor@gmail.com>, "Mayor Louise C. Rivera" <Mayorlcrivera.tatuha@gmail.com>, "Vice Mayor Albert M. Toves" <atoves.tatuha@gmail.com>, Umatac Mayor <umatacmo@gmail.com>, "Mayor Anthony P. Sanchez" <ymayortony@gmail.com>, "Vice Mayor Loreto V. Leones" loretoleones@gmail.com>, "Mayor Bill A. Quenga" <yonamayor2020@gmail.com>, jolene@postguam.com, Phil Leon Guerrero <phil@postguam.com>, Gerry Partido <gerrypartido@gmail.com>, gerry@spbguam.com, Damen Borja <damen@spbguam.com>, tlamorena@gmail.com, jsantotoma@guampdn.com, "Taitano, Joseph" <JTaitano@guampdn.com>, "Leevin T. Camacho" <lcamacho@guamag.org>, OAG General Counsel <generalcounsel@oagguam.org>, Camarine Ann Hopkins <camhopkins@oagguam.org>, "Stephanie E. Mendiola" <smendiola@oagguam.org>, Samantha at GCASAFV @yahoo.com>, varoguam1@yahoo.com, <dwayne@guamcoalition.org>, Pale' Mike Crisostomo alee@catholicsocialserviceguam.org, healing.hearts@mail.dmhsa.guam.gov, healing.hearts@mail.gbhwc.guam.gov, Stephen Hattori <sphattori@guampdsc.org>, "John P. Morrison" <jmorrison@guampdsc.org>, Masatomo Nadeau <masatomo.nadeau@dphss.guam.gov>, "Arthur U. San Agustin" <arthur.sanagustin@dphss.guam.gov>, Guam Pharmacists @gmail.com>, Guam Medical Society <theguammedicalsociety@gmail.com>, Nathaniel Berg <nberg@guamradiology.com>, "Dr. John Ray Taitano" @gmail.com>, "Thomas Shieh, MD, FA<doctorshieh@yahoo.com>, Zennia Pecina <Zennia.Pecina@dphss.guam.gov>, Guam Bar Association @gmail.com>, "Thomas Shieh, MD, FACOG" <info@guambar.org>, "Ciana V. Galindo" <Ciana.galindo@dphss.guam.gov>, Arania Adolphson @yahoo.com>, Philip Flores <philipf@bankpacific.com>, <aadolphson@amc.clinic>, "Yahoo Mailing (US)" @gmail.com, "Annie Bordallo (Medical Director)" <annie.bordallo@gmha.org>, lillian perez-posadas lillian.perez-posadas@gmha.org>, Joleen Aguon <joleen.aguon@gmha.org>, "Dr. Vince Akimoto" @yahoo.com>, "Dr. Vincent Duenas" <vincent.duenas@gmha.org>, Cyrus Luhr <cyrus.luhr@guamanimals.org>, stephen ignacio <stephen.ignacio@gpd.guam.gov>, Daniel Stone

<daniel.stone@gfd.guam.gov>, Phyliss LeonGuerrero <Phyliss.LeonGuerrero@disid.guam.gov>, Michelle Perez <Michelle.Perez@disid.guam.gov>, Fire Chief Joey San Nicolas <joey.sannicolas@gfd.guam.gov>, vincent perez <vincent.perez@cqa.guam.gov>, Jenna Gaminde <jenna.g.blas@ghs.guam.gov>, chief@gpd.guam.gov

January 11, 2022

MEMORANDUM

To: All Senators, Stakeholders and Media

From: Speaker Therese M. Terlaje, Chairperson

Committee on Health, Land, Justice and Culture

Subject: FIRST NOTICE of Virtual Public Hearing – Wednesday, January 19, 2022 beginning at 9:00AM

Buenas yan Håfa Adai,

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Wednesday</u>, <u>January 19, 2022, beginning at 9:00 a.m.</u> for the following agenda item:

9:00 AM:

- <u>Bill No. 168-36 (LS)</u> Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- <u>Bill No. 169-36 (LS)</u> Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

2:00 PM:

• <u>Bill No. 147-36 (LS)</u> - Frank Blas Jr.- AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

• <u>Bill No. 237-36 (COR)</u> - Sabina Flores Perez- AN ACT TO AMEND § 34406 (e) AND § 34406 (f) OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO UPDATING VIOLATIONS OF PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE.

To register to provide virtual testimony, please email senatorterlajeguam@gmail.com or call 472-3586 by <u>JANUARY 18, 2022</u>. Written testimony can be submitted via email to the Office of the Speaker, or hand delivered to the Guam Congress Bldg.; 163 Chalan Santo Papa, Hagåtña, Guam.

All hearings broadcast on GTA TV Channel 21, Docomo Channel 117/112.4, and stream online at the Guam Legislature YouTube Channel: https://www.youtube.com/c/GuamLegislatureMedia and will be available on the Guam Legislature YouTube after the hearing.

In compliance with the Americans with Disabilities Act, Individuals needing assistance or accommodations can contact the Office of Speaker Therese M. Terlaje. We look forward to your participation! *Si Yu'os Ma'åse'!*

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910 T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

January 11, 2022

MEMORANDUM

To: All Senators, Stakeholders and Media

From: Speaker Therese M. Terlaje, Chairperson

Committee on Health, Land, Justice and Culture

Subject: FIRST NOTICE of Virtual Public Hearing – Wednesday, January 19,

2022 beginning at 9:00AM

Buenas yan Håfa Adai,

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Wednesday</u>, **January 19, 2022, beginning at 9:00 a.m.** for the following agenda item:

9:00 AM:

- Bill No. 168-36 (LS) Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806
 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26,
 GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE
 REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM
 PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

2:00 PM:

• <u>Bill No. 147-36 (LS)</u> - Frank Blas Jr.- AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

• <u>Bill No. 237-36 (COR)</u> - Sabina Flores Perez- AN ACT TO AMEND § 34406 (e) AND § 34406 (f) OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO UPDATING VIOLATIONS OF PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE.

To register to provide virtual testimony, please email <u>senatorterlajeguam@gmail.com</u> or call 472-3586 by <u>JANUARY 18, 2022.</u> Written testimony can be submitted via email to the Office of the Speaker, or hand delivered to the Guam Congress Bldg.; 163 Chalan Santo Papa, Hagåtña, Guam.

All hearings broadcast on GTA TV Channel 21, Docomo Channel 117/112.4, and stream online at the Guam Legislature YouTube Channel: https://www.youtube.com/c/GuamLegislatureMedia and will be available on the Guam Legislature YouTube after the hearing.

In compliance with the Americans with Disabilities Act, Individuals needing assistance or accommodations can contact the Office of Speaker Therese M. Terlaje. We look forward to your participation! *Si Yu'os Ma'åse'!*

Philippines prepares more hospital beds with record COVID-19 cases



WAITING FOR A BOOSTER: Filipinos wait for a booster dose of the COVID-19 vaccine amid rising infections, in Makati City, Metro Manila, Philippines, Jan 5. Eloisa Lopez/Reuters

MANILA (Reuters) - The Philippines ordered an increase in hospital beds and medical resources in and around the capital Manila, a senior government official said on Sunday, as the country set another record for new COVID-19 infections.

Nearly 60% of the 28,707 cases came from the capital region, which has seen a steady increase in admissions in recent days, although hospital capacity in the area was still below critical levels, government data showed.

Health authorities were also directed to increase inoculation rates outside the region, with many provinces lagging, acting presidential spokesperson Karlo Nograles said in a statement.

Another 15 people died from COVID-19, the health ministry said in a bulletin, bringing the death toll to 52,150. The country has reported a total of more than 2.96 million cases since the pandemic started, among the highest in Southeast Asia.

Government offices including the Senate, the House of Representatives and the Presidential Communications Operations Office have announced temporary closures as a precaution after several of their staff have been infected.

The rise in COVID-19 cases prompted the government to tighten mobility curbs last week. President Rodrigo Duterte has threatened unvaccinated people with arrest if they disobey stay-at-home orders.

At the end of last year, 45% of the country's 110 million people had been fully vaccinated. Under existing rules, unvaccinated people in the capital region can only step out of their homes for essential trips.

Japan, US to cooperate on tech for next-generation nuclear reactors

(Japan News) - Japan and the United States will work together to develop technology related to core equipment and systems of nuclear reactors in a next-generation fast reactor project, according to the outline of a memorandum of understanding.

The memorandum is expected to be signed later this month by U.S. nuclear start-up TerraPower LLC, the Japan Atomic Energy Agency and Mitsubishi Heavy Industries Ltd. They also plan to sign a confidentiality agreement on sensitive technologies. After the Japanese side receives design information from the U.S. side, they will sign a formal

agreement, perhaps this summer.

According to sources, the candidate areas of cooperation will include equipment for placing new fuel in a reactor and removing spent fuel; a system for locating damaged fuel while a reactor is in operation; a technology for pumps and heat exchangers to circulate liquid sodium, which serves as a coolant that extracts heat from the core; and technology related to in-core structures such as plates to block radiation. Based on the design of the fast reactor, the two sides will discuss technical details regarding

With support from the U.S. Energy

Department, TerraPower plans to begin construction of the reactor in Wyoming in 2024 and will aim to put it into operation in 2028.

On Thursday, Economy, Trade and Industry Minister Koichi Hagiuda held a videoconference with U.S. Energy Secretary Jennifer Granholm, during which he mentioned the Japanese government's intention to support the technical cooperation. Granholm expressed her high hopes regarding Japanese technology.

Preventing an accident

The envisaged fast reactor is designed to transfer heat, which is generated in the core, to a heat exchanger using sodium, and the heat will be used to convert water into steam to activate a power generation turbine. Liquid sodium is silvery-white and opaque. unlike water, which is used as a coolant in mainstream nuclear reactors, so the fuel and structures inside a reactor cannot be directly seen by a camera.

Of particular interest to the U.S. side is the technology to safely remove fuel and replace it as planned. This is essential for the stable operation of fast reactors and the efficiency of maintenance and checkups. If damaged fuel can be identified, it would be possible to restore operations promptly and prevent an accident.



SPEAKER THERESE M. TERLAJE

Committee on Health, Land, Justice & Culture l Mina'trentai Sais na Liheslaturan Gudhan



9:00 AM

- BILL No. 168-36 (LS) Senator Telena Cruz Nelson- AN ACT TO ADD NEW SS 41806 AND AMEND SS 41810 OF ARTICLE 18. CHAPTER 4. DIVISION 1. TITLE 26. GUAM ADMINISTRATIVE RULES AND REGULATIONS. RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Senator Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B. APPENDIX C. APPENDIX D, AND APPENDIX E OF CHAPTER 26. TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT

2:00 PM:

BILL No. 147-36 (LS) - Senator Frank Blas Jr. - AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

Bill No. 237–36 (COR) – Senator Sabina Flores Perez – An act to amend \S 34406 (e) and \S 34406 (f) of chapter 34, title 10, guam code annotated. Relative to updating violations of PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE

Contact the Office of the Speaker at 472-3586 or senatorterlajeguam@gmail.com. to register to provide live or written testimony. All hearings broadcast on GTA TV Channel 21. Docomo Channel 117/112.4, and livestream on the Guam Legislature YouTube: https://www.youtube.com/c/GuamLegislatureMedia. In compliance with the Americans with Disabilities Act, Individuals needing special accommodations can contact the Office of Speaker Therese M. Terlaje. This Ad was paid with Legislature Funds.



THE OFFICE OF SENATOR TELENA CRUZ NELSON

NOTICE OF VIRTUAL PUBLIC HEARING WEDNESDAY, JANUARY 19, 2022 5:00 P.M.

- Resolution No. 234-36 (COR) -"Relative to expressing the utmost support of I Mina'trentai Sais Na Liheslaturan Guåhan (the 36th Guam Legislature) for S. 3284, the "Veterans Assistance Helpline Act of 2021," which seeks to permanently establish a toll-free telephone helpline for veterans to use in order to quickly obtain information and assistance with all services from the U.S. Department of Veterans Affairs."
- Resolution No. 215-36 (COR) -"Relative to expressing the utmost support of I Liheslaturan Guāhan for the passage of H.R. 5606, the "Return Home to Housing Act," which seeks to amend Title 38 of the United States Code to adjust the rate of per diem payments provided by the Secretary of Veterans Affairs to grantees that provide services to homeless veterans; and further requesting parity and inclusion of all veterans residing in Guam and in all territories."

Written testimonies may be delivered to the Office of Senator Telena Cruz Nelson or via email to senatortenelson@guamlegislature.org. The Committee requests that testimonies be submitted on or before January 14, 2022. In compliance with the Americans with Disabilities Act (ADA), individuals requiring assistance or accommodations should contact the Office of Senator Telena Cruz Nelson at 671-989-7696. All hearings will be broadcast on GTA TV Channel 21, Documo-Channel [17/112.4, and the Guam Legislature Youtbue.



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

SECOND NOTICE of Virtual Public Hearing – Wednesday, January 19, 2022 beginning at 9:00AM

4 messages

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> Sun, Jan 16, 2022 at 8:18 AM To: phnotice@guamlegislature.org Cc: Audio / Video <av@guamlegislature.org>, Guam MIS <mis@guamlegislature.org>, Ibarra Hernandez <ihernandez@quamleqislature.org>, Tom Unsioq <sqtarms@quamleqislature.org> Bcc: mindy@postguam.com, The Post Editor in Chief <editor@postguam.com>, Oyaol Ngirairikl <managingeditor@postguam.com>, haidee@postguam.com, John Oconnor <john@postguam.com>, reporters@postguam.com, rlimtiaco@guampdn.com, Rindraty Limtiaco <slimtiaco@guampdn.com>, Guam PDN <news@guampdn.com>, Jerick Sablan <jpsablan@guampdn.com>, life@guampdn.com, dmgeorge@guampdn.com, Mar-Vic Cagurangan <publisher@pacificislandtimes.com>, Pacific Island Times <pacificislandtimes@gmail.com>, Maureen Maratita <publisher@glimpsesofquam.com>, bryan@mvariety.com, emmanuel@mvariety.com, <jason@kuam.com>, Sabrina Salas Matanane <sabrina@kuam.com>, Chris Malafunkshun Barnett <Chris@kuam.com>, Nestor Licanto <nestor@kuam.com>, reporters@kuam.com, K57 <news@k57.com>, Patti Rodriguez <parroyo@spbguam.com>, pattiontheradio@yahoo.com, Sorensen Pacific Broadcasting <news@spbguam.com>, raygibsonshow@gmail.com, manasilva626@yahoo.com, KISH <kstokish@gmail.com>, Manuel Cruz <cruzma812@gmail.com>, Troy Torres <troy@kanditnews.com>, Maria Louella Losinio <louella.losinio@gmail.com>, "Mayors' Council of Guam - Admin." <mcogadmin@teleguam.net>, "Mayor Paul M. McDonald" <mayor.mcdonald671@gmail.com>, agatmayor@yahoo.com, agatvice.chrisfejeran@yahoo.com, "Mayor Frankie A. Salas" <asanmainamayor@gmail.com>, June Blas <mayorbarrigada@gmail.com>, Jessie Bautista <jessie.bautista007@gmail.com>, Jessy Gogue <ocp.mayor@gmail.com>, MELISSA SAVARES <melissa.savares@gmail.com>, "Vice Mayor Peter John S. Benavente" <onedededo@gmail.com>, hagatnamayor@hotmail.com, Mayor Anthony Chargualaf <inalahanmayor@gmail.com>, Allan Ungacta <mayorallan.ungacta@yahoo.com>, Vice Mayor Kevin AN Delgado <mangilao.vicemayor@gmail.com>, mayorernestc@yahoo.com, mtmmayorpaco17@gmail.com, Jesse Alig <jesse.alig@pitiguam.com>, Dale Alvarez <daleealvarez@gmail.com>, Robert Hofmann <guammayor@gmail.com>, rudy iriarte <rudyiriarte@gmail.com>, Mayor Taitague <talofofomayor@gmail.com>, "Mayor Louise C. Rivera" <Mayorlcrivera.tatuha@gmail.com>, "Vice Mayor Albert M. Toves" <atoves.tatuha@gmail.com>, Umatac Mayor <umatacmo@gmail.com>, "Mayor Anthony P. Sanchez" <ymayortony@gmail.com>, "Vice Mayor Loreto V. Leones" lloretoleones@gmail.com>, "Mayor Bill A. Quenga" <yonamayor2020@gmail.com>, jolene@postguam.com, Phil Leon Guerrero <phil@postguam.com>, Gerry Partido <gerrypartido@gmail.com>, gerry@spbguam.com, Damen Borja <damen@spbguam.com>, tlamorena@gmail.com, jsantotoma@guampdn.com, "Taitano, Joseph" <JTaitano@guampdn.com>, "Leevin T. Camacho" <lcamacho@guamag.org>, OAG General Counsel <generalcounsel@oagguam.org>, Camarine Ann Hopkins <camhopkins@oagguam.org>, "Stephanie E. Mendiola" <smendiola@oagguam.org>, Samantha at GCASAFV @yahoo.com>, varoguam1@yahoo.com, <dwayne@guamcoalition.org>, Pale' Mike Crisostomo alee@catholicsocialserviceguam.org, healing.hearts@mail.dmhsa.guam.gov, healing.hearts@mail.gbhwc.guam.gov, Stephen Hattori <sphattori@guampdsc.org>, "John P. Morrison" <jmorrison@guampdsc.org>, Masatomo Nadeau <masatomo.nadeau@dphss.guam.gov>, "Arthur U. San Agustin" <arthur.sanagustin@dphss.guam.gov>, Guam Pharmacists @gmail.com>, Guam Medical Society <theguammedicalsociety@gmail.com>, Nathaniel Berg <nberg@guamradiology.com>, "Dr. John Ray Taitano" @gmail.com>, "Thomas Shieh, MD, FA<doctorshieh@yahoo.com>, Zennia Pecina <Zennia.Pecina@dphss.guam.gov>, Guam Bar Association @gmail.com>, "Thomas Shieh, MD, FACOG" <info@guambar.org>, "Ciana V. Galindo" <Ciana.galindo@dphss.guam.gov>, Arania Adolphson @yahoo.com>, Philip Flores <philipf@bankpacific.com>, <aadolphson@amc.clinic>, "Yahoo Mailing (US)" @gmail.com, "Annie Bordallo (Medical Director)" <annie.bordallo@gmha.org>, lillian perez-posadas lillian.perez-posadas@gmha.org>, Joleen Aguon <joleen.aguon@gmha.org>, "Dr. Vince Akimoto" @yahoo.com>, "Dr. Vincent Duenas" <vincent.duenas@gmha.org>, Cyrus Luhr <cyrus.luhr@guamanimals.org>, stephen ignacio <stephen.ignacio@gpd.guam.gov>, Daniel Stone

<daniel.stone@gfd.guam.gov>, Phyliss LeonGuerrero <Phyliss.LeonGuerrero@disid.guam.gov>, Michelle Perez <Michelle.Perez@disid.guam.gov>, Fire Chief Joey San Nicolas <joey.sannicolas@gfd.guam.gov>, vincent perez <vincent.perez@cqa.guam.gov>, Jenna Gaminde <jenna.g.blas@ghs.guam.gov>, chief@gpd.guam.gov, @qmail.com, jedsana@hawaii.edu, @hotmail.com, @quam.net

January 16, 2022

MEMORANDUM

To: All Senators, Stakeholders and Media

From: Speaker Therese M. Terlaje, Chairperson

Committee on Health, Land, Justice and Culture

Subject: SECOND NOTICE of Virtual Public Hearing – Wednesday, January 19, 2022 beginning at 9:00AM

Buenas yan Håfa Adai,

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Wednesday</u>, <u>January 19, 2022, beginning at 9:00 a.m.</u> for the following agenda item:

9:00 AM:

- <u>Bill No. 168-36 (LS)</u> Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- <u>Bill No. 169-36 (LS)</u> Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

2:00 PM:

• <u>Bill No. 147-36 (LS)</u> - Frank Blas Jr.- AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

• <u>Bill No. 237-36 (COR)</u> - Sabina Flores Perez- AN ACT TO AMEND § 34406 (e) AND § 34406 (f) OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO UPDATING VIOLATIONS OF PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE.

To register to provide virtual testimony, please email senatorterlajeguam@gmail.com or call 472-3586 by <u>JANUARY 18, 2022</u>. Written testimony can be submitted via email to the Office of the Speaker, or hand delivered to the Guam Congress Bldg.; 163 Chalan Santo Papa, Hagåtña, Guam.

All hearings broadcast on GTA TV Channel 21, Docomo Channel 117/112.4, and stream online at the Guam Legislature YouTube Channel: https://www.youtube.com/c/GuamLegislatureMedia and will be available on the Guam Legislature YouTube after the hearing.

In compliance with the Americans with Disabilities Act, Individuals needing assistance or accommodations can contact the Office of Speaker Therese M. Terlaje. We look forward to your participation! *Si Yu'os Ma'åse'!*

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910 T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com

website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

9 attachments

Meeting ID: Passcode

07/3017/3010/01/01

June of Military Lehrenconson

TAXABLE PROPERTY OF THE PARTY O

Disclaimer: This message is intended only for the use of the individual or entity to which it is addressed and may contain information which is privileged, confidential, proprietary, or exempt from disclosure under applicable law. If you are not the intended recipient or the individual responsible for delivering the message to the intended recipient, you are strictly prohibited from disclosing, distributing, copying, or in any way using this message. If you have received this communication in error, please notify the sender and immediately delete any copies you may have received. Thank you.



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

January 16, 2022

MEMORANDUM

To: All Senators, Stakeholders and Media

From: Speaker Therese M. Terlaje, Chairperson That

Committee on Health, Land, Justice and Culture

Subject: SECOND NOTICE of Virtual Public Hearing – Wednesday, January

19, 2022 beginning at 9:00AM

Buenas yan Håfa Adai,

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Wednesday</u>, **January 19, 2022, beginning at 9:00 a.m.** for the following agenda item:

9:00 AM:

- Bill No. 168-36 (LS) Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806
 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26,
 GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE
 REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM
 PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

2:00 PM:

• <u>Bill No. 147-36 (LS)</u> - Frank Blas Jr.- AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

• <u>Bill No. 237-36 (COR)</u> - Sabina Flores Perez- AN ACT TO AMEND § 34406 (e) AND § 34406 (f) OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO UPDATING VIOLATIONS OF PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE.

To register to provide virtual testimony, please email <u>senatorterlajeguam@gmail.com</u> or call 472-3586 by <u>JANUARY 18, 2022.</u> Written testimony can be submitted via email to the Office of the Speaker, or hand delivered to the Guam Congress Bldg.; 163 Chalan Santo Papa, Hagåtña, Guam.

All hearings broadcast on GTA TV Channel 21, Docomo Channel 117/112.4, and stream online at the Guam Legislature YouTube Channel: https://www.youtube.com/c/GuamLegislatureMedia and will be available on the Guam Legislature YouTube after the hearing.

In compliance with the Americans with Disabilities Act, Individuals needing assistance or accommodations can contact the Office of Speaker Therese M. Terlaje. We look forward to your participation! *Si Yu'os Ma'åse'!*

US officials: Russia preparing 'false flag' operation as pretext to invade Ukraine

By Tracy Wilkinson and Laura King Los Angeles Times

WASHINGTON - Reverting to a familiar "playbook," Russia is plotting a pretext to invade Ukraine, a "false flag" operation that would justify its actions despite a week of intense U.S.-Russia negotiations that apparently failed to move Moscow away from a scheme of regional aggression, U.S. officials said Friday.

The White House also said Moscow is using social media to mount a disinformation campaign that portrays Ukraine, a former Soviet republic interested in joining Western alliances, as an aggressor that would attack Russia and must be tamed.

"We are concerned that the Russian government is preparing for an invasion in Ukraine that may result in widespread human rights violations and war crimes should diplomacy fail to meet their objectives," White House press secretary Jen Psaki said Friday.

She said that laying the pretext included sabotage activities in addition to the disinformation campaigns.

On Friday, Kyiv reported cyberattacks on about 70 government and other websites, shutting them down temporarily. It was unclear who was responsible, but a top aide to Ukrainian President Volodymyr Zelenskiy framed the incidents as part of efforts to "destabilize" the country.

NATO Secretary-General Jens Stoltenberg pledged access for Ukraine to the alliance's malware information-sharing platform.

Russia invaded Ukraine in 2014 and occupied its Crimea peninsula follow-



FRONTLINES: A Ukrainian Military Forces serviceman walks in a trench on the frontline with Russia-backed separatists near to Avdiivka, Donetsk, southeastern Ukraine, Jan. 9.

Anatolii Stepanov/AFP via Getty Images/Tribune News Service

ing a similar series of propaganda efforts. Moscow is also backing separatist rebels in eastern Ukraine fighting government forces, a simmering conflict that has claimed thousands of Ukrainian lives.

In recent months, Russia has amassed some 100,000 troops along its border with Ukraine and moved heavy weaponry in behind the manpower. There were reports of live-fire exercises during the last week.

"We saw this playbook before," Psaki said.

Citing fresh U.S. intelligence reports, Psaki said Russia has already dispatched operatives trained in urban warfare who could use explosives to carry out acts of sabotage against Russia's own proxy forces - blaming the acts on Ukraine - if Russian President Vladimir Putin decides he wants to move forward with an invasion.

Pentagon spokesman John Kirby described the intelligence as "very

credible." The intelligence findings suggested that a military invasion could begin between mid-January and mid-February, experts said, in part with a view toward a deepening winter that freezes the muddy plains between the two countries and makes it easier for Russia to move heavy

equipment into Ukraine.

The dire allegations about Moscow's intentions, which came from across the administration - the State Department and Pentagon as well as the White House - marked a jarring coda to what had been a week of relatively civil if inconclusive diplomatic sessions involving the U.S., Russia, NATO and most of Europe.

Senior U.S. diplomats' meetings

with Russian officials in bilateral venues, as well as with other NATO and European allies, made little evident progress toward easing tensions over Ukraine.

Putin insists that Washington agree that Ukraine never be allowed to join NATO, a "nonstarter" for the U.S. and the trans-Atlantic alliance, who insist that any nation that wants to be a part of NATO be allowed to apply.

The Russian president is also demanding that NATO pull back its expanding presence in eastern Europe. Putin's overarching goal, analysts say, is to try to preserve a degree of control over events in the former Soviet Union, encompassing now-independent countries like Ukraine.

"I think his aim is definitely to keep the U.S. and NATO out of what he considers Russia's sphere of influence, the former Soviet states," Liana Fix, a resident fellow at the German Marshall Fund in Washington, said of the former KGB agent.

After taking part in meetings this week with Russian and European officials, a senior U.S. diplomat said he believed war seemed more likely than ever.

"At the present time, we're facing a crisis in European security," the U.S. ambassador to the Organization for Security and Cooperation in Europe, Michael Carpenter, said in a news conference. "The drumbeat of war is sounding loud and the rhetoric has gotten rather shrill."



SPEAKER THERESE M. TERLAJE

Committee on Health, Land, Justice & Culture I Mina trentai Sais na Liheslaturan Gudhan



NOTICE OF VIRTUAL PUBLIC HEARING - Wednesday, January 19, 2022 AGENDA:

9:00 AM

- Bill No. 168-36 (LS) Senator Telena Cruz Nelson—An act to add new §§ 41806 and amend §§
 41810 of article 18. Chapter 4. Division 1. Title 26. Guam administrative rules and
 Regulations, relative to the required registration of prescribers to the Guam
 Prescription Monitoring Program (PDMP).
- Bill No. 169–36 (LS) Senator Telena Cruz Nelson—an act to amend appendix a. Appendix B, Appendix C, appendix D, and appendix E of Chapter 26. Title 9 of Guam Code Annotated, Relative to updating the List of Scheduled Controlled Substances Provided in the Guam Uniform Controlled Substances act,

2:00 PM:

 Bill No. 147–36 (LS) — Senator Frank Blas Jr. – An ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

BiU No. 237-36 (COR) - Senator Sabina Flores Perez-AN ACT TO AMEND § 34406 (e) AND § 34406 (f)
OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED. RELATIVE TO UPDATING VIOLATIONS OF
PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE

Contact the Office of the Speaker at 472–3586 or <u>senatorterlajeguam@gmail.com</u>, to register to provide live or written testimony. All hearings broadcast on 67A TV Channel 21, Docomo Channel 117/112.4, and livestream on the Guam Legislature YouTube: https://www.youtube.com/c/Guam_LegislatureMedia. In compliance with the Americans with Disabilities Act. Individuals needing special accommodations can contact the Office of Speaker Therese M. Terlaje. This Ad was paid with Legislature Funds.



SENATOR SABINA FLORES PEREZ

Committee on Environment, Revenue and Taxation, Labor, Procurement, and Statistics, Research, and Planning

Virtual Public Hearing (Zoom Video Conference) Tuesday, January 18, 2022, at 9:00 a.m.

9:00 A.M.

Executive Appointment of Mr. Steven P. Carbuilido to serve as a Member of the Guam Environmental Protection Agency Board of Directors.

BHI NO. 235-36 (COR) - James C. Moylan, Amanda L. Shelton, Mary Camacho Torres - An Act 10 Refeal and Refaals 8 3011 and 8 3017 of Chapter 5, title 5, quam gool annotate), relative to procurement policies in favor of Disability Owner Business Enterprises.

Bill No. 236-36 (COR) - Sabina Flores Perez, Therese M. Terlaje, Joanne Brown, Telena Cruz Nelson, James C. Moylan, Joe S. San Agustin, Clynton E. Riggell, Telo T. Taitague: AND TIO AMENO \$272 0F-CHAPITES. AILLE: S. GIAM. GODE ANNOMATIO, RELAYEVE IS STRENSHENING HE REQUIREMENTS OF SMALL PURCHASES.

These interested in participating, please confirm your attendence by contacting the office of Senator Sabrua Fluies Perex via email at office@senatorperez orgion via phone at 660 2968, no later than January 14, 2022, for further quidance.

Itestimonius anoulo be addressed to Senator Subina Flores Perez, Chairperson, and will be accepted via hand delivery to our office, our mailbox at the Quam Congress Building of 183 Chalan Santo Paga, Hagátha, Buam Sélfic, or pre-mail to office@senatorperez.org, no later than 4gm January 15, 2022. In compliance with the Americans with Dispatilities Act, individuals requiring appetal acceptanced before to restrives should stanted the Office of Senator Santor Flores Perez 1898-2986. The hearing will bracked no focal toleristion, GTA Channel 21, Decome Channel 112-4, and stream online via 1 Libestaturan Buáhan's live feed on Yeufube. A recording of the nearing will be available online via Quam Lagistaturé Media on YouTube after the hearing. We look Torward to your outcomes.



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

INVITATION TO VIRTUAL PUBLIC HEARING-TUESDAY. OCTOBER 19, 2021

9 messages

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>
Tue, Oct 12, 2021 at 12:32 PM
To: Masatomo Nadeau <masatomo.nadeau@dphss.guam.gov>
Cc: "Arthur U. San Agustin" <arthur.sanagustin@dphss.guam.gov>, "Rosanna Y. Rabago"
<Rosanna.Rabago@dphss.guam.gov>, Jeffrey Pinaula <Jeffrey.Pinaula@dphss.guam.gov>

October 12, 2021

Transmitted via Electronic Mail:

Masatomo Nadeau Chief EPHO Division of Environmental Health, DPHSS Masatomo.Nadeau@dphss.guam.gov

SUBJECT: INVITATION TO VIRTUAL PUBLIC HEARING- TUESDAY. OCTOBER 19, 2021

Buenas yan Håfa Adai Chief Nadeau:

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Tuesday, October 19, 2021, for</u> the following agenda items:

9:00 AM:

• <u>BILL NO. 209-36 (COR)</u>- THERESE M. TERLAJE- "AN ACT TO ADOPT THE PROPOSED AMENDMENTS TO ARTICLE 5 OF CHAPTER 4, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, AS TRANSMITTED TO I LIHESLATURAN GUÅHAN PURSUANT TO THE ADMINISTRATIVE ADJUDICATION LAW, ATTACHED HERETO AS EXHIBIT A." BILL LINK: https://www.guamlegislature.com/36th_Guam_Legislature/Bills_Introduced_ 36th/Bill%20No.%20209-36%20(COR).pdf

3:00 PM

- <u>BILL NO. 168-36 (LS)</u>- TELENA C. NELSON- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP). BILL LINK: https://www.guamlegislature.com/36th_Guam_Legislature/Bills_Introduced_36th/Bill%20No.%20168-36%20(LS).pdf
- <u>BILL NO. 169-36 (LS)</u>- *TELENA C. NELSON* AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF

GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT. **BILL LINK:** https://www.guamlegislature.com/36th_Guam_Legislature/Bills_Introduced_36th/Bill%20No.%20169-36%20(LS).pdf

The Committee kindly requests the feedback of DPHSS's Division on Environmental Health on the agenda items. Please confirm yours and/or the availability of other Division personnel to attend the hearing. Should the Division not be able to attend, please confirm any written testimony that will be submitted on the bills prior to the hearing. Your feedback is valuable, and we look forward to your participation!

Si Yu'os Ma'åse',

Speaker Therese M. Terlaje

CC: Arthur San Agustin, Director, Department of Public Health & Social Services

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture *I Mina'trentai Sais na Liheslaturan Guåhan* 36th Guam Legislature
Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910
T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

INVITATION TO VIRTUAL PUBLIC HEARING- TUES, OCTOBER 19, 2021_DPHSS CHIEF EPHO M. NADEAU.pdf
416K

Masatomo Nadeau <Masatomo.Nadeau@dphss.guam.gov>
To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

Tue, Oct 12, 2021 at 1:49 PM

Thank you for the notice.

Tom



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

October 12, 2021

Transmitted via Electronic Mail:

Masatomo Nadeau Chief EPHO Division of Environmental Health, DPHSS <u>Masatomo.Nadeau@dphss.guam.gov</u>

SUBJECT: INVITATION TO VIRTUAL PUBLIC HEARING- TUESDAY. OCTOBER 19, 2021

Buenas yan Håfa Adai Chief Nadeau:

Please be advised that the Committee on Health, Land, Justice and Culture will convene a virtual public hearing, using the Legislature's virtual Zoom platform on <u>Tuesday, October 19, 2021, for</u> the following agenda items:

9:00 AM:

• <u>BILL NO. 209-36 (COR)</u>- THERESE M. TERLAJE- "AN ACT TO ADOPT THE PROPOSED AMENDMENTS TO ARTICLE 5 OF CHAPTER 4, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, AS TRANSMITTED TO I LIHESLATURAN GUÅHAN PURSUANT TO THE ADMINISTRATIVE ADJUDICATION LAW, ATTACHED HERETO AS EXHIBIT A." **BILL**

LINK: https://www.guamlegislature.com/36th Guam Legislature/Bills Introduced 36th/Bil 1%20No.%20209-36%20(COR).pdf

3:00 PM

• <u>BILL NO. 168-36 (LS)</u>- TELENA C. NELSON- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP). **BILL**

LINK: https://www.guamlegislature.com/36th Guam Legislature/Bills Introduced 36th/Bil 1%20No.%20168-36%20(LS).pdf

• <u>BILL NO. 169-36 (LS)</u>- TELENA C. NELSON- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT. BILL

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910
Tel: (671) 472-3586 | Fax: (671) 969-3590 | Email: senatorterlajeguam@gmail.com | www.senatorterlaje.com
*For transmittal of official Messages & Communications to the Guam Legislature to be distributed to all Senators,
please send to: speaker@guamlegislature.org

Letter addressed to DPHSS Chief EPHO Masatomo Nadeau

RE: Invitation to Virtual Public Hearing on Tuesday, October 19, 2021

LINK: https://www.guamlegislature.com/36th Guam Legislature/Bills Introduced 36th/Bil 1%20No.%20169-36%20(LS).pdf

The Committee kindly requests the feedback of DPHSS's Division on Environmental Health on the agenda items. Please confirm yours and/or the availability of other Division personnel to attend the hearing. Should the Division not be able to attend, please confirm any written testimony that will be submitted on the bills prior to the hearing. Your feedback is valuable, and we look forward to your participation!

Si Yu'os Ma'åse',

Speaker Therese M. Terlaje

CC: Arthur San Agustin, Director, Department of Public Health & Social Services



Speaker Therese M. Terlaje Asenatorterlojuguani@gmail.com/>

Invitation to January 19, 2022, 9:00AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

	-		~					

Speaker Therese M. Terlaje <sen< th=""><th>atorterlajeguam@gmail.com></th><th>Wed, Jan 12, 2022 at 10:51 AM</th></sen<>	atorterlajeguam@gmail.com>	Wed, Jan 12, 2022 at 10:51 AM
To: SUPERDRUG DEDEDO	@paylessmarkets.com>	
Cc: eustaquioam@gmail.com,	@gmail.com,	@gmail.com, Zennia Pecina
<zennia.pecina@dphss.guam.gov< td=""><td>>, "Ciana V. Galindo" <ciana.galir< td=""><td>ndo@dphss.guam.gov></td></ciana.galir<></td></zennia.pecina@dphss.guam.gov<>	>, "Ciana V. Galindo" <ciana.galir< td=""><td>ndo@dphss.guam.gov></td></ciana.galir<>	ndo@dphss.guam.gov>

January 12, 2022

Transmitted via Electronic Mail:

Jerry Caruso, Chairperson
The Guam Board of Examiners for Pharmacy
Department of Public Health & Social Services

@paylessmarkets.com

SUBJECT: Invitation to January 19, 2022, 9:00AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai Chairperson Caruso:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday</u>, <u>January 19</u>, <u>2022</u>, <u>at 9:00 AM.</u>, and kindly requests the feedback of the Board:

- <u>Bill No. 168-36 (LS) Senator Telena Cruz Nelson-</u> AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- <u>Bill No. 169-36 (LS) Senator Telena Cruz Nelson</u>_AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Therese M. Terlaje

CC: All members, Guam Board of Examiners for Pharmacy, Zennia Pecina, DPHSS HPLO Administrator, DPHSS; Ciana D. Galindo, Word Processing Secretary I, DPHSS HPLO

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910

T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com


website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

5 attachments









Bill No. 169-36 (LS)-2.pdf 1215K

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

Wed, Jan 12, 2022 at 1:50 PM

To: csolis96913@gmail.com, jedsana@hawaii.edu, artsmariano@hotmail.com, meggs@guam.net Cc: SUPERDRUG DEDEDO <sddededo@paylessmarkets.com>

Hafa Adai GBEP members,

The forwarded email is an invitation from Speaker Therese Terlaje to attend and participate in a virtual public hearing scheduled for January 19, 2022 at 9:00 a.m. on Bill No. 168-36 (LS) and Bill No. 169-36 (LS). The bills are attached to the email with the invitation for your convenience.

Respectfully, Natasha Charfauros

Policy Analyst

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910 T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com

website: www.senatorterlaje.com


Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

[Quoted text hidden]

5 attachments









Bill No. 169-36 (LS)-2.pdf 1215K

SuperDrug Dededo <sddededo@paylessmarkets.com>

Mon, Jan 17, 2022 at 6:51 PM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, csolis96913@gmail.com, jedsana@hawaii.edu, artsmariano@hotmail.com, meggs@guam.net

To: Senator Therese M. Terlaje

Madame Speaker,

Thank you for your invitation to the virtual public hearing scheduled for January 19, 2022, regarding Bills No. 168-36(LS) and No. 169-36(LS). At this time, I would like to offer my comments below in lieu of my attending the virtual meeting since I will be working at that time.

Gm

At this time, all I can offer is my personal opinion regarding both Bills, since the GBEP meets this coming Thursday, which is the day after the public hearing and will not have them as a topic on the agenda that has been published. Furthermore, it is my opinion is that neither Bill would, nor, should be, under any special consideration by the Pharmacy Board, as I will explain below.

Bill 168 relates to medical prescribers being required to avail themselves of the Guam PDMP program on a routine basis, which in my view is an excellent idea, but that only affects them. Consequently, any input by the GBEP would only offer support for that Bill. Personally, I whole heartedly support the intent of the Bill, and I am sure that most pharmacists would also be supportive of it. Currently, most pharmacies that dispense controlled substances(CS) do, as far as I know, make use of the PDMP to check if and when their customers have a history of chronic CS use or if their prescriptions are for immediate and short term use, such as when prescribed by dentists for possible pain following dental procedures. In addition, the PDMP lets the pharmacist know if and when their customer has used another pharmacy, or received CS prescriptions from other practitioners. Personally, I find it a valuable tool in my practice of pharmacy.

Now, regarding Bill 169, it looks like "house keeping" with regard to updating the current recognized list of legal and non-legal CS. I believe most pharmacies are already aware that the Federal Drug Enforcement Administration(DEA) already maintains a complete list of both types of controlled substances. Admittedly, I was not aware that our Public Health Department was required to maintain a list of their own. And, likewise, I do not think there is any need for the GBEP to concern itself regarding this Bill since it most directly affects DPHSS.

Most respectfully,

Jerry Caruso

Thomas J. Caruso, RPh(Jerry)

P.I.C., Super Drug Pharmacy

Ph: 671

Fax: 671-637-9747

Email: sddededo@paylessmarkets.com

[Quoted text hidden]



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

January 12, 2022

Transmitted via Electronic Mail:

Jerry Caruso, Chairperson
The Guam Board of Examiners for Pharmacy
Department of Public Health & Social Services

@paylessmarkets.com

SUBJECT: Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai Chairperson Caruso:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday, January 19, 2022, at 9:00 AM.</u>, and kindly requests the feedback of the Board:

- Bill No. 168-36 (LS) Senator Telena Cruz NelsonAN ACT TO ADD NEW §§ 41806 AND
 AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM
 ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED
 REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM
 (PDMP).
- <u>Bill No. 169-36 (LS) Senator Telena Cruz Nelson</u>—AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Si Yu'os Ma'åse',

Therese M. Terlaje

CC: All members, Guam Board of Examiners for Pharmacy, Zennia Pecina, DPHSS HPLO Administrator, DPHSS; Ciana D. Galindo, Word Processing Secretary I, DPHSS HPLO

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910
Tel: (671) 472-3586 | Fax: (671) 969-3590 | Email: senatorterlajeguam@gmail.com | www.senatorterlaje.com *For transmittal of official Messages & Communications to the Guam Legislature to be distributed to all Senators, please send to: speaker@guamlegislature.org



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

4 messages

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> Wed, Jan 12, 2022 at 4:02 PM To: Theresa Arriola <theresa.arriola@gbhwc.guam.gov>, Carissa Pangelinan <Carissa.pangelinan@gbhwc.guam.gov>

January 12, 2022

Transmitted via Electronic Mail:

Therese Arriola, Director Guam Behavioral Health & Wellness Center theresa.arriola@gbhwc.guam.gov

Carissa Pangelinan, Deputy Director Guam Behavioral Health & Wellness Center carissa.pangelinan@gbhwc.guam.gov

SUBJECT: Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai Director Arriola and Deputy Director Pangelinan:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday, January 19, 2022, at 9:00 AM.</u>, and kindly requests the feedback of the GBHWC:

- <u>Bill No. 168-36 (LS) Senator Telena Cruz Nelson-</u> AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- <u>Bill No. 169-36 (LS) Senator Telena Cruz Nelson-</u> AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Si Yu'os Ma'åse'.

Therese M. Terlaje

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature


Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910

T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com

website: www.senatorterlaje.com


Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

5 attachments









Bill No. 169-36 (LS)-2.pdf

Theresa Arriola < Theresa. Arriola@gbhwc.guam.gov>

Wed, Jan 12, 2022 at 4:33 PM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, Carissa Pangelinan <Carissa.Pangelinan@gbhwc.guam.gov>

Cc: "Christina T. Dela Cruz" < Christina. Dela Cruz@gbhwc.guam.gov>

Thank you Speaker for invite.

I saw the invite earlier this week and had calendared to attend and provide testimony.

Stay well and safe.

Un Dankalu na Saina Ma'ase (Thank you),



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

January 12, 2022

Transmitted via Electronic Mail:

Therese Arriola, Director Guam Behavioral Health & Wellness Center theresa.arriola@gbhwc.guam.gov

Carissa Pangelinan, Deputy Director Guam Behavioral Health & Wellness Center carissa.pangelinan@gbhwc.guam.gov

SUBJECT: Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai Director Arriola and Deputy Director Pangelinan:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday</u>, <u>January 19</u>, <u>2022</u>, <u>at 9:00 AM.</u>, and kindly requests the feedback of the GBHWC:

- Bill No. 168-36 (LS) Senator Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Senator Telena Cruz Nelson– AN ACT TO AMEND APPENDIX A,
 APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF
 GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED
 CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED
 SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Si Yu'os Ma'åse',

Therese M. Terlaje



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

1 message

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> Wed, Jan 12, 2022 at 10:59 AM To: "Dr. John Ray Taitano" @gmail.com>, "Thomas Shieh, MD, FACOG" <doctorshieh@yahoo.com>

January 12, 2022

Transmitted via Electronic Mail:

Dr. John Taitano, President Guam Medical Society @gmail.com

Dr. Thomas Shieh, President Guam Medical Association doctorshieh@yahoo.com

SUBJECT: Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai President Taitano and President Shieh:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday, January 19, 2022, at 9:00 AM.</u>, and kindly requests the feedback of the Guam Medical Society and Guam Medical Association:

- <u>Bill No. 168-36 (LS) Senator Telena Cruz Nelson-</u> AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- <u>Bill No. 169-36 (LS) Senator Telena Cruz Nelson-</u> AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Si Yu'os Ma'åse'.

Therese M. Terlaje

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910


T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com

website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.

5 attachments







Bill No. 169-36 (LS)-2.pdf 1215K

Joint GMS & GMA Invite to 01.19.22, 9AM Virtual Public Hearing on B168, B169_TMT.pdf 432K



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

January 12, 2022

Transmitted via Electronic Mail:

Dr. John Taitano, President Guam Medical Society @gmail.com

Dr. Thomas Shieh, President Guam Medical Association doctorshieh@yahoo.com

SUBJECT: Invitation to January 19, 2022, 9:00 AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

Hafa Adai President Taitano and President Shieh:

The Legislature's Committee on Health, Land, Justice and Culture has scheduled a virtual public hearing on the following agenda items, on <u>Wednesday</u>, <u>January 19</u>, <u>2022</u>, <u>at 9:00 AM.</u>, and kindly requests the feedback of the Guam Medical Society and Guam Medical Association:

- Bill No. 168-36 (LS) Senator Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Senator Telena Cruz Nelson– AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Please contact my office at (671) 472-3586 or senatorterlajeguam@gmail.com, to confirm your attendance, or that of a representative, or any written testimony that is forthcoming. The Zoom link to the hearing will be sent upon confirmation of attendance. Your assistance is greatly appreciated.

Si Yu'os Ma'ase'.

Therese M. Terlaje

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910
Tel: (671) 472-3586 | Fax: (671) 969-3590 | Email: senatorterlajeguam@gmail.com | www.senatorterlaje.com *For transmittal of official Messages & Communications to the Guam Legislature to be distributed to all Senators, please send to: speaker@guamlegislature.org



I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

Virtual Public Hearing

Wednesday, January 19, 2022,

beginning at 9:00 a.m.

AGENDA

9:00 AM:

- Bill No. 168-36 (LS) Telena Cruz Nelson- AN ACT TO ADD NEW §§ 41806 AND AMEND §§ 41810 OF ARTICLE 18, CHAPTER 4, DIVISION 1, TITLE 26, GUAM ADMINISTRATIVE RULES AND REGULATIONS, RELATIVE TO THE REQUIRED REGISTRATION OF PRESCRIBERS TO THE GUAM PRESCRIPTION MONITORING PROGRAM (PDMP).
- Bill No. 169-36 (LS) Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

2:00 PM:

 Bill No. 147-36 (LS) - Frank Blas Jr.- AN ACT TO ADD A NEW SUBSECTION 160.101 TO CHAPTER 160 OF TITLE 8, GUAM CODE ANNOTATED RELATIVE TO THE PRIVACY OF A VICTIM OF A SEXUAL OFFENSE.

3:00 PM:

• Bill No. 237-36 (COR) - Sabina Flores Perez- AN ACT TO AMEND § 34406 (e) AND § 34406 (f) OF CHAPTER 34, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO UPDATING VIOLATIONS OF PROTECTING ANIMAL WELFARE AND SAFETY (PAWS) FOR ANIMALS PROVIDING ASSISTANCE.

All hearings broadcast on GTA TV Channel 21, Docomo Channel 117/112.4, and stream online at the Guam Legislature YouTube Channel: https://www.youtube.com/c/GuamLegislatureMedia and will be available on the Guam Legislature YouTube after the hearing.



a'trentai Sais na Liheslaturan Guåhan | 36th Guam Legislature Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture

Date: WEDNESDAY, JANUARY 19, 2022 Time: 9:00 AM

VIRTUAL PUBLIC HEARING: Bill No. 169-36 (LS) – Senator Telena Cruz Nelson- AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

					Type of T	Sup	Support	
	NAME	ADDRESS	CONTACT NO.	E-MAIL	WRITTEN	ORAL	Yes	No
1	Masatomo Nadeau, Chief EPHO, Division of Environmental Health, DPHSS					x		
2	William W. Weare, M.D.					x		
3								
4								
5								
6								
7								
8								
9								
10					P	age 1 c	of 1	



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

Invitation to January 19, 2022, 9:00AM Virtual Public Hearing on Bill No. 168-36 (LS) and Bill No. 169-36 (LS)

SuperDrug Dededo < Mon, Jan 17, 2022 at 6:51 PM To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, , ,

To: Senator Therese M. Terlaje

Madame Speaker,

Thank you for your invitation to the virtual public hearing scheduled for January 19, 2022, regarding Bills No. 168-36(LS) and No. 169-36(LS). At this time, I would like to offer my comments below in lieu of my attending the virtual meeting since I will be working at that time.

At this time, all I can offer is my personal opinion regarding both Bills, since the GBEP meets this coming Thursday, which is the day after the public hearing and will not have them as a topic on the agenda that has been published. Furthermore, it is my opinion is that neither Bill would, nor, should be, under any special consideration by the Pharmacy Board, as I will explain below.

Bill 168 relates to medical prescribers being required to avail themselves of the Guam PDMP program on a routine basis, which in my view is an excellent idea, but that only affects them. Consequently, any input by the GBEP would only offer support for that Bill. Personally, I whole heartedly support the intent of the Bill, and I am sure that most pharmacists would also be supportive of it. Currently, most pharmacies that dispense controlled substances(CS) do, as far as I know, make use of the PDMP to check if and when their customers have a history of chronic CS use or if their prescriptions are for immediate and short term use, such as when prescribed by dentists for possible pain following dental procedures. In addition, the PDMP lets the pharmacist know if and when their customer has used another pharmacy, or received CS prescriptions from other practitioners. Personally, I find it a valuable tool in my practice of pharmacy.

Now, regarding Bill 169, it looks like "house keeping" with regard to updating the current recognized list of legal and non-legal CS. I believe most pharmacies are already aware that the Federal Drug Enforcement Administration(DEA) already maintains a complete list of both types of controlled substances. Admittedly, I was not aware that our Public Health Department was required to maintain a list of their own. And, likewise, I do not think there is any need for the GBEP to concern itself regarding this Bill since it most directly affects DPHSS.

Most respectfully,

Jerry Caruso

Thomas J. Caruso, RPh(Jerry)

P.I.C., Super Drug Pharmacy



Email:

[Quoted text hidden]



GOVERNOR MAGATHÁGA

JOSHUA F. TENORIO

LT. GOVERNOR, SIGUNDO MAGA'LÂHI

GOVERNMENT OF GUAM

DEPARTMENT OF PUBLIC HEALTH AND SOCIAL SERVICES DIPATTAMENTON SALUT PUPBLEKO YAN SETBISION SUSIAT



JAN 1 8 2022

DIRECTOR

LAURENT SF DUENAS, MPH, BSN
DEPUTY DIRECTOR

TERRY G. AGUON
DEPUTY DIRECTOR

TESTIMONY ON BILL 169-36 (LS)

Hafa Adai Speaker and Health Chair Therese Terlaje, Senator Telena Nelson, and members of the Committee on Health, Land, Justice and Culture. I am Arthur U. San Agustin, Director of the Department of Public Health and Social Services. Thank you for allowing the Department to present its testimony on Bill 169-36 (LS) relative to updating the list of scheduled controlled substances provided in the Guam Uniform Controlled Substances Act of Title 9 Guam Code Annotated, Chapter 67.

We would like to first point out that there is a typographical error in the chapter numbering in Bill 169-36. The correct chapter should read "67" and not "26". Thus, Bill 169-36 should read to amend Appendices A, B, C, D, and E of Chapter 67 [underlined for emphasis] of Title 9 of the Guam Code Annotated.

The Department of Public Health and Social Services supports Bill 169-36. As you may know, the Division of Environmental Health of this Department administers the Guam Uniform Controlled Substances Act and it is mandated by §67.301(f) of the said Act to update the controlled substances schedules pursuant to the Administrative Adjudication Law. The schedule listing of controlled substances was last updated on September 30, 2011, via Public Law 31-110, and thus, it is due for an update and Bill 169-36 will address that need. The passage of Bill 169-36 will properly align Guam's schedule listing to mirror those of the U.S. Drug Enforcement Administration (DEA) (Title 21 Code of Federal Regulations Section 1308).

We support the following changes that will update the controlled substances schedules as proposed in Bill 169-36:

- 1. Schedule I (Appendix A)
 - A total of 15 new Opiates, 43 Hallucinogenic Substances, and 22 Temporary Listing
 of Substances Subject to Emergency Scheduling were added to Appendix A. A total
 of 14 Cannabimimetic Agents were re-classified as Hallucinogenic Substances and
 12 were deleted from Appendix A.
- 2. Schedule II (Appendix B)
 - An Opium and Opiate were added to Appendix B.
- 3. Schedule III (Appendix C)
 - One (1) Narcotic drug, and one (1) Anabolic Steroid was added to Appendix C. A
 total of two (2) Anabolic Steroids were deleted from Appendix C.

- 4. Schedule IV (Appendix D)
 - One (1) Narcotic drug was added and one (1) was deleted from Appendix D. A
 total of four (4) Depressant drugs, one (1) Stimulant drug, and one (1) Other
 substances were added to Appendix D
- 5. Schedule V (Appendix E)
 - A total of four (4) Depressant drugs were added to Appendix E.

After almost a decade, it is crucial that the list of scheduled drugs be updated and aligned with DEA. Not only will this benefit our law enforcement officers, attorney general's office, but also medical practitioners in the treatment of their patients.

The Department would like to thank you, Speaker Terlaje, and Senator Telena Nelson, for assisting us in sponsoring this important legislation.

Dangko'lo na Si Yu'os Ma'ase.

M. THOMAS NADEAU

Chief EPHO

Division of Environmental Health, DPHSS

ARTHUR U. SAN AGUSTIN, MHR

Director

Department of Public Health and Social Services

ARTICLE 3 REGULATION OF MANUFACTURE, DISTRIBUTION AND DISPENSING OF CONTROLLED SUBSTANCES

SOURCE: Article 3 was repealed and reenacted by P.L. 24-149:2 (Mar. 25, 1998).

§ 67.301.	Rules.
§ 67.302.	Registration Requirements.
§ 67.303.	Registration.
§ 67.304.	Suspension or Revocation of Registration.
§ 67.306.	Records of Registrants.
§ 67.307.	Order Forms.
§ 67.308.1.	Prescriptions.
§ 67.308.2.	Administering or Dispensing of Narcotic Drugs.
§ 67.309.	Diversion Prevention and Control.

§ 67.301. Rules.

- (a) DPHSS shall adopt rules and charge reasonable fees relating to the registration and control of the manufacture, distribution and dispensing of controlled substances in Guam.
- (b) The fees provided for in this Section shall be collected to combat diversion of controlled substances and must be forwarded to the Department of Administration for the use provided in Subsection (c). The Department of Administration shall establish the Controlled Substances Diversion Fund where fees shall be deposited.
- (c) Moneys collected under the "Controlled Substances Diversion Fund" account shall be utilized by the Department of Public Health and Social Services for their use of:
 - (1) existing programs, or created, in monitoring of controlled substances to identify and detect its diversion;
 - (2) acquiring equipment and supplies, and entering into contracts, necessary to monitor controlled substances; and
 - (3) training of employees assigned to administer the Act.

- (d) Moneys in the account are appropriated on a continuing basis and are not subject to lapsing and related appropriations restraints.
- (e) The Department of Public Health and Social Services shall administer expenditures from the fund. Expenditures may be made only for the monitoring of controlled substances through acquisition of equipment and supplies, entering into contracts, and training of employees administering the Act to keep them abreast of new and changing information regarding controlled substances and related matters. Moneys from the Fund may not supplant other local, state or Federal funds.
- (f) Guam Uniform Controlled Substances Act Review. The Director may, in accordance with the Administrative Adjudication Law, conduct an annual review of the U.S. Drug Enforcement Administration Schedule Listing to determine whether the Guam Uniform Controlled Substances Act shall be revised in accordance.

SOURCE: Subsection (f) added by P.L. 31-110:19 (Sept. 30, 2011).

§ 67.302. Registration Requirements.

- (a) A person who manufactures, distributes or dispenses a controlled substance within Guam or who proposes to engage in the manufacture, distribution or dispensing of a controlled substance within Guam, shall obtain annually a registration issued by DPHSS in accordance with rules adopted by DPHSS.
- (b) A person registered by DPHSS under this Act to manufacture, distribute, dispense or conduct research with controlled substances may possess, manufacture, distribute, dispense or conduct research with controlled substances to the extent authorized by the registration and in conformity with this Article.
- (c) The following persons need not register and may lawfully possess controlled substances under this Act:
 - (1) an agent or employee of a registered manufacturer, distributor or dispenser of a controlled substance if the agent or employee is acting in the usual course of business or employment;

- (2) a common or contract carrier or warehouseman, or an employee thereof, whose possession of any controlled substance is in the usual course of business or employment; and
- (3) an ultimate user or a person in possession of a controlled substance pursuant to a lawful order of a practitioner or in lawful possession of a substance included in Schedule V.
- (d) DPHSS, by rule, may waive the requirement for registration of certain manufacturers, distributors or dispensers upon finding it consistent with the public health and safety.
- (e) A separate registration is required for each principal place of business or professional practice where the applicant manufactures, distributes or dispenses controlled substances.
- (f) DPHSS may inspect the establishment of a registrant or applicant for registration in accordance with rules adopted by DPHSS.
- (g) A government operated or government contracted animal shelter recognized by the Department of Agriculture is authorized to purchase, possess, and administer sodium pentobarbital and Xylazine for the purpose of humane euthanasia of animals provided that a U.S. Drug Enforcement Administration controlled substance permit is also secured. The possession and administering of sodium pentobarbital and Xylazine for euthanasia pursuant to Subsections (g) and (h) of this Section is restricted solely to the premises of a government operated or government contracted animal shelter recognized by the Department of Public Health and Social Services.
- (h) Agents of a government operated or government contracted animal shelter recognized by the Department of Public Health and Social Services shall possess a current animal euthanasia technician license issued by the Guam Board of Allied Health Examiners to administer sodium pentobarbital and Xylazine for the euthanasia of animals. The requirements for the issuance of an animal euthanasia technician license shall be determined and developed by the Guam Board of Allied Health Examiners.

SOURCE: Subsections (g) and (h) added by P.L. 28-034:4 (Apr. 22, 2005).

§ 67.303. Registration.

- (a) DPHSS shall register an applicant to manufacture or distribute substances included in Schedules I through V, unless DPHSS determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, DPHSS shall consider the following factors:
 - (1) maintenance of effective controls against diversion of controlled substances into other than legitimate medical, scientific research or industrial channels;
 - (2) compliance with Federal and local law;
 - (3) promotion of technical advances in the art of manufacturing controlled substances and the development of new substances;
 - (4) convictions of the applicant under laws of another country or Federal or state laws relating to a controlled substance;
 - (5) past experience of the applicant in the manufacture or distribution of controlled substances, and the existence in the applicant's establishment of effective controls against diversion of controlled substances into other than legitimate medical, scientific, research or industrial channels;
 - (6) furnishing by the applicant of false or fraudulent material in an application filed under this Act;
 - (7) suspension or revocation of the applicant's Federal registration or the applicant's registration in another state to manufacture, distribute or dispense controlled substances as authorized by Federal law; and
 - (8) any other factors relevant to and consistent with the public health and safety.
- (b) Registration under Subsection (a) entitles a registrant to manufacture or distribute a substance included in Schedule I or II only if it is specified in the registration.

- (c) A practitioner must be registered with DPHSS before dispensing a controlled substance or conducting research with respect to a controlled substance included in Schedules II through V. DPHSS need not require separate registration under this Article for a practitioner engaging in research with non-narcotic substances included in Schedules II through V if the registrant is already registered under this Article in another capacity. A practitioner registered under Federal law to conduct research with a substance included in Schedule I may conduct research with the substance in Guam upon furnishing DPHSS evidence of the Federal registration.
- (d) A manufacturer or distributor registered under the Federal Controlled Substances Act (21 U.S.C. § 801, et seq.) may submit a copy of the Federal application as an application for registration as a manufacturer or distributor under this Section. DPHSS may require a manufacturer or distributor to submit information in addition to the application for registration under the Federal act.
- (e) A dispenser of narcotic drugs to a narcotic drug dependent person, as defined in § 67.308.2(a), registered under the Federal Controlled Substances Act (21 U.S.C. § 801, et seq.) may submit a copy of the Federal application as an application for registration as a dispenser of narcotic drugs to a drug dependent person under this Section. DPHSS may require a dispenser to submit information in addition to the application for registration under the Federal act.

§ 67.304. Suspension or Revocation of Registration.

- (a) DPHSS may suspend or revoke a registration under § 67.303 to manufacture, distribute or dispense a controlled substance upon finding that the registrant has:
 - (1) furnished false or fraudulent material information in an application filed under this Act;
 - (2) been convicted of a felony under state or Federal law relating to a controlled substance;
 - (3) had the registrant's Federal registration suspended or revoked and is no longer authorized by Federal law to

manufacture, distribute or dispense controlled substances; or

- (4) committed an act that would render registration under § 67.303 inconsistent with the public interest as determined under that Section.
- (b) DPHSS may limit revocation or suspension of a registration to the particular controlled substance with respect to which grounds for revocation or suspension exist.
- (c) If a registration is suspended or revoked, DPHSS may place under seal all controlled substances owned or possessed by the registrant at the time of suspension or the effective date of the revocation order. No disposition may be made of substances under seal until the time for taking an appeal has elapsed or until all appeals have been concluded unless a court, upon application, orders the sale of perishable substances and the deposit of the proceeds of the sale with the court. When a revocation order becomes final, the court may order the controlled substances forfeited to DPHSS.
- (d) DPHSS may seize or place under seal any controlled substance owned or possessed by a registrant whose registration has expired or who has ceased to practice or do business in the manner permitted by the registration. The controlled substance must be held for the benefit of the registrant or the registrant's successor in interest. DPHSS shall notify a registrant, or the registrant's successor in interest, whose controlled substance is seized or placed under seal, of the procedures to be followed to secure the return of the controlled substance and the conditions under which it will be returned. DPHSS may not dispose of a controlled substance seized or placed under seal under this Subsection until the expiration of one hundred eighty (180) days after the controlled substance was seized or placed under seal. Costs incurred by seizing, placing under seal, maintaining custody and disposing of any controlled substance under this Subsection may be recovered from the registrant, any proceeds obtained from the disposition of the controlled substance, or from both. All monies collected from this Section shall be deposited in the Controlled Substances Diversion Fund, as provided in § 67.301.

§ 67.305. Order to Show Cause.

- (a) Before denying, suspending, revoking or refusing to renew a registration, DPHSS shall serve upon the applicant or registrant an order to show cause why registration should not be denied, suspended or revoked, or the renewal refused. The order must state its grounds and direct the applicant or registrant to appear before DPHSS at a specified time and place not less than thirty (30) days after the date of service of the order. In case of a refusal to renew a registration, the order must he served not later than thirty (30) days before expiration of the registration. The proceedings must be conducted in accordance with the Administrative Adjudication Law, 5 GCA § 9100, et seq. The proceedings do not preclude any criminal prosecution or other proceeding. A proceedings to refuse to renew a registration does not affect the existing registration, which remains in effect until completion of the proceedings.
- (b) DPHSS may suspend, without an order to show cause, a registration simultaneously with the institution of proceedings under § 67.304, or if renewal, of registration is refused, upon finding that there is an imminent danger to the public health and safety which warrants the action. The suspension continues in effect until the conclusion of the proceedings, including judicial review, unless earlier by DPHSS or dissolved by a court of competent jurisdiction.

§ 67.306. Records of Registrants.

A person registered to manufacture, distribute or dispense controlled substances under this Act shall keep records and maintain inventories in compliance with Federal law, and rules adopted by DPHSS.

§ 67.307. Order Forms.

A registrant may distribute a substance included in Schedule I or II to another registrant only by means of an order form. Compliance with Federal law respecting order forms constitutes compliance with this Section.

§ 67.308.1. Prescriptions.

- (a) As used in this Section, "medical treatment" includes dispensing or administering a narcotic drug for pain, including intractable pain; however, this does not include dispensing any controlled substance to a fighting cock or a competitive racing dog for their performance or appearance enhancement.
- (b) A person may dispense a controlled substance only as provided in this Section.
- (c) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, a substance included in Schedule II may not be dispensed without the written prescription of a practitioner and pursuant to rules adopted by DPHSS. A prescription for a Schedule II, III, IV or V substance shall not be filled by a pharmacist more than seven (7) days after its date of issuance; however, refill(s) indicated on a prescription submitted within the seven (7) days for controlled substance listed in Schedule III, IV or V, may be filled after the seven (7) days of issuance. Any original prescription in need of being filled after the seven (7) days shall be renewed by a practitioner.
- (d) In an emergency, as defined by rules of DPHSS, a substance included in Schedule II may be dispensed upon oral prescription of a practitioner, reduced promptly to writing, signed by the practitioner, and filed by the pharmacy. The pharmacy shall keep prescriptions in conformity with § 67.306. A prescription for a substance included in Schedule II may not be refilled.
- (e) Except when dispensed directly by a practitioner, other than a pharmacy, to an ultimate user, a substance included in Schedule III or IV, which is a prescription drug as determined under this Act, may not be dispensed without a written or oral prescription of a practitioner. The prescription must not be refilled more than six (6) months after its date unless renewed by the practitioner.
- (f) A substance included in Schedule V may be distributed or dispensed only for a medical purpose, including medical treatment or authorized research
- (g) A practitioner may dispense or deliver a controlled substance to or for an individual or animal only for medical

treatment or authorized research in the ordinary course of that practitioner's profession.

- (h) No civil or criminal liability or administrative sanction may be imposed on a pharmacist for action taken in reliance on a reasonable belief that an order purporting to be a prescription was issued by a practitioner in the usual course of professional treatment or in authorized research.
- (i) An individual practitioner may not dispense a substance included in Schedule II, III or IV for that individual practitioner's personal use except in a medical emergency.

2011 NOTE: P.L. 24-149:2 repealed and reenacted this section without subsection (a) designation which Compiler assigned to harmoniously fit this chapter.

§ 67.308.2. Administering or Dispensing of Narcotic Drugs.

- (a) Narcotic drug dependent means an individual who physiologically needs heroin or a morphine-like drug to prevent the onset of signs of withdrawal.
- (b) The administering or dispensing, but not prescribing, of narcotic drugs listed in any schedule to a narcotic drug dependent person for "detoxification treatment" or "maintenance treatment" as defined in § 102 of the Federal Controlled Substances Act (21 U.S.C. § 802) shall be deemed to be within the meaning of the term "in the course of his professional practice or research" in § 308(e) and § 102(20) of the Federal Controlled Substances Act (21 U.S.C. § 828(e)); provided, that the practitioner is separately registered with the United States Attorney General as required by § 303(g) of the Federal Controlled Substances Act (21 U.S.C. § 823(g)) and then thereafter complies with the regulatory standards imposed relative to treatment qualification, security, records and unsupervised use of drugs pursuant to the Federal Controlled Substances Act.
- (c) Nothing in this Section shall prohibit a physician who is not specifically registered to conduct a narcotic treatment program from administering, but not prescribing, narcotic drugs to a person for the purpose of relieving acute withdrawal symptoms when necessary while arrangements are being made

for referral for treatment. Not more than one (1) day's medication may be administered to the person or for the person's use at one time. Such emergency treatment may be carried out for not more than three (3) days and may not be renewed or extended. This Section is not intended to impose any limitations on a physician or authorized hospital staff member to administer or dispense narcotic drugs in a hospital to maintain or detoxify a person as an incidental adjunct to medical or surgical treatment of conditions other than addiction, or to administer or dispense narcotic drugs to persons with intractable pain in which no relief or cure is possible or none has been found after reasonable efforts.

§ 67.309. Diversion Prevention and Control.

- (a) In this Section, "diversion" means the transfer of a controlled substance from a lawful to an unlawful channel of distribution or use.
- (b) DPHSS may periodically prepare and make available to other state regulatory, licensing and law enforcement agencies a report on the patterns and trends of distribution, diversion and abuse of controlled substances.
- (c) DPHSS and the Guam Police Department, with the assistance of the Attorney General, shall enter into written agreements with state and Federal agencies to improve identification of sources of diversion and to improve enforcement of and compliance with this Act and other laws and regulations pertaining to unlawful conduct involving controlled substances. An agreement must specify the roles and responsibilities of each agency that has information or authority to identify, prevent or control drug diversion and drug abuse. DPHSS, GPD and the Attorney General shall arrange for cooperation and exchange of information among agencies and with other states and the Federal government. DPHSS, GPD and the Attorney General shall report annually to the Governor and to the Speaker of the Guam Legislature on the outcome of the program with respect to its effect on distribution and abuse of controlled substances, including recommendations for improving control and prevention of the diversion of controlled substances in Guam.

Article 8. Salvia Divinorum. [Repealed]

NOTE: Appendices A, B, C, D, and E can be found at the end of the Chapter.

ARTICLE 1 DEFINITIONS

SOURCE: Article 1 was repealed and reenacted by P.L. 24-149:2 (Mar. 25, 1998).

NOTE: Pursuant to the authority granted by 1 GCA § 1606, numbers and/or letters were altered to adhere to the Compiler's general and alpha-numeric scheme.

§ 67.101. Definitions.

As used in this Act:

- (a) Act means the Uniform Controlled Substances Act of Guam.
- (b) Administer, unless the context otherwise requires, means to apply a controlled substance, whether by injection, inhalation, ingestion or any other means, directly to the body of a patient, an animal, or research subject by:
 - (1) a practitioner, or in the practitioner's presence, by the practitioner's authorized agent; or
 - (2) the patient or research subject at the direction and in the presence of the practitioner.
- (c) Anabolic Steroid means any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestin, and corticosteroids) that promotes muscle growth.
- (d) Attorney General means the Attorney General of Guam or any individual he designates.
- (e) (1) Controlled substance analog means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in or added to Schedule I or II and:

- (A) which has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II; or
- (B) with respect to a particular individual, which the individual represents or intends to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II; but
- (2) the term does not include:
 - (A) a controlled substance;
- (B) a substance for which there is an approved new drug application;
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under § 505 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355) to the extent conduct with respect to the substance is permitted by the exemption; or
- (D) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance.
- (f) Deliver or Delivery, unless the context otherwise requires, means to transfer a substance, actually or constructively, from one person to another, whether or not there is an agency relationship.
- (g) Guam Behavioral Health and Wellness Center ("GBHWC") means the Director of the Guam Behavioral Health and Wellness Center of the government of Guam, or its successor, or any individual he designates.

- (h) Department of Public Health and Social Services ("DPHSS") means the Director of the Department of Public Health and Social Services of the government of Guam, or its successor, or any individual of the department he designates.
- (i) Dispense means to deliver a controlled substance to the ultimate user, patient or research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling or compounding necessary to prepare the substance for that delivery.
 - (j) Dispenser means any person who dispenses.
- (k) Distribute means to deliver other than by administering or dispensing a controlled substance.
 - (1) Distributor means a person who distributes.
 - (m) Drug means:
 - (1) a substance recognized as a drug in the official United States Pharmacopoeia, National Formulary, or the official Homeopathic Pharmacopoeia of the United States, or a supplement to any of them;
 - (2) a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in individuals or animals;
 - (3) a substance, other than food, intended to affect the structure or a function of the body of individuals or animals; and
 - (4) a substance intended for use as a component of an article specified in this Paragraph. The term does not include a device or its components, parts or accessories.
- (n) Drug Enforcement Administration ("DEA") means the Drug Enforcement Administration of the United States Department of Justice, or its successor agency.

- (o) Guam Police Department ("GPD") means the Chief of Police of the Guam Police Department of Guam, or its successor, or any individual he designates.
 - (p) Immediate Precursor means a substance:
 - (1) that the Department of Public Health and Social Services has found to be, and by rule has designated to be, the principal compound used, or produced primarily for use, in the manufacture of a controlled substance:
 - (2) that is an immediate chemical intermediary used or likely to be used in the manufacture of the controlled substance; and
 - (3) the control of which is necessary to prevent, curtail or limit the manufacture of the controlled substance.
- (q) Inventory means all factory and branch stocks in finished form of a controlled substance manufactured or otherwise acquired by a registrant, whether in bulk, commercial containers or contained in pharmaceutical preparations in the possession of the registrant, including stocks held by the registrant under separate registration as a manufacturer, importer, exporter or distributor, and a list of such.
- (r) Isomer means an optical isomer, but in § 67.101(u)(5) Appendix A: (a)(12) and (a)(34), and Appendix B: (a)(4) of this Act, the term includes a geometric isomer; in Appendix A: (a)(1), (a)(8) and (a)(42), and Appendix D: (c). of this Act the term includes a positional isomer; and in Appendix A: (a)(35) and (c), and Appendix C: (a) of this Act the term includes a positional or geometric isomer.
- (s) Manufacture means to produce, prepare, propagate, compound, convert or process a controlled substance, directly or indirectly, by extraction from substances of natural origin, chemical synthesis, or a combination of extraction and chemical synthesis, and includes packaging

or repackaging of the substance or labeling or relabeling of its container. The term does not include the preparation, compounding, packaging, repackaging, labeling or relabeling of a controlled substance:

- (1) by a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner, or by the practitioner's authorized agent under the practitioner's supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale.
- (t) [Repealed].
- (u) Narcotic drug means any of the following, however manufactured:
 - (1) Opium, opium derivative and any derivative of either, including any salts, isomers and salts of isomers of them that are theoretically possible within the specific chemical designation, but not isoquinoline alkaloids of opium;
 - (2) synthetic opiate and any derivative of synthetic opiate, including any isomers, esters, ethers/salts, and salts of isomers, esters, and ethers of them that are theoretically possible within the specific chemical designation;
 - (3) poppy straw and concentrate of poppy straw;
 - (4) coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine and derivatives of ecgonine, or their salts, have been removed;
 - (5) cocaine, or any salt, isomer or salt of isomer of cocaine;
 - (6) cocaine base:

- (7) ecgonine, or any derivative, salt, isomer or salt of isomer of ecgonine; and
- (8) compound, mixture or preparation containing any quantity of a substance listed in this Paragraph.
- (v) Narcotic Treatment Program ("NTP") means a program engaged in maintenance and/or detoxification treatment with narcotic drugs.
- (w) Opiate means a substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. The term includes opium, opium derivatives and synthetic opiates. The term does not include, unless specifically scheduled as a controlled substance pursuant to § 67.201, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). The term includes the racemic and levorotatory forms of dextromethorphan.
- (x) Opium poppy means the plant of the species Papaver somnifarum L., except its seeds.
- (y) Person means an individual, corporation, business trust, estate, trust, partnership, association, joint venture, government or governmental subdivision or agency, or any other legal or commercial entity.
- (z) Pharmacist means any pharmacist licensed on Guam to practice his/her profession and any other person (e.g. pharmacist intern) authorized by Guam to practice under the supervision of a pharmacist licensed on Guam.
- (aa) Physician, dentist, veterinarian and podiatrist means any persons who are licensed to practice those respective professions in Guam.
- (bb) Poppy straw means all parts, except the seeds, of the opium poppy, after mowing.
- (cc) Practitioner means a physician, dentist, veterinarian, scientific investigator, pharmacist, pharmacy, hospital, government operated or government contracted

animal shelter, or other person licensed, registered, or otherwise permitted, by Guam, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research.

- (dd) Prescription means an order for medication which is dispensed to or for an ultimate user, but does not include an order for medication which is dispensed for immediate administration to the ultimate user (e.g. an order to dispense a drug to a bed patient for immediate administration in a hospital is not a prescription).
- (ee) Production, unless the context otherwise requires, includes the manufacturing of a controlled substance and the planting, cultivating, growing or harvesting of a plant from which a controlled substance is derived.
- (ff) Registrant means any person registered pursuant to this Act.
- (gg) State means a state of the United States, the District of Columbia, the Commonwealth of Puerto Rico or a territory or insular possession subject to the jurisdiction of the United States, including Guam.
- (hh) Ultimate user means an individual who lawfully possesses a controlled substance for the individual's own use or for the use of a member of the individual's household or for administering to an animal owned by the individual or by a member of the individual's household.
- (ii) Drug Free School Zone means any area within one thousand (1,000) feet of a public or private elementary, secondary or post secondary educational institution or its accompanying grounds; or within the vehicle of any school bus which transports students while in motion; or within two hundred fifty feet (250') of any school bus not in motion or a designated school bus stop or shelter, including any school bus transfer station. Notwithstanding the provisions of this Section, a Drug Free School Zone shall not include private real property which is not a school or the accompanying grounds of a school.

- (jj) School means any establishment, public or private, for the care and education of students from kindergarten through grade twelve (12) and any college or university or educational institution of higher learning.
- (kk) Accompanying Grounds means the respective campuses, recreational areas, athletic fields, student housing, or other property of each school which are owned, used, or operated by their respective governing boards of the schools or chief administrative officers in the case of a private school.
- (ll) Retailer or Retail Distributor means a grocery store, general merchandise store, drug store, other merchandise store, or other entity or person whose activities as a distributor relating to pseudoephedrine products are limited exclusively both in number of sales and volume of sales to on site sales.
- (mm) Synthetic cannabinoid means any chemical compound that is chemically synthesized and either:
 - (1) has been demonstrated to have binding activity at one or more cannabinoid receptors; or
 - (2) is a chemical analog or isomer of a compound that has been demonstrated to have a binding activity at one or more cannabinoid receptors.

SOURCE: Repealed and reenacted by P.L. 24-149:2. Subsections (35), (36) and (37) added by P.L. 26-125:3(a) (Sept. 4, 2002). Subsections (2) and (29) amended by P.L. 28-034:2 and 3 (Apr. 22, 2005). Subsection (38) added as subsection (33) by P.L. 28-088:1 (Dec. 12, 2005), renumbered by Compiler since subsections (33) through (37) are currently occupied. Subsection (mm) added by P.L. 32-018:1 (Apr. 11, 2013). Subsection (t) repealed pursuant to P.L. 35-005:4 (April 4, 2019).

2019 NOTE: P.L. 35-005:4 (April 4, 2019) stated: "marijuana is hereby declassified as a Schedule I Controlled Substance. Any reference by the Guam Uniform Controlled Substances Act to marijuana, such as 'marihuana,' 'tetrahydrocannabinol,' 'cannabis,' and derivatives thereof, shall be deemed repealed, null, and void upon the passage of this Act." In light of this language, subsection (t) was deemed repealed.

2013 NOTE: Pursuant to P.L. 32-024:2 (May 6, 2013) which renamed the Department of Mental Health and Substance Abuse (DMHSA) to the



Office of the Speaker THERESE M. TERLAJE

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

COMMITTEE REPORT DIGEST

I. OVERVIEW

<u>Bill No. 169-36 (LS)</u> was introduced on <u>Wednesday</u>, <u>August 4</u>, <u>2021</u>, by Senator Telena Cruz Nelson, and was referred by the Committee on Rules to the Committee on Health, Land, Justice and Culture on <u>Monday</u>, <u>August 9</u>, <u>2021</u>.

The Committee on Health, Land, Justice, and Culture convened a virtual public hearing on <u>Wednesday</u>, <u>January 19</u>, <u>2022</u>, <u>at 9:00 AM</u> utilizing the Guam Legislature's Virtual Hearing Platform.

Public Notice Requirements

Notices for this Virtual Public Hearing were published in the Guam Daily Post on Tuesday, January 11, 2022 (5 day Notice) again on Sunday, January 16, 2022 (48 Hour Notice), and via email to all senators and all main media broadcasting outlets on the same days.

Senators Present:

Speaker Therese M. Terlaje, Committee Chairperson
Senator Telena Cruz Nelson, Bill Sponsor and Committee Member
Senator Sabina Flores Perez, Committee Co Chairperson
Senator Amanda L. Shelton, Committee Member
Senator Telo T. Taitague, Committee Member
Senator Joanne M. Brown, Committee Member
Senator Christopher Dueñas, Committee Member
Senator V. Anthony Ada
Senator Mary Camacho Torres

Appearing Before the Committee:

Masatomo Nadeau, Chief EPHO, Division of Environmental Health, Department of Public Health & Social Services (DPHSS) William W. Weare, M.D.

Written Testimony Submitted:

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910

Tel: (671) 472-3586 | Fax: (671) 969-3590 | Email: senatorterlajeguam@gmail.com | www.senatorterlaje.com

*For transmittal of official Messages & Communications to the Guam Legislature to be distributed to all Senators,

please send to: Speaker@guamlegislature.org

Masatomo Nadeau, Chief Environmental Public Health Officer (EPHO), Division of Environmental Health, DPHSS, and Arthur San Agustin, Director, DPHSS

II. SUMMARY OF TESTIMONY & DISCUSSION

The virtual public hearing was Called to Order at <u>9:05 AM</u>. Bill No. 169 36(LS) was the second item on the agenda. Chairperson Therese M. Terlaje opened the hearing by inviting the Sponsor of the bill, Senator Telena Cruz Nelson, to provide a statement on the bill, before receiving public testimony on the bill.

SENATOR TELENA CRUZ NELSON: Thank you, Madam Chair. Bill Number 169 36 (LS), it's an act to amend Appendix A, Appendix B, Appendix C, Appendix D, and Appendix E of Chapter 26, Title 9 of Guam Code Annotated, relative to updating the list of scheduled controlled substances provided in the Guam Uniform Controlled Substances Act. The intent of this legislation is to properly update the list of scheduled controlled substance or substances to reflect federal regulations provided by Sections 1308.11, 1308.12, 1308.13, 1308.14 and 1308.15 of Title 21 of the Code of Federal Regulations relative to schedules of controlled substances. Pursuant to Chapter 67 of Title 9 of the Guam Code Annotated, DPHSS has the authority to administer this act and to add, delete, or otherwise update appendices A, B, C, D, and E in accordance with Section 67.201. The continued health and public safety of our island residents necessitates a unified legal framework that regulates the use dispensation and categorization of controlled substances with bill number 169 36 (LS), it updates Schedule One (1) through Schedule Five (5) of controlled substances based on their medical utility and potential for dependence or abuse. Thank you, Madam Speaker.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you very much, Senator Nelson. I'd like to acknowledge the presence of my colleagues. Senator Nelson, Senator Mary Torres, Senator Amanda Shelton, Senator Anthony Ada, Senator Telo Taitague, Senator Chris Duenas and Senator Joanne Brown. Thank you, colleagues. We'll now proceed with testimony beginning again with Masatomo Nadeau, Chief of the Division of Environmental Health, Department of Public Health and Social Services. Please proceed Mr. Nadeau.

MASATOMO NADEAU, CHIEF EPHO, DIVISION OF ENVIRONMENTAL HEALTH, DPHSS: Thank you, Speaker. *Håfa adai* Speaker, Health Chair Therese

2

Terlaje, Senator Telena Nelson and members of the Committee on Health, Land, Justice and Culture. I am Tom Nadeau, the Chief Environmental Public Health Officer with the Division of Environmental Health with the Department of Public Health and Social Services. On behalf of our Director, Arthur San Agustin, I would like to thank you for allowing the department to present his testimony on Bill 169 36, relative to update the list of schedule control substances provided in the Guam Uniform Controlled Substance Act of Title 9 Guam Code Annotated, Chapter 67. Before I begin, I would like to first point out that there's a typographical error and the Chapter numbering in Bill 169. The correct Chapter should read 67, not 26. This Bill 169 36 should be to amend appendices A, B, C, D, and E of chapters 67 of title 9 of GCA. The Department of Public Health and Social Services supports Bill 169 36.

As you may know, the Division of Environmental Health of this department administered the Guam Uniform Controlled Substance Act and is mandated by Section 67.301 F of the said Act to update the Controlled Substance Schedules pursuant to the Administrative Adjudication law. The schedule and listing of controlled substances were last updated on September 30th, 2011, via Public Law 31 110 and thus it was due for an update and Bill 169 36 will address that need. The passage of Bill 169 36 will properly align Guam's schedule listing to mirror those of the U.S. Drug Enforcement illustration under Federal Code of Regulations, Section 1308. We support the following changes to update the controlled substance schedule as proposed Bill 169 36.

I don't know if you'd like me to, but it's on the testimony there. Some of these are difficult to pronounce and I hate to butcher these words but definitely for Schedule One (1) Appendix A there are a total of 15 new opiates, 43 hallucinogenic substances and 22 temporary listing of substances, subject emergency scheduling that added to appendix A, a total of 40 cannabinoid agents were reclassified as well as halogenic substances and 12 daily from Appendix A. And for Schedule Two (2), which is Appendix B, opiate, opium and opiates were added to Schedule B. Schedule Three (3), which is Appendix C narcotic drug and now steroids, were added to Appendix C as well as the deletion of a couple of anabolic steroids. Scheduled Four (4) were requesting some changes as well, such as a narcotic drug to be added as well as one that was divided. Schedule Five (5), a total of four depressant drugs were added to Appendix E. So after almost a decade it is crucial that the list of scheduled drugs be updated and aligned with DEA. Not only will this benefit our law enforcement officers, the Attorney General's office, but also medical

practitioners in treatment of their patients. The department would like to thank you Speaker, and Senator Nelson for assisting us in sponsoring this important legislation. *Dångkulu na si yu'os ma'åse'*, thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you very much, Chief Nadeau. Is there anyone else on behalf of Public Health who would like to testify? If not, then we'll proceed with Dr. Weare.

WILLIAM W. WEARE, M.D.: Thank you, Senator Terlaje. I think this bill is long overdue and is basically the administrative manner that Public Health should be able to do on an ongoing basis. The one problem that I see is that Guam's laws and DEA's pronouncements differ widely when it comes to marijuana, and we need to make sure that any local rules apply here. I can see some other drugs that could have equal problems in the future. I don't think we need to discuss those now, but there needs to be some flexibility built in. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you very much, Dr. Weare. Is there anyone else who'd like to testify? I don't see anyone. I'd like to recognize the presence of Senator Sabina Perez who has joined us, and I'd like to note that we have a fiscal impact note from BMR, which states that the bill wasn't administrative in nature and poses no fiscal impact upon any of the funds of the government of Guam. Mr. Nadeau or Chief Nadeau, could you please confirm that for the Department of Public Health, that there would be no fiscal impact?

MASATOMO NADEAU, CHIEF EPHO, DIVISION OF ENVIRONMENTAL HEALTH, DPHSS: That's correct, Speaker. We're not just anticipating any kind of additional fee or any kind of financial challenges in regulations or this bill. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Alright, thank you and I want to note for the record we received immediately prior to the hearing, the legal review which states that some of the citations in this bill need to be corrected, as Mr. Nadeau stated earlier and there are additional ones where the existing code sections are not reflected properly. So, we will have to ensure that that is done.

So, my only question is the treatment of cannabis. Mr. Nadeau, if you could explain how this bill affects that?

MASATOMO NADEAU, CHIEF EPHO, DIVISION OF ENVIRONMENTAL

HEALTH, DPHSS: My understanding is it does not. There is no reference to cannabis sativa, the plant of marijuana. This addresses the other controlled substances that are not on the local listing, that are on the federal listing Speaker.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Right. Okay. Just want to make sure we're still consistent with our other laws. Right. So locally, this will not add any of that. Alright. So, Senator Nelson, you're recognized.

SENATOR TELENA CRUZ NELSON: Thank you, Madam Speaker. Yes, I wanted to make that comment that this bill is not inclusive of cannabis. So, it's not conflicting with our current local statute, and we did receive the response back from legal for the technical changes onto the bill. However, the content remains. That's all I have and thank you, Chief Nadeau for being present again, and Jeff and Dr. Weare. Thank you for being here.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Nelson. Senator Torres, you're recognized.

SENATOR MARY CAMACHO TORRES: Thank you. I have no questions or comments to the bill that is administrative in nature and long overdue. So, I certainly support it and thank the author for bringing it to our attention. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Torres. Legislative Secretary Shelton.

SENATOR AMANDA L. SHELTON: Thank you very much, Madam Speaker. I have no questions or comments for this bill other than to thank all those who are here today to testify, to contribute to this public hearing. Thank you very much.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Shelton. Senator Ada.

SENATOR V. ANTHONY ADA: Thank you Madam chair, Madam Speaker. I have no questions. I'd just like to thank everyone again for their testimony on this bill and I look forward to having this bill move forward in our session. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you. Senator Taitague.

SENATOR TELO T. TAITAGUE: *Si yu'os ma'åse'* Madam chair or Madam Speaker for the opportunity and again, thank those who are here today. Tom, especially Public Health for being here and testifying as well as others, Dr. Weare. And I hope this bill does not have any kind of delay as the other bill that was mentioned by other physicians to hold off on it. This bill doesn't need that type of delay. So, I'm looking forward to moving forward as expeditiously as possible. Thank you so much, Madam Chair for the opportunity.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Taitague. Chief Nadeau could you please on behalf of Public Health, let us know whether you believe this bill needs to be postponed?

MASATOMO NADEAU, CHIEF EPHO, DIVISION OF ENVIRONMENTAL HEALTH, DPHSS: No, I do not believe this bill needs to be postponed. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you very much. Senator Duenas. You're recognized, Minority Leader.

SENATOR CHRISTOPHER M. DUENAS: *Si yu'os ma'åse'* Madam Chair and I just share the comments by my colleagues. Thank you for those who have appeared today, and I look forward to supporting this bill going forward. *Si Yu'os ma'åse'* Madam chair.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: *Si Yu'os ma'åse'*. Senator Brown, you are recognized.

SENATOR JOANNE M. BROWN: Thank you very much, Madam Speaker. I really don't have any comments. I think the presentation has been relatively straightforward with regards to updating these, you know, listings for these controlled substances and I certainly also concur with our colleagues and thank the members of the panel from Public Health and our physicians that have participated and contributed their input with regards to bill 169. With that I have no further comment. Thank you.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Brown. Senator Sabina Perez.

SENATOR SABINA F. PEREZ: Thank you Speaker and thank you, Madam chair. Yeah, no comments except that I do appreciate the work that went into this to make sure that

it's up to date with the federal regulations considering a lot of changes in the ten years. So, *si Yu'os ma'åse'* to the sponsor. Thank you, Madam Speaker.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senators. Senator Nelson, you make close on the bill.

SENATOR TELENA CRUZ NELSON: Thank you, Madam chair. I just want to thank the DPHSS team for working with our office. It took us several months to make sure that we had the correct substances and their spelling. Right? So, thank you for vigorously working with us to get this updated into our current statute and thank you for all the hard work you've been doing throughout this time and the pandemic.

MASATOMO NADEAU, CHIEF EPHO, DIVISION OF ENVIRONMENTAL HEALTH, DPHSS: Thank you. You're welcome, ma'am.

CHAIRPERSON, SPEAKER THERESE M. TERLAJE: Thank you, Senator Nelson. There being no additional testimony this committee will consider Bill 169 36(LS) duly heard. The committee will remain open for submission of additional written testimony on Bill 168 36 (LS) and 169 36 (LS) for the next ten working days following the hearing. That isn't until February 2nd, 2022.

Testimony can be sent via email to <u>senatorterlajeguam@gmail.com</u> or hand delivered here to the Congress Building. This public hearing is now adjourned. The time is 10:51am. *Si Yu'os ma'åse' todus*.

The public hearing for Bill No. 169 36 (LS) was adjourned at 10:51AM.

III. FINDINGS & RECOMMENDATIONS

- Bill No. 169 36 (LS) received the support of the Division of Environmental Health, Department of Public Health and Social Services, and Dr. William W. Weare.
- Technical amendments were made to the title and body of the bill by the Committee, per the recommendations of the Guam Legislature's Legal Bureau, and the Department of Public Health & Social Services.

The Committee on Health, Land, Justice and Culture hereby reports out Bill No. 169-36 (LS)- As Amended by the Committee on Health, Land, Justice and Culture- Introduced by Senator Telena Cruz Nelson- "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT," with the recommendation TO DO PASS.

8

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN 2021 (FIRST) Regular Session

Bill No. 169-36 (LS)

Introduced b	by:
--------------	-----

1

Telena Cruz Nelson

AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE PEOPLE OF GUAM:

- 2 Section 1. Legislative Intent
- 3 I Liheslaturan Guåhan finds that the continued health and public
- 4 safety of the People of Guam necessitates a unified legal framework that regulates
- 5 the use, dispensation, and categorization of controlled substances. The purpose of
- 6 this bill is to update Schedule I through Schedule V of controlled substances based
- 7 on their medical utility and potential for dependence or abuse.
- 8 I Liheslaturan Guåhan further finds that the Department of Public health and
- 9 Social Services has the authority to administer this Act and to add, delete, or
- otherwise update Appendices A, B, C, D, and E in accordance with §67.201 under
- 11 Chapter 67, Title 9 of GCA. The following updated lists of controlled substances
- 12 are in accordance with DPHSS's findings and research.

1	It is therefore the intent of <i>I Liheslaturan Guåhan</i> and DPHSS to properly
2	update the list of scheduled drugs to reflect with federal regulations provided by
3	§1308.11, §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, Code of
4	Federal Regulations, relative to schedules of controlled substances.
5	Section 2. Appendix A of Title 9, Guam Code Annotated, is amended to
6	read:
7	(a) <i>Opiates</i> . Any of the following synthetic opiates,
8	including any their isomers, esters, ethers, salts, and
9	salts of isomers, esters, and ethers, whenever the
0	existence of such isomers, esters, ethers and salts is
11	others of them that are theoretically possible within the
12	specific chemical designation (for purposes of 3-
13	methylthiofentanyl only, the term isomer includes the
14	optical and geometric isomers):
15	(1) acetyl-alpha-methylfentanyl (N-[1-(l-
16	methyl-2-phenethyl)-4-piperidinyl]-N-
17	phenylacetamide);
18	(2) acetylmethadol;
9	(3) acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
20	N-phenylacetamide);
21	(4) acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-
	N-phenylacrylamide; other name:
22	acryloylfentanyl);
22 23 24	(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
25	cyclohexylmethyl]benzamide;
26	(3) (6) allylprodine;
	· ·
27	(4) (7) alphacetylmethadol (except levo-alphacetylmethadol
28	also known as levo-alpha- acetylmethadol, levomethadyl
29	acetate, or LAAM);
30	$\frac{(5)(8)}{(8)}$ alphameprodine;
31	(6) (9) alphamethadol;
32	$\frac{(7)(10)}{(7)}$ alpha-methylfentanyl (N-[1-(alpha-
33	methyl-beta-phenyl)ethyl-4-piperidyl]
34	propionanilide; 1-(l- methyl-2-phenylethyl)-4-(N-
35	propanilido) piperidine);
36	$\frac{(8)}{(11)}$ alpha-methylthiofentanyl (N-[1-methyl-2-
37	(2-thienyl)ethyl-4-piperidinyl]-N-

1 2	phenylpropanamide); (9) (12) benzethidine;
3 4 5	(10) (13) betacetylmethadol; (11) (14) beta-hydroxyfentanyl (<i>N</i> -[1-(2-hydroxy-2- phenethyl)-4-piperidinyl]- <i>N</i> -phenylpropamide);
6 7 8	(12) (15) beta-hydroxy-3-methylfentany1 (other name: N- [1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
9 10 11	(13) (16) <i>N</i> -[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]- <i>N</i> -phenylpropionamide (other name: <i>beta</i> -Hydroxythiofentanyl);
12 13	(14) (17) betameprodine; (15) (18) betamethadol;
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	(16) (19) betaprodine; (17) (20) butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); (18) (21) clonitazene; (19) (22) cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); (20) (23) dextromoramide; (21) (24) diampromide; (22) (25) diethylthiambutene; (23) (26) difenoxin; (24) (27) dimenoxadol; (25) (28) dimepheptanol; (26) (29) dimethylthiambutene; (27) (30) dioxaphetyl butyrate;
29 30	(28) (31) dipipanone; (29) (32) ethylmethylthiambutene;
31 32 33 34 35 36	(30) (33) etonitazene; (31) (34) etoxeridine; (32) (35) 4-Fluoroisobutyryl fentanyl (<i>N</i> -(4-fluorophenyl)- <i>N</i> -(1-phenethylpiperidin-4-yl)isobutyramide; other name: <i>para</i> -fluoroisobutyryl fentanyl);

1 2 3 4	(33) (36) furanyl fentanyl (<i>N</i> -(1-phenethylpiperidin-4-yl)- <i>N</i> -phenylfuran-2-carboxamide); (34) (37) furethidine;
5 6	(35) (38) hydroxypethidine; (36) (39) ketobemidone;
7 8 9 10 11	(37) (40) levomoramide; (38) (41) levophenacylmorphan; (39) (42) methoxyacetyl fentanyl (2-methoxy- <i>N</i> -(1-phenethylpiperidin-4-yl)- <i>N</i> -phenylacetamide); (40) (43) 3-methylfentanyl (<i>N</i> -[3-methyl-l-(2-
12 13	phenylethyl)-4-piperidyl]- <i>N</i> -phenylpropanamide);
14 15 16	(41) (44) 3-methylthiofentanyl (<i>N</i> -[(3-methyl-l-(2-thienyl)ethyl-4-piperidinyl]- <i>N</i> -phenylpropanamide);
17 18 19 20 21 22 23	(42) (45) morpheridine; (43) (46) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); (44) (47) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine); (45) (48) noracymethadol; (46) (49) norlevorphanol;
24 25	(47) (50) normethadone; (48) (51) norpipanone;
26 27 28	(49)-(52) ocfentanil (<i>N</i> -(2-fluorophenyl)-2-methoxy- <i>N</i> -(1-phenethylpiperidin-4-yl)acetamide);
29 30 31	(50)(53) ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide); other name: 2-fluorofentanyl;
32 33 34	(51)(54) para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
35 36 37	(52) (55) para-fluorofentanyl (<i>N</i> -(4-fluorophenyl)- <i>N</i> -[1-(2- phenethyl)-4-piperidinyl] propanamide; (53) (56) PEPAP (1-(-2-phenethyl)-4-phenyl-4-

1	acetoxypiperidine);
2	(54) (57) phenadoxone;
3	(55) (58) phenampromide;
4	(56) (59) phenomorphan;
5	(57) (60) phenoperidine;
6	(58) (61) piritramide;
7	(59) (62) proheptazine;
8	(60) (63) properidine;
9	(61) (64) propiram;
10	(62) (65) racemoramide;
11	(63) (66) tetrahydrofuranyl fentanyl (N-(1-
12	phenethylpiperidin-4-yl)-N-
13	<pre>phenyltetrahydrofuran-2-carboxamide);</pre>
14	(64) (67) thiofentanyl (<i>N</i> -phenyl- <i>N</i> -[1-(2-
15	thienyl)ethyl-4- piperidinyl]-propanamide);
16	(65) <u>(68)</u> tilidine; and
17	(66) (69) trimeperidine; and
18	(67)(70) U-47700(3,4-Dichloro-N-[2-
19	(dimethylamino)cyclohexyl]-N-
20	methylbenzamide).
21	(b) Opium derivatives. Any of the following opium
22	derivatives, including any its salts, isomers and salts of
23	isomers whenever the existence of such salts, isomers,
24	and salts of isomers is of them that are theoretically
25	possible within the specific chemical designation:
26	(1) acetorphine;
27	(2) acetyldihydrocodeine;
28	(3) benzylmorphine;
29	(4) codeine methylbromide;
30	(5) codeine-N-Oxide;
31	(6) cyprenorphine;
32	(7) desomorphine;
33	(8) dihydromorphine;
34	(9) drotebanol;
35	(10) etorphine (except hydrochloride salt);
36	(11) heroin;

1	(12) 111111111
1	(12) hydromorphinol;
2	(13) methyldesorphine;
3	(14) methyldihydromorphine;
4	(15) morphine methylbromide;
5	(16) morphine methylsulfonate;
6	(17) morphine-N-Oxide;
7	(18) myrophine;
8	(19) nicocodeine;
9	(20) nicomorphine;
10	(21) normorphine;
11	(22) pholcodine; and
12	(23) thebacon.
13	
14	(c) Hallucinogenic <u>substances</u> . Any material,
15	compound, mixture, or preparation which containsing
16	any quantity of the following hallucinogenic
17	substances, or which contains including any of its salts,
18	isomers, and salts of isomers whenever the existence of
19	such salts, isomers, and salts of isomers is of them that
20	are theoretically possible within the specific chemical
21	designation (for purposes of this paragraph only, the term
22	"isomer" includes the optical, position and geometric
23	isomers):
24	(1) Alpha-ethyltryptamine (some trade or other
25	names: etryptamine; Monase; alpha α-ethyl-lH-
26	indole-3-ethanamine; 3-(2-aminobutyl) indole;
27	alpha α-ET; and AET);
28	(2) 4-bromo-2,5-dimethoxy-amphetamine
29	(some trade or other names: 4-bromo-2,5-
30	dimethoxy- alpha α-methylphenethylamine; 4-
31	bromo-2,5-DMA);
32	(3) 4-bBromo-2,5-dimethoxyphenethylamine
33	(some trade or other names: 2-(4-bromo-2,5-
34	dimethoxyphenyl)-1-aminoethane; alpha-
35	desmethyl DOB; 2C-B, Nexus);
36	(4) 2,5-dimethoxyamphetamine (some trade or

1 2	other names: 2,5-dimethoxy- alpha α-methylphenethylamine; 2,5-DMA);
3 4	(5) 2,5-dimethoxy-4-ethylamphet-amine (some trade or other names: DOET);
5 6 7 8 9 10 11	 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7); (7) 4-methoxyamphetamine (some trade or other names: 4-methoxy-alphaα-methylphenethylamine;paramethoxyamphe tamine, PMA);
12 13 14 15 16 17	 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alphaα-methylphenethylamine; "DOM"; and "STP"); (10) 3,4-methylenedioxy amphetamine;
18 19 20 21 22	(11) 3,4-methylenedioxymethamphetamine (MDMA); (12) 3,4-methylenedioxy-N-ethylamphetamine (other names also known as: N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
23 24 25 26 27	(13) N-hydroxy-3,4- methylenedioxyamphetamine (other names also known as: N-hydroxy-alpha-methyl- 3,4(methylenedioxy)-phenethylamine, and N- hydroxy MDA);
28 29 30 31 32	(14) 3,4,5-trimethoxy amphetamine; (15) 5-methoxy-N,N-dimethyltryptamine (<u>some trade or</u> other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT; (16) Alpha-methyltryptamine (other name: AMT);
33 34 35 36 37	(17) bufotenine (<u>some trade or</u> other names: 3- (<u>betaβ</u> -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N- dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine);

1 2 3 4	 (18) diethyltryptamine (<u>some trade or</u> other names: N,N- Diethyltryptamine; DET); (19) dimethyltryptamine (<u>some trade or</u> other name: DMT);
5 6	(20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
7 8 9 10 11	(21) ibogaine (some trade or other names: 7- Ethyl-6,6Betaβ,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1²/,2²/:1,2] azepino [5,4-b] indole; Tabernanthe iboga); (22) lysergic acid diethylamide;
12 13 14 15 16	(23) [Repealed]; (24) mescaline; (25) parahexyl (<u>some trade or</u> other names: 3- Hexyl-l-hydroxy-7,8,9,10- tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl);
17 18 19 20 21 22 23	(26) peyote (meaning all parts of the plant presently classified botanically as <i>Lophophora</i> williamsii Lemaire, whether growing or not, it's the seeds thereof, any extract from any part of the such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts);
24 25	(27) N-ethyl-3-piperidyl benzilate;(28) N-methyl-3-piperidyl benzilate;
26 27 28	(29) psilocybin;(30) psilocyn;(31) [Repealed];
29 30 31 32 33	(32) ethylamine analog of phencyclidine (some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexy-1)ethylamine, N-(1-phenylcyclohexy-1)ethylamine, cyclohexamine, PCE);
34 35 36	(33) pyrrolidine analog of phencyclidine (<u>some</u> <u>trade or</u> other names: 1-(l-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);

1 2 3 4	(34) thiophene analog of phencyclidine (some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP); and
5	(35) TCPy (other name: 1-[1-(2-thieny-1)cyclohexyl]pyrrolidine)
6	(36) 4-methylmethcathinone (Mephedrone);
7	(37) 3,4-methylenedioxypyrovalerone (MDPV);
8 10	(38) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
11 12	(39) 2-(2,5-Dimethoxy-4- methylphenyl)ethanamine (2C-D);
13 14	(40) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
15 16	(41) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
17 18	(42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
19 20	(43) 2-[4-(Isopropylthio)-2,5- dimethoxyphenyl]ethanamine (2C-T-4);
21 22	(44) 2-(2,5-Dimethoxypheny-1)ethanamine (2C-H);
23 24	(45) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
25 26	(46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
27 28	(47) 3,4-Methylenedioxy-N-methylcathinone (Methylone);
29 30	(48) (1-pentyl-1 <i>H</i> -indol-3-yl)(2,2,3,3- tetramethylcyclopropy-1)methanone (UR-144);
31 32 33	(49) [1-(5-fluoro-pentyl)-1 <i>H</i> -indol-3-yl](2,2,3,3-tetramethylcyclopropy-1)methanone (5-fluoro-UR-144, XLR11);
34	(50) N-(1-adamantyl)-1-pentyl-1H-indazole-3-

1	carboxamide (APINACA, AKB48);
2 3	(51) quinolin-8-yl 1-pentyl-1 <i>H</i> -indole-3-carboxylate (PB-22; QUPIC);
4 5	(52) quinolin-8-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22);
6 7 8	(53) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);
9 10 11	(54) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 1-pentyl-1 <i>H</i> -indazole-3-carboxamide (ADB-PINACA);
12 13 14	(55) 2-(4-iodo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25I-NBOMe, 2C-I-NBOMe);
15 16 17	(56) 2-(4-chloro-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25C-NBOMe, 2C-C-NBOMe);
18 19 20	(57) 2-(4-bromo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)ethanamine (25B-NBOMe, 2C-B-NBOMe);
21	(58) 4-methyl- <i>N</i> -ethylcathinone (4-MEC);
22 23	(59) 4-methyl- <i>alpha</i> -pyrrolidinopropiophenone (4-MePPP);
24	(60) <i>alpha</i> -pyrrolidinopentiophenone (α-PVP);
25 26	(61) 1-(1,3-benzodioxol-5-yl)-2- (methylamino)butan-1-one (butylone, bk-MBDB);
27 28	(62) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
29 30 31	(63) 1-(1,3-benzodioxol-5-yl)-2- (methylamino)pentan-1-one (pentylone, bk- MBDP);
32 33	(64) 4-fluoro- <i>N</i> -methylcathinone (4-FMC; flephedrone);
34	(65) 3-fluoro-N-methylcathinone (3-FMC);

1 2	(66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-
_	yl)pentan-1-one (naphyrone);
3	(67) alpha-pyrrolidinobutiophenone (α -PBP);
4	(68) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
5	(cyclohexylmethyl)-1 <i>H</i> -indazole-3-carboxamide
6	(AB-CHMINACA);
7	(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
8	pentyl-1 <i>H</i> -indazole-3-carboxamide (AB-
9	PINACA);
10	(70) [1-(5-fluoropentyl)-1 <i>H</i> -indazol-3-
11	yl](naphthalen-1-yl)methanone (THJ-2201);
12	(71) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
13	1-(cyclohexylmethyl)-1 <i>H</i> -indazole-3-
14	carboxamide (MAB-CHMINACA; ADB-
15	<u>CHMINACA);</u>
16	(72) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
17	carboxamido)-3,3-dimethylbutanoate (Other
18	names: 5F-ADB; 5F-MDMB-PINACA);
19	(73) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
20	carboxamido)-3-methylbutanoate (Other names:
21	<u>5F-AMB);</u>
22	(74) <i>N</i> -(adamantan-1-yl)-1-(5-fluoropentyl)-1 <i>H</i> -
23	indazole-3-carboxamide (Other names: 5F-
24	APINACA, 5F-AKB48);
25	(75) <i>N</i> -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
26	1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-carboxamide
27	(Other names: ADB-FUBINACA);
28	(76) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-
29	3-carboxamido)-3,3-dimethylbutanoate (Other
30	names: MDMB-CHMICA, MMB-CHMINACA);
31	(77) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-
32	carboxamido)-3,3-dimethylbutanoate (Other
33	names: MDMB-FUBINACA); and
34	(78) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-
35	carboxamido)-3-methylbutanoate, (FUB-AMB,

1	MMB-FUBINACA, AMB-FUBINACA).
2	(d) <u>Depressants</u> . Any <u>Mm</u> aterial, compound,
3	mixture or preparation which containsing any quantity
4	of the following substances having a depressant effect
5	on the central nervous system, including any its salts,
6	isomers and salts of isomers whenever the existence of
7	such salts, isomers, and salts of isomers is of them that
8	are theoretically possible within the specific chemical
9	designation:
10	(1) gamma-hydroxybutyric acid (some other
11	names include GHB; gamma-hydroxybutyrate; 4-
12	hydroxybutyrate; 4-hydroxybutanoic acid; sodium
13	oxybate; sodium oxybutyrate);
14	(2) mecloqualone; and
15	(3) methaqualone.
16	(e) Stimulants. Any Mmaterial, compound,
17	mixture, or preparation which containsing any quantity
18	of the following substances having a stimulant effect on
19	the central nervous system, including its their salts,
20	isomers and salts of isomers:
21	(1) Aminorex (other names: aminoxaphen; 2-
22	amino- 5-phenyl-2-oxazoline; or 4,5-dihydro-5-
23	phenyl-2- oxazolamine);
24	(2) N-Benzylpiperazine (other names: BZP,
25	1- benzylpiperazine);
26	(3) Cathinone (other names: 2-amino-1-
27	phenyl-1- propanone; alpha-
28	aminopropiophenone; 2-
29	aminopropiophenone; and norephedrone);
30	(4) Fenethylline;
31	(5) Methcathinone (other names: 2-
32	(methylamino)- propiophenone; alpha-
33	(methylamino)propiophenone; 2-(methylamino)-
34	1-phenylpropan-l-one; alpha-N-
35	methylaminopropiophenone; monomethylpropion
36	ephedrone; <i>N</i> -methylcathinone; methylcathinone;
37	AL-464; AL-422; AL-463 and UR1432), its salts,
38	ontical isomers and salts of ontical isomers):

1 2 3 4 5 6 7	(6) (±/-±)cis-4-methylaminorex (other name: (±/- ±)cis-4,5-dihydro-4-methyl-5-phenyl-2- oxazolamine); (7) N-ethylamphetamine; and (8) N,N-dimethylamphetamine (other names: N,N- alpha-trimethyl-benzeneethanamine; N,N- alpha- trimethylphenethylamine).
8	(f) Cannabimimetic agents. Any material,
9	compound, mixture or preparation which contains any
10	quantity of the following substances or which contains
11	their salts, isomers, and salts of isomers whenever the
12	existence of such salts, isomers, and salts of isomers is
13	possible within the specific chemical designation:
14	(1) $5-(1,1-Ddimethylheptyl)-2-[(1R,3S)-3-$
15	hydroxycyclohexyl]-phenol, its optical, positional,
16	and geometric isomers, salts and salts of isomers
17	(other names: CP-47,497);
18	(2) 5-(1,1- <u>Dd</u> imethyloctyl)-2-[(1R,3S)-3-
19	hydroxycyclohexyl]-phenol, its optical, positional,
20	and geometric isomers, salts and salts of isomers
21	(other names: cannabicyclohexanol or CP-47,497
22	C8-homolog ue);
23	(3) 1-Butyl-3-(1-naphthoyl)indole, its optical,
24	positional, and geometric isomers, salts and salts
25	of isomers (other names: JWH- 073);
26	(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-
27	naphthoyl)indole, its optical, positional, and
28	geometric isomers, salts and salts of isomers
29	(other names: JWH-200);
30	(5) 1-Pentyl-3-(1-naphthoyl)indole, its optical,
31	positional, and geometric isomers, salts and salts
32	of isomers (other names: JWH-018 and AM678);
33	(6) (6aR,10aR)-9-(hydroxymethyl)-6,6-
34	dimethyl-3- (2methyloctan-2-yl)-6a,7,10,10a-
35	tetrahydrobenzo[c]chromen-1-ol (some trade or
36	other names: HU-210)
37	Salvia divinorum or Salvinorum A; all parts of

1 2 3 4 5 6	the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts;
7	(8) (7) 1-hexyl-3-(1-naphthoyl)indole (JWH–019);
8 9	(9) (8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250);
10 11 12 13 14 15 16 17 18	(10) (9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081); (11) (10) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122); (12) (11) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH– 398); (13) (12) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); (14) (13) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694); and
20 21	(15) (14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19 and RCS–4);
22 23 24	(16) (15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8); and
25 26 27	(17) (16) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH– 203); and (18) 4-methylmethcathinone (Mephedrone);
28 29	(19) 3,4-methylenedioxypyrovalerone (MDPV); (20)3,4-methylenedioxymethcathinone (methylone);
30 31 32 33 34	(21) Naphthylpyrovalerone (naphyrone); (22) 4-fluoromethcathinone (flephedrone); (23) 4-methoxymethcathinone (methedrone; Bk—PMMA); (24) Ethcathinone;
35 36 37	(25) 3,4-methylenedioxyethcathinone (ethylone); (26) Beta-keto-N-methyl-3,4- benzodioxyolybutanamine (butylone);

1 2	(27) N,N-dimethylcathinone (metamfepramone); (28) Alpha-pyrrolidinopropiophenone (alpha-PPP);
3	(29) 4-methoxy-alpha-
4	pyrrolidinopropiophenone (MOPPP);
5	(30) 3,4-methylenedioxy-alpha-
6	pyrrolidinopropiophenone (MDPPP);
7	(31) Alpha-pyrrolidinovalerophenone (alpha-PVP);
8	(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-
9	amine) (MDAI);
10	(33) 3-fluoromethcathinone;
11	(34) 4'-Methyl-α-pyrrolidinobutiophenone (MPBP);
12	(35) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
13	(2C E);
14	(36) 2-(2,5-Dimethoxy-4-
15	methylphenyl)ethanamine (2C D);
16	(37) 2-(4-Chloro-2,5-
17	dimethoxyphenyl)ethanamine (2C C);
18	(38) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine
19	(2C I);
20	(39) 2-[4-(Ethylthio)-2,5-
21	dimethoxyphenyl]ethanamine (2C-T-2);
22	(40) 2-[4-(Isopropylthio)-2,5-
23	dimethoxyphenyl]ethanamine (2C-T-4);
24	(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C H);
25	(42) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine
26	(2C N);
27	(43) 2-(2,5-Dimethoxy-4-(n)-
28	propylphenyl)ethanamine (2C P); and
29	(44) (17) any synthetic cannabinoid.
30	(g) <u>Temporary listing of substances subject to</u>
31	emergency scheduling. Any material, compound, mixture
32	or preparation which contains any quantity of the
33	following substances:
34	(1) N-(1-phenethylpiperidin-4-yl)-N-
35	phenylpentanamide, its isomers, esters, ethers,
36	salts and salts of isomers, esters and ethers (other
37	name: valeryl fentanyl);
38	(2) N-(4-methoxyphenyl)-N-(1-

1	phenethylpiperidin-4-yl)butyramide, its isomers,
2	esters, ethers, salts and salts of isomers, esters and
3	ethers (other name: para-methoxybutyryl
4	fentanyl);
5	(3) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
6	yl)isobutyramide, its isomers, esters, ethers, salts
7	and salts of isomers, esters and ethers (other name:
8	para-chloroisobutyryl fentanyl);
9	(4) N-(1-phenethylpiperidin-4-yl)-N-
10	phenylisobutyramide, its isomers, esters, ethers,
11	salts and salts of isomers, esters and ethers (other
12	name: isobutyryl fentanyl);
13	(5) N-(1-phenethylpiperidin-4-yl)-N-
14	phenylcyclopentanecarboxamide, its isomers,
15	esters, ethers, salts and salts of isomers, esters and
16	ethers (other name: cyclopentyl fentanyl);
17	(6) Naphthalen-1-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole-
18	3-carboxylate, its optical, positional, and
19	geometric isomers, salts and salts of isomers
20	(other names: NM2201; CBL2201);
21	(7) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
22	fluoropentyl)-1 <i>H</i> -indazole-3-carboxamide, its
23	optical, positional, and geometric isomers, salts
24	and salts of isomers (other names: 5F-AB-
25	PINACA);
26	(8) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-
27	1 <i>H</i> -indazole-3-carboximide, its optical, positional,
28	and geometric isomers, salts and salts of isomers
29	(other names: 4-CN-CUMYL-BUTINACA; 4-
30	cyano-CUMYL-BUTINACA; 4-CN-CUMYL
31	BINACA; CUMYL-4CN-BINACA; SGT-78);
32	(9) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-3-
33	carboxamido)-3-methylbutanoate, its optical,
34	positional, and geometric isomers, salts and salts
35	of isomers (other names: MMB-CHMICA, AMB-
36	CHMICA);
37	(10) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
38	1 <i>H</i> -pyrrolo[2,3-b]pyridine-3-carboxamide, its
39	optical, positional, and geometric isomers, salts
40	and salts of isomers (other names: 5F-CUMYL-

	D= (101)
1	P7AICA);
2	(11) N-Ethylpentylone, its optical, positional, and
3	geometric isomers, salts and salts of isomers
4	(other names: ephylone, 1-(1,3-benzodioxol-5-yl)-
5	2-(ethylamino)-pentan-1-one);
6	(12) ethyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
7	carboxamido)-3,3-dimethylbutanoate, its optical,
8	positional, and geometric isomers, salts and salts
9	of isomers (trivial name:5F-EDMB-PINACA);
10	(13) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indole-3-
11	carboxamido)-3,3-dimethylbutanoate, its optical,
12	positional, and geometric isomers, salts and salts
13	of isomers (trivial name: 5F-MDMB-PICA);
14	(14) <i>N</i> -(adamantan-1-yl)-1-(4-fluorobenzyl)-1 <i>H</i> -
15	indazole-3-carboxamide, its optical, positional,
16	and geometric isomers, salts and salts of isomers
17	(trivial names: FUB-AKB48; FUB-APINACA;
18	AKB48 N-(4-FLUOROBENZYL));
19	(15) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
20	1H-indazole-3-carboxamide, its optical, positional,
21	and geometric isomers, salts and salts of isomers
22	(trivial names: 5F-CUMYL-PINACA; SGT-25);
23	(16) (1-(4-fluorobenzyl)-1 <i>H</i> -indol-3-yl)(2,2,3,3-
24	tetramethylcyclopropyl) methanone, its optical,
25	positional, and geometric isomers, salts and salts
26	of isomers (trivial name: FUB-144);
27	(17) N-Ethylhexedrone, its optical, positional, and
28	geometric isomers, salts and salts of isomers
29	(Other name: 2-(ethylamino)-1-phenylhexan-1-
30	one;
31	(18) <i>alpha</i> -Pyrrolidinohexanophenone, its optical,
32	positional, and geometric isomers, salts and salts
33	of isomers (Other names: α -PHP; $alpha$ -
34	pyrrolidinohexiophenone; 1-phenyl-2-
35	(pyrrolidine-1-yl)hexan-1-one);
36	(19) 4-Methyl- <i>alpha</i> -ethylaminopentiophenone, its
37	optical, positional, and geometric isomers, salts
38	and salts of isomers (Other names: 4-MEAP; 2-
39	(ethylamino)-1-(4-methylphenyl)pentan-1-one);
40	(20) 4'-Methyl-alpha-pyrrolidinohexiophenone, its

1	optical, positional, and geometric isomers, salts
2	and salts of isomers (Other names: MPHP; 4'-
3	methyl-alpha-pyrrolidinohexanophenone; 1-(4-
4	methylphenyl)-2-(pyrrolidine-1-yl)hexan-1-one);
5	(21) alpha-Pyrrolidinoheptaphenone, its optical,
6	positional, and geometric isomers, salts and salts
7	of isomers (Other names: PV8; 1-phenyl-2-
8	(pyrrolidine-1-yl)heptan-1-one); and
9	(22) 4'-Chloro-alpha-pyrrolidinovalerophenone,
10	its optical, positional, and geometric isomers, salts
11	and salts of isomers (Other names: 4-chloro- α -
12	PVP; 4'-chloro-alpha-pyrrolidinopentiophenone;
13	1-(4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-
14	<u>one).</u>
15	
16	Section 3. Appendix B of Title 9, Guam Code Annotated, is amended to
10	Section 6. Appendix B of Thie 9, Suam Code Amnounced, is amended to
17	read:
1.0	(a) Substances reseatable evisive or chemical
18	(a) <u>Substances, vegetable origin or chemical</u>
19	synthesis. Any of the following substances, however-
20	manufactured whether produced directly or indirectly by
21 22	extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a
22	independently by means of chemical synthesis, or by a
23	combination of extraction and chemical synthesis:
24	(1) Opium and opiate, and any salt, compound,
25	derivative, or preparation of opium or opiate
26	excluding apomorphine, thebaine-derived
27	butorphanol, dextrorphan, nalbuphine,_
28	<u>naldemedine</u> , nalmefene, <u>naloxegol</u> , naloxone, <u>6β-</u>
29	<u>naltrexol</u> and naltrexone, and their respective
30	salts, but including the following:
31	(A) raw opium codeine;
32	(B) -opium extracts dihydroetorphine;
33	(C) opium fluidethylmorphine;
34	(D) powdered opiumetorphine hydrochloride;
35	(E) granulated opium;
35 36	(F) tincture of opiumhydrocodone;

(G)-codeinehydromorphone;
(H) ethylmorphine metopon;
(I) etorphinehydrochloridemorphine;
(J) hydrocodonenoroxymorphone;
(K) hydromorphoneopium extracts;
(L) metoponopium fluid;
(M) morphine or ipavine;
(N) oxycodone;
(O) oxymorphone;
(P) thebainepowdered opium;
(Q) dihydroetorphineraw opium; and
(R) oripavine.thebaine; and
(S) tincture of opium.
(2)Any salt, compound, derivative, or
preparation thereof which that is chemically
equivalent or identical with any of the
substances listed in Subparagraph (1)paragraph
(a) (1) of this section, except that these
substances shallbut not include the isoquinoline
alkaloids of opium;
(3) Opium poppy and poppy straw;
(4) Coca leaves and any salt, compound,
derivative, or preparation of coca leaves,-
(including cocaine and ecgonine and their salts,
isomers, derivatives, and salts of isomers and
derivatives), and any salt, compound,
derivative, or preparation that is thereof which
is chemically equivalent or identical with any of
these substances listed in this subparagraph, but
not including decocainized coca leaves or
extractions of coca leaves which do not contain
cocaine or ecgonine; and, except that the
substances shall not include:
(A) decocainized coca leaves or extraction
of coca leaves, which extractions do not
contain cocaine or ecgonine; or
(B) ioflupane; and

1 2 3 4	(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).
5 6 7 8 9 10 11 12	(b) <u>Opiates</u> . Any of the following synthetic opiates, including anyits isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, esters, and salts isof them that are theoretically possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted: (1) alfentanil;
13 14	(2) alphaprodine;(3) anileridine;
15 16 17	 (4) bezitramide; (5) carfentanilbulk dextropropoxyphene (non-dosage forms); (6) bulk dextropropoxyphene (non-dosage forms)carfentanil;
18 19	(7) dihydrocodeine;(8) diphenoxylate;
20 21 22 23 24	 (9) fentanyl; (10) isomethadone; (11) levomethorphanlevo-alphacetylmethadol [some other names: levo-alpha-acetylmethadol, levomethadyl acetate, LAAM];
25 26	(12) levorphanol levomethorphan;(13) metazocine levorphanol;
27 28 29 30	(14) methadonemetazocine; (15) methadone-intermediate,4-cyano- 2- dimethylamino-4,4-diphenyl butanemethadone;
31 32 33 34 35 36	(16) moramide-intermediate,2-methyl-3-morpholinō- 1,1-diphenylpropane-carboxylic acidmethadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane; (17) pethidine (meperidine)moramide-intermediate,2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid; (18) pathiding intermediate, A. 4, ayang 1
3/	(18) pethidine-intermediate-A,4-cyano-l-

1 2	methyl-4-phenylpiperidinepethidine (meperidine);
3	(19) pethidine-intermediate-B,ethyl-
4	4- phenylpiperidine-4-
5	carboxylatepethidine-intermediate-A,
6	4-cyano-1-methyl-4-
7	phenylpiperidine;
8 9	(20) pethidine-intermediate-C,1-methyl-
10	4- phenylpiperidine-4-carboxylic acidpethidine-intermediate-B, ethyl-4-
11	phenylpiperidine-4-carboxylate;
12 13	(21) phenazocinepethidine-intermediate-C, 1-methyl-4-
13	<pre>phenylpiperidine-4-carboxylic acid; (22) piminodinephenazocine;</pre>
15	(23) racemethorphan piminodine;
16	(24) racemorphan racemethorphan;
17	(25) remifentanil racemorphan;
18	(26) sufentanilremifentanil;
19	(27) levo-alphacetylmethadol (other names:
20	levo-alphaacetylmethadol, levomethadyl
21 22	acetate, LAAM); and sufentanil;
23	(28) tapentadol-; and
24	(29) thiafentanil.
25	(c) <u>Stimulants.</u> Any <u>Mm</u> aterial, compound,
26 27	mixture, or preparation containing which contains any quantity of the following substances having a
28	stimulant effect on the central nervous system:
29	(1) amphetamine, its salts, optical isomers, and
30	salts of its optical isomers;
31	
32	(2) methamphetamine, its salts, isomers, and salts of its isomers;
	ŕ
33	(3) phenmetrazine and its salts;
34	(4) methylphenidate; and (5) lighter forming, its solts, isomers, and solts.
35	(5) lisdexamfetamine, its salts, isomers, and salts
36 37	of its isomers. (d) Danyassants Any Mmaterial compound
31	(d) <u>Depressants</u> . Any <u>Mmaterial</u> , compound,

1	mixture, or preparation containing wnich contains any
2	quantity of the following substances having a depressant
3	effect on the central nervous system, including any its
4	salts, isomers, and salts of isomers of them that are
5	theoretically whenever the existence of such salts,
6	isomers, and salts of isomers is possible within the
7	specific chemical designation:
8	(1) amobarbital;
9	(2) pentobarbital;
10	(3) phencyclidine; and
11	(4) secobarbital; and
12	(5) glutethimide;
13	(e) Hallucinogenic substances.
14	(1) Nabilone (other names Another name for
15	nabilone: (+/-)-transtrans-3-(1,1-dimethylheptyl)-
16	6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6-
17	dimethyl-9H-dibenzo[b,d] pyran-9-one).
18	(f) Immediate precursors. Any Mmaterial, compound,
19	mixture, or preparation containing any quantity of the
20	following substances:
21	(1) Immediate precursor to amphetamine and
22	methamphetamine:
23	(A) phenylacetone (other names: phenyl-2-
24	propanone; P2P; benzyl methyl ketone;
25	methyl benzyl ketone);
26	(2) Immediate precursors to phencyclidine (PCP):
27	(A) 1-phenylcyclohexylamine; and
28	
29	(B) 1-piperidinocyclohexanecarbonnitrile (PCC).
	(3) Immediate precursor to fentanyl:
30	(A) 4-anilino-N-phenethylpiperidine (ANPP)
31	
32	Section 4. Appendix C of Title 9, Guam Code Annotated, is <i>amended</i> to read
33	
34	(a) Stimulants. Any A material, compound, mixture, or
35	
36	
37	

1	preparation which containings any quantity of the
2	following substances having a stimulant effect on the
3	central nervous system, including anyits salts, isomers
4	(whether optical, positional, or geometric), and salts of
5	such isomers whenever the existence of such salts,
6	isomers, and salts of isomers is of them that are
7	theoretically possible within the specific chemical
8	designation:
9	(1) Those A compounds, mixtures, or preparations in
10	dosage unit form containing any stimulant
11	substance included in Schedule II and which
12	compounds, mixtures, or preparations were
13	was listed as an excepted compound on August 25,
14	1971, pursuant to the federal Controlled
15	Substances Act, and any other drug of the
16	quantitative composition shown in that list for
17	those drugs or which is the same except for
18	containing a lesser quantity of controlled
19	substances;
20	(2) benzphetamine;
21	(3) chlorphentermine;
22	(4) clortermine; and
23	(5) phendimetrazine.
24	(b) <u>Depressants</u> . A Any material, compound,
25	mixture, or preparation containing any quantity of the
26	following substances having a depressant effect on the
27 27	central nervous system:
28	(1) A any compound, mixture, or preparation containing:
29 20	any of the following drugs or their salts and one
30	or more other active medicinal ingredients not
31	included in any schedule:
32	(A) amobarbital;
33	(B) secobarbital; and
34	(C) pentobarbital;
35	or any salt thereof and one or more other active medicinal
36	ingredients which are not listed in any schedule.
37	(2) any of the following drugs, or their salts, in
38	suppository dosage form, approved by the Federal

1 2	Food and Drug Administration for marketing only as a suppository:
3 4 5	(A) amobarbital;(B) secobarbital, and(C) pentobarbital.
6 7 8	(3) a substance containing any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid;
9	(4) chlorhexadol;
10	(5) embutramide;
11 12 13 14 15 16 17 18	(6) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug, and Cosmetic Act; (7) ketamine, its salts, isomers, and salts of isomers [(other names: (±)-2-(2-chlorophenyl)-2-(methylamino)- cyclohexanone)];
19 20 21	(8) lysergic acid;(9) lysergic acid amide;(10) methyprylon;
22	(11) sulfondiethylmethane; perampanel, and its salts, isomers
23	and salts of isomers.
24	(12) sulfonethylmethane; sulfondiethylmethane;
25 26 27 28 29 30 31 32	(13) sulfonmethane; sulfonethylmethane; (14) tiletamine and zolazepam, or any salt thereof (other names for a tiletamine-zolazepam combination product: Telazol; other names for tiletamine: 2- (ethylamino)-2-(2-thienyl)-cyclohexanone; other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8- trimethylpyrazolo-[3,4-ee] [1,4]-diazepin-7(1HH)-one, flupyrazapon; sulfonmethane; (15) tiletamine and zolazepam, or any salt thereof
34 35 36 37	(Some trade or other names for a tiletamine-zolazepam combination product: Telazol;. Some trade or other names fortiletamine: 2-

1 2 3 4	(ethylamino)-2-(2-thienyl)-cyclohexanone; <u>Some trade or</u> other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-ee] [1,4]-diazepin-7(1HH)-one, flupyrazapon;
5	(c) Nalorphine
6	(d) Narcotic Drugs.
7	(1) A Any material, compound, mixture, or preparation containing any
8	of the following narcotic drugs, or their salts calculated as the free
9	anhydrous base or alkaloid, in limited quantities as set forth below:
10	(A) not more than 1.8 grams of codeine
11	per 100 milliliters or not more than 90 milligrams per dosage
12	unit, with an equal or greater quantity of an isoquinoline alkaloid
13	of opium
14	(B) not more than 1.8 grams of codeine per
15	100 milliliters or not more than 90 milligrams per
16	dosage unit, with one or more active, nonnarcotic
17	ingredients in recognized therapeutic amounts;
18	(C) not more than 300 milligrams of
19	dihydrocodeine (hydrocodone) per 100 milliliters
20	or not more than 15 milligrams per dosage unit,
21	with one or more active-nonnarcotic ingredients in
22	recognized therapeutic amounts;
23	(D) (C) not more than 300 milligrams of
24	dihydrocodeine (hydrocodone) per 100 milliliters
25	or not more than 15 milligrams per dosage unit,
26	with one or more active-nonnarcotic ingredients in
27	recognized therapeutic amounts;
28	(E) (D) not more than 1.8 grams of
29	dihydrocodeine per 100 milliliters or not more
30	than 90 milligrams per dosage unit, with one or
31	more active, nonnarcotic ingredients in recognized
32	therapeutic amounts;
33	(F) (E) not more than 300 milligrams of
34	ethylmorphine per 100 milliliters or not more than
35	15 milligrams per dosage unit, with one or more
36	active, nonnarcotic ingredients in recognized
37	therapeutic amounts;
38	(G) (F) not more than 500 milligrams of
	25

100 1111
opium per 100 milliliters or per 100 grams, or not
more than 25 milligrams per dosage unit, with one
or more active, nonnarcotic ingredients in
recognized therapeutic amounts; and
(H) (G) not more than 50 milligrams of
morphine per 100 milliliters or per 100 grams
with one or more active, nonnarcotic ingredients
in recognized therapeutic amounts.
(2) A Any material, compound, mixture, or
preparation containing any of the following narcotic
drugs and or its their or their salts as set below: (A) Buprenorphine;
(e) Anabolic Steroids.
Any drug or hormonal substance chemically and
pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
dehydroepiandrosterone), and includes:
(1) 3 <u>β[beta]</u> ,17-dihydroxy-5a-androstane;
. , , , , , , , , , , , , , , , , , , ,
(2) $3\alpha \frac{\text{[alpha]}}{17\beta \text{[beta]}}$ -dihydroxy-5a-androstane;
(3) 5 <u>α[alpha]</u> -androstan-3,17-dione;
(4) 1-androstenediol (3 $\underline{\beta}$ [beta],17 $\underline{\beta}$ [beta]-
dihydroxy-5 α [alpha]-androst-1-ene);
(5) 1-androstenediol (3 <u>α[alpha]</u> ,17 <u>β[beta]</u> -
dihydroxy-5 <u>α[alpha]</u> -androst-1-ene);
(6) 4-androstenediol $(3\underline{\beta}[\text{beta}], 17\underline{\beta}[\text{beta}]$ -
dihydroxy-androst-4-ene;
(7) 5-androstenediol (3 $\underline{\beta}$ [beta],17 $\underline{\beta}$ [beta]-
dihydroxy-androst-5-ene);
(8) 1-androstenedione ($[5\underline{\alpha}\{alpha\}\}]$ -androst-1-en-3,17-
dione;
(9)4-androstenedione (androst-4-en-3,17-dione);
(10)5-androstenedione (androst-5-en-3,17-dione);
(11) bolasterone (7 <u>α[alpha]</u> ,17 <u>α[alpha]</u> -
dimethyl-17 <u>β[beta]</u> -hydroxyandrost-4-en-3 <u>-</u> one);
(12) boldenone (17 <u>β[beta]</u> -hydroxyandrost-1,4-
diene-3-one);
(13) boldione (androsta-1,4-diene-3,17-dione);
(14) calusterone (7 <u>β[beta]</u> ,17 <u>α[alpha]</u> -dimethyl-

1 2 3 4 5 6	17 <u>β[beta]</u> -hydroxyandrost-4-en-3-one); (15) chlorotestosterone (4 chlortestosterone), (16) (15) clostebol (4-chloro-17 <u>β[beta]</u> -hydroxyandrost-4-en-3-one); (17) (16) dehydrochloromethyltestosterone (4-chloro- 17 <u>β[beta]</u> -hydroxy-17 <u>α[alpha]</u> -methyl-
7	androst-1,4-dien-3-one);
8	(18) (17) desoxymethyltestosterone
9	$(17\underline{\alpha}[alpha]-methyl-5\underline{\alpha}[alpha]-androst-2-en-170[betal, al) (a.lr. a. 'madal')$
10 11	17 <u>β[beta]</u> -ol) (a.k.a 'madol <u>'</u>) (19) <u>(18) [Delta]</u> <u>Δ</u> 1-dihydrotestosterone
12	(a.k.a. '1- testosterone') $(17\underline{\beta} \text{ [beta]}$ -
13	hydroxy- 5α [alpha]-androst-1-en-3-one);
14	(20) (19) 4-dihydrotestosterone
15	$(17\underline{\beta}[\text{beta}]-\text{hydroxy-androstan-3-one});$
16	(21) (20) drostanolone $(17\underline{\beta}[beta]-hydroxy-$
17	$2\underline{\alpha}$ [alpha]-methyl- $5\underline{\alpha}$ [alpha]-androstan-3-one);
18	(22) (21) ethylestrenol (17 α [alpha]-
19	ethyl-17 <u>β[beta]</u> -hydroxyestr-4-ene);
20	(23) (22) fluoxymesterone (9-fluoro-17 α [alpha]-
21	methyl- $11\underline{\beta}[\text{beta}], 17\underline{\beta}[\text{beta}]$ -dihydroxyandrost-
22	4-en-3-one);
23	(24) (23) formebolone (2-formyl-17 α [alpha]-
24	methyl- $11\underline{\alpha}$ [alpha], $17\underline{\beta}$ [beta]-
25	dihydroxyandrost-1,4-dien-3-one);
26	(25) (24) furazabol $(17\alpha \text{[alpha]}\text{-methyl-}$
27	$17\underline{\beta}$ [beta]-hydroxyandrostano[2,3-c]-
28	furazan);
29	(26) (25) $13\underline{\beta}$ [beta]-ethyl- $17\underline{\beta}$ [beta]-hydroxygon-4-en-3-one;
30	(27) (26) 4-hydroxytestosterone $(4,17\underline{\beta}[beta]$ -
31	dihydroxy-androst-4-en-3-one);
32	(28) (27) 4-hydroxy-19-nortestosterone
33	$(4,17\underline{\beta}[\text{beta}]-\text{dihydroxy-estr-4-en-3-}$
34 35	one);mestanolone ($17\underline{\alpha}$ [alpha]-methyl- $17\underline{\beta}$ [beta]-hydroxy-5-androstan-3-one);
36	(29) desoxymethyltestosterone $(17\alpha[alpha]$
37	methyl- 5α [alpha]-androst-2-en- 17β [beta]-ol)
51	

(a.k.a 'madol')
(30) (28) mestanolone (17 α [alpha]-methyl-17
$\underline{\beta}$ [beta]-hydroxy-5-androstan-3-one);
(31) (29) mesterolone $(1\alpha \text{ alpha})$ methyl-
$17\underline{\beta}$ [beta]-hydroxy-[5 $\underline{\alpha}$ [alpha]]-androstan-3-
one);
(32) (30) methandienone $(17\alpha[alpha]$
methyl-17 <u>β[beta]</u> -hydroxyandrost-1,4-dien-
3-one);
(33) (31) methandriol (17 α [alpha]-methyl-
$3\underline{\beta}$ [beta], $17\underline{\beta}$ [beta]-dihydroxyandrost-5-ene);
(34) (32) methasteroneandranone (2α [alpha], 17α [alpha]-dimethyl- 5α [alpha]-androstan- 17α [beta]-ol-3-one);
(35) methandrostenolone;
(36) (33) methandrostenorone, (36) (33) methandrostenorone (1-methyl-17 β [beta]-hydroxy-
$5\underline{\alpha}$ [alpha]-androst-1-en-3-one);
(37) (34) 17α [alpha]-methyl- 3β [beta], 17β [beta]-
dihydroxy-5a-androstane;
(38) (35) 17α [alpha]-methyl-
$3\underline{\alpha}$ [alpha], $17\underline{\beta}$ [beta]-dihydroxy-5a-androstane;
(39) (36) 17α [alpha]-methyl-
$3\underline{\beta}$ [beta], $17\underline{\beta}$ [beta]-
dihydroxyandrost-4-ene;
$(40) (37) 17 \alpha [alpha]$ -methyl-4-
hydroxynandrolone($17\underline{\alpha}$ [alpha]-methyl-
4-hydroxy-17 <u>β[beta]</u> -hydroxyestr-4-en-
3-one);
(41) (38) methyldienolone (17 α [alpha]-
methyl-17 $\underline{\beta}$ [beta]-hydroxyestra-4,9(10)-dien-
3-one); (42) (39) methyltrienolone (17 α [alpha]-
methyl-17 $\underline{\beta}$ [beta]-hydroxyestra-4,9-11-trien-
3-one);
(43) (40) methyltestosterone $(17\alpha = 17)$
methyl-17 <u>β[beta]</u> -hydroxyandrost-4-en-3-one);
(44) (41) mibolerone

```
1
                                                        (7\alpha \frac{\text{falpha}}{1}, 17\alpha \frac{\text{falpha}}{1} - \text{dimethyl}
  2
                                                        17β<del>[beta]</del>-hydroxyestr-4-en-3-one);
  3
                                                        (45) (42) 17\alpha [alpha]-methyl-[Delta]\Delta1-
                                                        dihydrotestosterone (17<u>β</u><del>[beta]</del>-hydroxy-
  4
  5
                                                        17\alpha[alpha]-methyl-5\alpha[alpha]-androst-1-en-3-
  6
                                                        one) (a.k.a. '17-\alpha[alpha]-methyl-1-
  7
                                                        testosterone";);
  8
                                                        (46) (43) nandrolone (17\beta[beta]-hydroxyestr-4-en-3-one);
  9
                                                        (47) (44) 19-nor-4-androstenediol
10
                                                        (3\beta fbeta], 17\beta fbeta]-dihydroxyestr-4-ene);
                                                        (48) (45) 19-nor-4-androstenediol
11
                                                        (3\alpha \frac{\text{[alpha]}}{17\beta \frac{\text{[beta]}}{1}} - \text{dihydroxyestr-4-ene)};
12
                                                        (49) (46) 19-nor-5-androstenediol (3\beta \text{Fbeta}),
13
                                                        17β<del>[beta]</del>-dihydroxyestr-5-ene);
14
                                                        (50) (47) 19-nor-5-androstenediol
15
                                                        (3\alpha \frac{\text{[alpha]}}{17\beta \frac{\text{[beta]}}{17\beta \frac{\text{[beta]}}}}}}
16
17
                                                        (51) (48) 19-nor-4,9(10)-
                                                        androstadienedione(estra-4,9(10)-diene-3,17-
18
19
                                                        dione);
20
                                                        (52)(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
                                                        (53)(50)19-nor-5-androstenedione(estr-5-en-3,17-dione);
21
                                                        (54) (51) norbolethone
22
                                                        (13\beta fbeta], 17\alpha falpha]-diethyl-17\beta fbeta]-
23
                                                        hydroxygon-4-en-3-one);
24
                                                        (55) (52) norclostebol (4-chloro-17β[beta]-
25
26
                                                        hydroxyestr-4-en-3-one);
27
                                                        (56) (53) norethandrolone (17\alpha[alpha]-
28
                                                        ethyl-17β<del>[beta]</del>-hydroxyestr-4-en-3-one);
29
                                                        (57) (54) normethandrolone (17\alpha[alpha]-
                                                        methyl-17β<del>[beta]-</del>hydroxyestr-4-en-3-one);
30
31
                                                        (58) (55) oxandrolone (17\alpha[alpha]-methyl-
32
                                                        17\underline{\beta}[beta]-hydroxy-2-oxa-[5\underline{\alpha}[alpha]]-androstan-
33
                                                        3-one);
34
                                                        (59) (56) oxymesterone (17\alpha[alpha]-methyl-4,17\beta[beta]-
35
                                                        dihydroxyandrost-4-en-3-one;
```

1 2 3 4	(60) (57) oxymetholone (17α[alpha]-methyl-2-hydroxymethylene-17 <u>β[beta]</u> -hydroxy-[5α[alpha]]-androstan-3-one); (61) stanolone;
5 6 7 8 9	$\frac{(62)}{(58)}$ prostanozol (17β[beta]-hydroxy-5α[alpha]-androstano[3,2-c]pyrazole); $\frac{(63)}{(59)}$ stanozolol (17α[alpha]-methyl-17β[beta]-hydroxy-[5α[alpha]]-androst-2-eno[3,2-c]-pyrazole);
10 11 12	(64) (60) stenbolone (17 <u>β[beta]</u> -hydroxy-2-methyl-[5 <u>α[alpha]]</u> -androst-1-en-3-one);
13 14 15 16 17 18 19 20 21 22	(65) (61) testolactone (13-hydroxy-3-oxo-13,17- secoandrosta-1,4-dien-17-oic acid lactone); (66) (62) testosterone (17 <u>β[beta]-hydroxyandrost-4-en-3-one);</u> (67) (63) tetrahydrogestrinone (13 <u>β[beta],17α[alpha]-diethyl-17β[beta]-hydroxygon-4,9,11-trien-3-one);</u> (68) (64) trenbolone (17 <u>β[beta]-hydroxyestr-4,9,11-trien-3-one);</u> and
23 24 25 26 27 28 29 30 31 32 33 34 35 36	(69) (65) Any salt, ester, or ether of a drug or substance described-or listed in (1) through (66) above, if that salt, ester, or ether promotes muscle growth. in this paragraph. Except such term does not include an anabolic steroid which that is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.

DPHSS may exempt by rule a compound, 1 mixture, or preparation containing a stimulant or 2 depressant substance listed in subsections A and B from 3 the application of all or part of this Act, if the 4 compound, mixture, or preparation contains one or 5 more active medicinal ingredients not having a stimulant 6 or depressant effect on the central nervous system and 7 the admixtures are in combinations, quantity, 8 proportion, or concentration that vitiate the potential 9 for abuse of the substances having a stimulant or 10 depressant effect on the central nervous system. 11 (f) *Hallucinogenic substances*. 12 Dronabinol (synthetic) in sesame oil and 13 encapsulated in a soft gelatin capsule in a 14 U.S. Food and Drug Administration approved product 15 (Some other names for dronabinol: (6aR-trans)-16 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*-17 dibenzo[b,d]pyran-1-ol]18 Section 5. Appendix D of Title 9, Guam Code 19 Annotated, is amended to 20 read: 21 (a) Narcotic drugs. A Any material, compound, mixture, 22 or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous 23 base or alkaloid, in limited quantities as set forth below: 24 (1) not more than 1 milligram of different and 25 not less than 25 micrograms of atropine sulfate 26 per dosage unit; 27 (2) dextropropoxyphene (dosage forms); and 28 dextropropoxyphene (alpha-(+)-4-dimethylamino-29 1,2- diphenyl-3-methyl-2-propionoxybutane); and 30 (3) 2-[(dimethylamino)methyl]-1-(3-31 methoxyphenyl)cyclohexanol, its salts, optical and geometric 32 isomers and salts of these isomers (including tramadol). 33 (b) <u>Depressants</u>. A Any material, compound, 34 mixture, or preparation which contain any quantity of 35 the following substances having a depressant effect on 36 the central nervous system, including any salts, 37

38

1	isomers, and salts of isomers whenever the existence
2	of such salts, isomers, and salts of isomers is of
3	them that are theoretically possible within the
4	specific chemical designation:
5	(1) alfaxalone
6	(1) <u>(2)</u> alprazolam;
7	(2) (3) barbital;
8	(3) (4) brexanolone;
9	$\frac{(4)}{(5)}$ bromazepam;
10	(5) <u>(6)</u> camazepam;
11	(6) <u>(7)</u> carisoprodol;
12	(7) (8) chloral betaine;
13	(8) (9) chloral hydrate;
14	(9) (10) chlordiazepoxide;
16	(10) <u>(11)</u> clobazam;
17	(11) (12) clonazepam;
18	(12) (13) clorazepate;
19	(13) (14) clotiazepam;
20	(14) <u>(15)</u> cloxazolam;
21	(15) (16) delorazepam;
22	(16) <u>(17)</u> diazepam;
23	(17) (18) dichloraphenazone;
24	(18) <u>(19)</u> estazolam;
25	(19) <u>(20)</u> ethchlorvynol;
26	(20) (21) ethinamate;
27	(21) (22) ethyl loflazepate;
28	(22) (23) fludiazepam;
29	(23) (24) flunitrazepam;
30	(24) (25) flurazepam;
31	(25) (26) fospropofol;
32	(26) (27) halazepam;
33	(27) <u>(28)</u> haloxazolam;
34	(28) <u>(29)</u> ketazolam;

1	(29) (30) loprazolam;
2	(30) (31) lorazepam;
3	(31) (32) lormetazepam;
4	(32) (33) mebutamate;
5	(33) (34) medazepam;
6	(34) (35) meprobamate;
7	(35) (36) methohexital;
8	(36) (37) methylphenobarbital (mephobarbital);
9	(37) (38) midazolam;
10	(38) (39) nimetazepam;
11	(39) (40) nitrazepam;
12	(40) (41) nordiazepam;
13	(41) (42) oxazepam;
14	(42) (43) oxazolam;
15	(43) (44) paraldehyde;
16	(44) (45) petrichloral;
17	(45) (46) phenobarbital;
18	(46) (47) pinazepam;
19	(47) (48) prazepam;
20	(48) (49) quazepam;
21	(49) (50) suvorexant;
22	(50) (51) temazepam;
23	(51) (52) tetrazepam;
24	(52) <u>(53)</u> triazolam;
25	(53) <u>(54)</u> zaleplon;
26	(54) (55) zolpidem; and
27	(55) (56) zopiclone.
28	(c) Fenfluramine. Any material, compound,
29	mixture, or preparation which contains any quantity of
30	the following substances, including its salts, isomers
31	(whether optical, position, or geometric), and salts of
32	such isomers, whenever the existence of such salts,
33	isomers, and salts of isomers is possible:
34	(1) fenfluramine.

1 2 3 4 5	(d) Lorcaserin. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts isomers and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible. (1) lorcaserin.
7	(e) Stimulants. AAny material, compound,
8	mixture, or preparation containing any quantity of the
9	following substances having a stimulant effect on the
10	central nervous system, including their salts, isomers,
11	and salts of isomers:
12	(1) cathine ((+)-norpseudoephedrine);
13	(2) diethylpropion;
14	(3) fencamfamin;
15	(4) fenproporex;
16	(5) mazindol;
17	(6) mefenorex;
18	(7) modafinil;
19	(8) pemoline (including organometallic
20	complexes and chelates thereof);
21	(9) phentermine;
22	(10) pipradrol;
23	(11) sibutramine;
24	(12) solriamfetol (2-amino-3-phenylpropyl carbamate;
25	benzenepropanol, beta-amino-carbamate (ester)); and
26	$\frac{(12)(13)}{(13)}$ SPA ((-)-1-dimethylamino-1,2-diphenylethane).
27	(e)(f) Other substances. A Any material,
28	compound, mixture, or preparation containing any
29	quantity of the following substance, including its salts:
30	(1) pentazocine;
31	(2) butorphanol (including its optical isomers); and
32	(3) eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-
33	dimethylphenyl]-1-oxopropyl][(1S)-1-4-phenyl-1H-imidazol-
34	2-yl)ethyl]amino]methyl]-2-methoxybenzoicacid)(including
35	its optical isomers) and salts of isomers.

(f) (g) DPHSS may exempt by rule any compound, 1 mixture, or preparation containing a depressant 2 substance listed in subsection B from the application 3 of all or part of this Act, if the compound, mixture, or 4 preparation contains one or more active medicinal 5 ingredients not having a depressant effect on the 6 central nervous system and the admixtures are in 7 combinations, quantity, proportion, or concentration 8 that vitiate the potential for abuse of the substances 9 having a depressant effect on the central nervous 10 system. 11 **Section 6.** Appendix E of Title 9, Guam Code Annotated, is *amended* to 12 13 read: (a) *Narcotic drugs*. Unless specifically excepted or 14 unless listed in another schedule, any material, 15 compound, mixture, or preparation containing any of 16 the following narcotic drugs and their salts, as set forth 17 below: 18 (b) Narcotic drugs containing non-narcotic active 19 medicinal ingredients. A Any compound, mixture, or 20 preparation containing any of the following narcotic 21 drugs, or their salts calculated as the free anhydrous 22 base or alkaloid, in limited quantities as set forth below, 23 which shall include also contains one or more non-24 narcotic active medicinal ingredients in sufficient 25 proportion to confer upon the compound, mixture, or 26 preparation, valuable medicinal qualities other than 27 those possessed by the narcotic drugalone: 28 (1) not more than 200 milligrams of codeine 29 per 100 milliliters or per 100 grams; 30 (2) not more than 100 milligrams of 31 dihydrocodeine per 100 milliliters or per 100 32 grams; 33 (3) not more than 100 milligrams of 34 ethylmorphine per 100 milliliters or per 100 35 grams; 36 (4) not more than 2.5 milligrams of 37

38

1 2 3 4 5 6 7 8 9 10 11 12	diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; (5) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and (6) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. (c) Stimulants. A Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:
13	(1) pyrovalerone;
14 15 16	(d) <u>Depressants</u> . A Any material, compound, mixture, or preparation which containsing any quantity of the following substances having a <u>depressant</u> stimulant
17	effect on the central nervous system, including their
18	its salts:, isomers and salts or isomers:
19 20 21 22	(1) brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts);
23 24 25 26 27 28	(2) cenobamate ([(1R)-1-(2-chlorophenyl)-2- (tetrazol-2-yl)ethyl]carbamate; 2 <i>H</i> -tetrazole-2- ethanol, alpha-(2-chlorophenyl)-, carbamate(ester), (alpha <i>R</i>)-; carbamic acid (<i>R</i>)- (+)-1-(2-chlorophenyl)-2-(2 <i>H</i> -tetrazol-2-yl)ethyl ester);
29 30 31	(3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethylester];
32 33	(1) (4) lacosamide $[(R)$ -2-acetoamido- N -benzyl-3- methoxy-propionamide];
34 35 36 37	(2) (5) lasmiditan [2,4,6-trifluoro- <i>N</i> -(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benz-amide]; and (6) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]

Section 7. Severability. If a provision of this act or its application to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the act that can be given effect without the invalid provision or application, and to this end the provisions of this act are severable.

1

2 3

4

I MINA'TRENTAI SAIS NA LIHESLATURAN GUÅHAN 2021 (FIRST) Regular Session

Bill No. 169-36 (LS)

As amended by the Committee on Health, Land, Justice and Culture.

Introduced by:

1

8

9

10

11

12

13

Telena Cruz Nelson

AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE PEOPLE OF GUAM:

Section 1. Legislative Intent. *I Liheslaturan Guåhan* finds that the continued health and public safety of the People of Guam necessitates a unified legal framework that regulates the use, dispensation, and categorization of controlled substances. The purpose of this bill is to update Schedule I through Schedule V of controlled substances based on their medical utility and potential for dependence or abuse.

I Liheslaturan Guåhan further finds that the Department of Public health and Social Services has the authority to administer this Act and to add, delete, or otherwise update Appendices A, B, C, D, and E in accordance with §67.201 under Chapter 67, Title 9 of GCA. The following updated lists of controlled substances are in accordance with DPHSS's findings and research.

It is therefore the intent of *I Liheslaturan Guåhan* and DPHSS to properly

1	update the list of scheduled drugs to reflect with federal regulations provided by		
2	3§1308.11, §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, Code o		
3	Federal Regulations, relative to schedules of controlled substances.		
4	Section 2. Appendix A of Chapter 67, Title 9, Guam Code Annotated, is		
5	amended to read:		
6	"(a) Opiates. Any of the following synthetic opiates, including any		
7	their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers		
8	whenever the existence of such isomers, esters, ethers and salts is others or		
9	them that are theoretically possible within the specific chemical designation		
10	(for purposes of 3- methylthiofentanyl only, the term isomer includes the		
11	optical and geometric isomers):		
12	(1) acetyl-alpha-methylfentanyl (N -[1-(l- methyl-2-		
13	phenethyl)-4-piperidinyl]-N- phenylacetamide);		
14	(2) acetylmethadol;		
15	(3) acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- N-		
16	phenylacetamide);		
17	(4) acryl fentanyl (N-(1-phenethylpiperidin-4-yl)- N-		
18	phenylacrylamide;other name: acryloylfentanyl);		
19	(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)		
20	cyclohexylmethyl]benzamide;		
21	(3) (6) allylprodine;		
22	(4) (7) alphacetylmethadol (except		
23	levoalphacetylmethadol also known as levo-alpha- acetylmethadol,		
24	levomethadyl acetate, or LAAM);		
25	(5) (8) alphameprodine;		
26	(6) (9) alphamethadol;		
27	(7) (10) alpha-methylfentanyl (N-[1-(alpha-methyl-beta-		

```
1
                     phenyl) ethyl-4-piperidyl] propionanilide; 1-(l-methyl-2-phenylethyl)-
 2
                     4-(N- propanilido) piperidine);
 3
                             <del>(8)</del> <u>(11)</u>
                                            alpha-methylthiofentanyl (N-[1-methyl-2-(2-
                     thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide);
 4
                                            benzethidine;
 5
                             <del>(9)</del> <u>(12)</u>
                                           betacetylmethadol;
 6
                             \frac{(10)}{(13)}
 7
                             \frac{(11)}{(14)}
                                            beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
 8
                     phenethyl)-4-piperidinyl]-N-phenylpropamide);
 9
                                            beta-hydroxy-3-methylfentany1 (other name: N-[1-
                             \frac{(12)}{(15)}
10
                     (2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-
                     phenylpropanamide);
11
12
                             (13) (16) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-
                     4-yl]-N-phenylpropionamide (other name: beta-Hydroxythiofentanyl);
13
14
                             <del>(14)</del> <u>(17)</u>
                                            betameprodine;
15
                             <del>(15)</del> <u>(18)</u>
                                            betamethadol:
                                            betaprodine;
16
                             <del>(16)</del> <u>(19)</u>
17
                             \frac{(17)}{(20)}
                                            butyryl fentanyl (N-(1- phenethylpiperidin-4-yl)-
18
                     N-phenylbutyramide);
19
                                            clonitazene;
                             <del>(18)</del> <u>(21)</u>
                             <del>(19)</del> (22)
20
                                            cyclopropyl fentanyl (N-(1- phenethylpiperidin-4-
                     yl)-N- phenylcyclopropanecarboxamide);
21
22
                             \frac{(20)}{(23)}
                                            dextromoramide;
                                           diampromide;
23
                             <del>(21)</del> <u>(24)</u>
                                            diethylthiambutene;
24
                             <del>(22)</del> <u>(25)</u>
25
                             <del>(23)</del> <u>(26)</u>
                                            difenoxin;
26
                             <del>(24)</del> <u>(27</u>
                                            imenoxadol;
27
                             \frac{(25)}{(28)}
                                            dimepheptanol;
```

1	(26) (29) dimethylthiambutene;
2	(27) (30) dioxaphetyl butyrate;
3	(28) (31) dipipanone;
4	(29) (32) ethylmethylthiambutene;
5	(30) (33) etonitazene;
6	(31) (34)etoxeridine;
7	(32) (35) 4-Fluoroisobutyryl fentanyl (<i>N</i> -(4- fluorophenyl)-
8	N-(1-phenethylpiperidin-4- yl)isobutyramide; other name: para-
9	fluoroisobutyryl fentanyl);
10	(33) (36) furanyl fentanyl (N-(1- phenethylpiperidin-4-yl)-N-
11	phenylfuran-2- carboxamide);
12	(34) (37) furethidine;
13	(35) (38) hydroxypethidine;
14	(36) (39) ketobemidone;
15	(37) (40) levomoramide;
16	(38) (41) levophenacylmorphan;
17	(39) (42) methoxyacetyl fentanyl (2-methoxy-N- (1-
18	phenethylpiperidin-4-yl)-N-phenylacetamide);
19	(40) (43) 3-methylfentanyl (N-[3-methyl-l-(2-phenylethyl)-
20	4-piperidyl]-N- phenylpropanamide);
21	(41) (44) 3-methylthiofentanyl (N-[(3-methyl-l-(2-
22	thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide);
23	(42) (45) morpheridine;
24	(43) (46) MPPP (1-methyl-4-phenyl-4-
25	propionoxypiperidine);
26	(44) (47) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl)
27	piperazine);

1	(45) (48) noracymethadol;
2	(46) (49) norlevorphanol;
3	(47) (50) normethadone;
4	(48) (51) norpipanone;
5	(49) (52) ocfentanil (N-(2-fluorophenyl)-2- methoxy-N-(1-
6	phenethylpiperidin-4- yl)acetamide);
7	(50)(53) ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-
8	phenethylpiperidin-4-yl)propionamide); other name: 2-fluorofentanyl;
9	(51)(54) <i>para</i> -Fluorobutyryl fentanyl (<i>N</i> -(4-fluorophenyl)-
10	N-(1-phenethylpiperidin-4- yl)butyramide);
11	(52) (55) para-fluorofentanyl (N-(4-fluorophenyl)- N-[1-(2-
12	phenethyl)-4-piperidinyl] propanamide;
13	(53) (56) PEPAP (1-(-2-phenethyl)-4-phenyl-4-
14	acetoxypiperidine);
15	(54) (57) phenadoxone;
16	(55) (58) phenampromide;
17	(56) (59) phenomorphan;
18	(57) (60) phenoperidine;
19	(58) (61) piritramide;
20	(59) (62) proheptazine;
21	(60) (63) properidine;
22	(61) (64) propiram;
23	(62) (65) racemoramide;
24	(63) (66) tetrahydrofuranyl fentanyl (N-(1-
25	phenethylpiperidin-4-yl)-N- phenyltetrahydrofuran-2-carboxamide);
26	(64) (67) thiofentanyl (N-phenyl-N-[l-(2- thienyl)ethyl-4-
27	piperidinyl]-propanamide);

(65) <u>(</u>	(68) tilidine; and	
(66) <u>(</u>	(69) trimeperidine; and	
(67) (70) U-47700(3,4-Dichloro-N-[2-	
(dimethylar	mino)cyclohexyl]-N- methylbenzamide).	
(b) Opiu	m derivatives. Any of the following opium derivatives,	
including any its s	alts, isomers and salts of isomers whenever the existence of	
such salts, isomers, and salts of isomers is of them that are theoretically		
possible within the specific chemical designation:		
(1)	acetorphine;	
(2)	acetyldihydrocodeine;	
(3)	benzylmorphine;	
(4)	codeine methylbromide;	
(5)	codeine-N-Oxide;	
(6)	cyprenorphine;	
(7)	desomorphine;	
(8)	dihydromorphine;	
(9)	drotebanol;	
(10)	etorphine (except hydrochloride salt);	
(11)	heroin;	
(12)	hydromorphinol;	
(13)	methyldesorphine;	
(14)	methyldihydromorphine;	
(15)	morphine methylbromide;	
(16)	morphine methylsulfonate;	
(17)	morphine-N-oxide;	
(18)	myrophine;	
(19)	nicocodeine;	
	(66) (67)((dimethylar (b) Opiu including any its seem such salts, isome possible within the (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18)	

1	(20) nicomorphine;
2	(21) normorphine;
3	(22) pholcodine; and
4	(23) thebacon.
5	(c) <u>Hallucinogenic substances</u> . Any <u>Mm</u> aterial, compound, mixture,
6	or preparation which containsing any quantity of the following
7	hallucinogenic substances, or which contains including any of its salts,
8	
	isomers, and salts of isomers whenever the existence of such salts, isomers.
9	and salts of isomers is of them that are theoretically possible within the
0	specific chemical designation (for purposes of this paragraph only, the term
1	"isomer" includes the optical, position and geometric isomers):
12	(1) Alpha-ethyltryptamine (some trade or other names:
13	etryptamine; Monase; alpha α-ethyl-lH- indole-3-ethanamine; 3-
4	(2-aminobutyl) indole; alpha <u>α</u>
15	-ET; and AET);
16	(2) 4-bromo-2,5-dimethoxy-amphetamine (<u>some trade or</u>
17	other names: 4-bromo-2,5- dimethoxy- $\frac{\text{alpha}}{\alpha}$ -
18	methylphenethylamine; 4- bromo-2,5-DMA);
19	(3) 4-bBromo-2,5-dimethoxyphenethylamine (some trade or
20	other names: 2-(4-bromo-2,5- dimethoxyphenyl)-1-aminoethane;
21	alpha- desmethyl DOB; 2C-B, Nexus);
22	(4) 2,5-dimethoxyamphetamine (<u>some trade or</u> other names:
23	2,5-dimethoxy-alphaα- methylphenethylamine; 2,5-DMA);
24	(5) 2,5-dimethoxy-4-ethylamphet-amine (some trade or other
25	name: DOET);
26	(6) 2,5-dimethoxy-4-(n)- propylthiophenethylamine (other
27	name: 2C-T- 7);
28	(7) 4-methoxyamphetamine (some trade or other names: 4-
29	methoxy-alpha α - methylphenethylamine;paramethoxyamphe
30	tamine, PMA);

1	(8) 5-methoxy-3,4-methylenedioxy-amphetamine;
2 3 4 5	 (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other names: 4-methyl-2,5- dimethoxy-alphaα-methylphenethylamine; "DOM"; and "STP"); (10) 3,4-methylenedioxy amphetamine;
6	(11) 3,4-methylenedioxymethamphetamine (MDMA);
7	(12) 3,4-methylenedioxy-N-ethylamphetamine(other names
8	also known as: N-ethyl-alpha-methyl-
9	3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
10	(13) N-hydroxy-3,4- methylenedioxyamphetamine (other
11	names also known as: N-hydroxy-alpha-methyl-
12	3,4(methylenedioxy)-phenethylamine, and N- hydroxy MDA);
13	(14) 3,4,5-trimethoxy amphetamine;
14	(15) 5-methoxy-N,N-dimethyltryptamine (some trade or other
15	names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT;
16	(16) Alpha-methyltryptamine (other name: AMT);
17 18 19 20 21	 (17) bufotenine (some trade or other names: 3- (betaβ-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N- dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine); (18) diethyltryptamine (some trade or other names: N,N-
22	Diethyltryptamine; DET);
23	(19) dimethyltryptamine (some trade or other name: DMT);
24	(20) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-
25	MeO-DIPT);
26 27 28 29	(21) ibogaine (<u>some trade or</u> other names: Ethyl-6,6 Beta β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1 ² ,2 ² :1,2] azepino [5,4-b] indole; Tabernanthe iboga);
30	(22) lysergic acid diethylamide;

l	(23) [Repealed];
2	(24) mescaline;
3	(25) parahexyl (some trade or other names: 3- Hexyl-l-
4	hydroxy-7,8,9,10- tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran;
5	Synhexyl);
6	(26) peyote (meaning all parts of the plant presently classified
7	botanically as Lophophora williamsii Lemaire, whether growing or not,
8	it's the seeds thereof, any extract from any part of the such plant, and
9	every compound, manufacture, salts, derivative, mixture, or preparation
10	of such plant, its seeds or extracts);
11	(27) N-ethyl-3-piperidyl benzilate;
12	(28) N-methyl-3-piperidyl benzilate;
13	(29) psilocybin;
14	(30) psilocyn;
15	(31) [Repealed];
16	(32) ethylamine analog of phencyclidine (some trade or other
17	names: N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexy-
18	<u>1</u>)ethylamine, N-(1-phenylcyclohexy- <u>1</u>)ethylamine, cyclohexamine,
19	PCE);
20	(33) pyrrolidine analog of phencyclidine (some trade or other
21	names: 1-(l-phenylcyclohexyl)- pyrrolidine, PCPy, PHP);
22	(34) thiophene analog of phencyclidine (some trade or other
23	names: 1-[1-(2-thienyl)-cyclohexyl]- piperidine, 2-thienylanalog of
24	phencyclidine, TPCP, TCP); and
25	(35) TCPy (other name: 1-[l-(2-thieny-
26	1)cyclohexyl]pyrrolidine)
27	(36) 4-methylmethcathinone (Mephedrone);

1	<u>(37)</u>	3,4-methylenedioxypyrovalerone (MDPV);
2	<u>(38)</u>	2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E);
3	<u>(39)</u>	2-(2,5-Dimethoxy-4- methylphenyl) ethanamine (2C-D);
4	<u>(40)</u>	2-(4-Chloro-2,5- dimethoxyphenyl) ethanamine (2C-C);
5	<u>(41)</u>	2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);
6	<u>(42)</u>	2-[4-(Ethylthio)-2,5- dimethoxyphenyl] ethanamine (2C-
7	<u>T-2);</u>	
8	<u>(43)</u>	2-[4-(Isopropylthio)-2,5- dimethoxyphenyl] ethanamine
9	<u>(2C-T-4);</u>	
10	<u>(44)</u>	2-(2,5-Dimethoxypheny-1) ethanamine (2C- H);
11	<u>(45)</u>	2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
12	<u>(46)</u>	2-(2,5-Dimethoxy-4-(n)- propylphenyl) ethanamine (2C-
13	<u>P);</u>	
14	<u>(47)</u>	3,4-Methylenedioxy-N-methylcathinone (Methylone);
15	<u>(48)</u>	(1-pentyl-1 <i>H</i> -indol-3-yl) (2,2,3,3- tetramethylcyclopropy-
16	1) methanor	ne (UR-144);
17	<u>(49)</u>	[1-(5-fluoro-pentyl)-1 <i>H</i> -indol-3-yl](2,2,3,3-
18	tetramethyl	cyclopropy-1) methanone (5-fluoro- UR-144, XLR11);
19	<u>(50)</u>	N-(1-adamantyl)-1-pentyl-1H-indazole-3- carboxamide
20	(APINACA	<u>, AKB48);</u>
21	<u>(51)</u>	quinolin-8-yl 1-pentyl-1 <i>H</i> -indole-3- carboxylate (PB-22;
22	QUPIC);	
23	<u>(52)</u>	quinolin-8-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole- 3-carboxylate
24	(5-fluoro-Pl	B-22; 5F-PB-22);
25	<u>(53)</u>	<u>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-</u>
26	fluorobenzy	vl)-1 <i>H</i> -indazole-3-carboxamide (AB- FUBINACA);
27	<u>(54)</u>	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-

1	indazole-3-carboxamide (ADB- PINACA);
2	(55) 2-(4-iodo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)
3	ethanamine (25I-NBOMe, 2C-I- NBOMe);
4	(56) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
5	ethanamine (25C-NBOMe, 2C-C-NBOMe);
6	(57) 2-(4-bromo-2,5-dimethoxyphenyl)- <i>N</i> -(2-methoxybenzyl)
7	ethanamine (25B-NBOMe, 2C-B-NBOMe);
8	(58) 4-methyl- <i>N</i> -ethylcathinone (4-MEC);
9	(59) 4-methyl-alpha-pyrrolidinopropiophenone(4-MePPP);
10	(60) <i>alpha</i> -pyrrolidinopentiophenone (α-PVP);
11	(61) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
12	(butylone, bk-MBDB);
13	(62) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
14	(63) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
15	(pentylone, bk- MBDP);
16	(64) 4-fluoro-N-methylcathinone (4-FMC; flephedrone);
17	(65) 3-fluoro- <i>N</i> -methylcathinone (3-FMC);
18	(66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one
19	(naphyrone);
20	(67) alpha-pyrrolidinobutiophenone (α-PBP);
21	(68) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
22	(cyclohexylmethyl)-1 <i>H</i> -indazole-3-carboxamide (AB-CHMINACA);
23	(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- pentyl-1H-
24	indazole-3-carboxamide (AB- PINACA);
25	(70) [1-(5-fluoropentyl)-1 <i>H</i> -indazol-3-yl](naphthalen-1-
26	yl)methanone (THJ-2201);
27	(71) <i>N</i> -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-

1	(cyclohexylmethyl)-1 <i>H</i> -indazole-3- carboxamide (MAB-
2	CHMINACA; ADB- CHMINACA);
3	(72) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
4	carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-
5	MDMB-PINACA);
6	(73) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
7	carboxamido)-3-methylbutanoate (Other names: 5F-AMB);
8	(74) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
9	carboxamide (Other names: 5F- APINACA, 5F-AKB48);
0	(75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 1-(4-
1	fluorobenzyl)-1H-indazole-3-carboxamide (Other names: ADB-
12	FUBINACA);
13	(76) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-3-
4	carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
15	CHMICA, MMB-CHMINACA);
16	(77) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-
17	carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-
18	FUBINACA); and
19	(78) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-
20	carboxamido)-3-methylbutanoate, (FUB-AMB, MMB-FUBINACA,
21	AMB-FUBINACA).
22	(d) <u>Depressants. Any Mmaterial</u> , compound, mixture or preparation
23	which containsing any quantity of the following substances having a
24	depressant effect on the central nervous system, including any its salts,
25	isomers and salts of isomers whenever the existence of such salts, isomers,
26	and salts of isomers is of them that are theoretically possible within the
27	specific chemical designation:

1	(1)	gamma-hydroxybutyric acid (some other names include
2	GHB; gamı	ma-hydroxybutyrate; 4- hydroxybutyrate; 4-
3	hydroxybut	anoic acid; sodium oxybate; sodium oxybutyrate);
4	(2)	mecloqualone; and
5	(3)	methaqualone.
6	(e) <u>Stimi</u>	ulants. Any Mmaterial, compound, mixture, or preparation
7	which containsing	any quantity of the following substances having a stimulan
8	effect on the centr	al nervous system, including its their salts, isomers and salts
9	of isomers:	
10	(1)	Aminorex (other names: aminoxaphen; 2- amino-5-
11	phenyl-2-ox	xazoline; or 4,5-dihydro-5- phenyl-2-oxazolamine);
12	(2)	N-Benzylpiperazine (other names: BZP, 1-
13	benzylpiper	razine);
14	(3)	Cathinone (other names: 2-amino-1- phenyl-1-
15	propanone;	alpha-aminopropiophenone; 2- aminopropiophenone; and
16	norephedro	ne);
17	(4)	Fenethylline;
18	(5)	Methcathinone (other names: 2-(methylamino)-
19	propiophen	one; alpha- (methylamino)propiophenone; 2-
20	(methylami	no)- 1-phenylpropan-l-one; alpha-N-
21	methylamir	nopropiophenone; monomethylpropion; ephedrone; N-
22	methylcath	inone; methylcathinone; AL-464; AL-422; AL-463 and
23	UR1432), i	ts salts, optical isomers and salts of optical isomers);
24	(6)	$(\pm/-\pm)$ cis-4-methylaminorex (other name: $(\pm/-\pm)$ cis-4,5-
25	dihydro-4-r	nethyl-5-phenyl-2- oxazolamine);
26	(7)	N-ethylamphetamine; and
27	(8)	<i>N</i> , <i>N</i> -dimethylamphetamine (other names: <i>N</i> , <i>N</i> -alpha-

1	trimethyl-benzeneethanamine; N,N- alpha-trimethylphenethylamine).
2	(f) <u>Cannabimimetic agents</u> . Any material, compound, mixture or
3	preparation which contains any quantity of the following substances or
4	which contains their salts, isomers, and salts of isomers whenever the
5	existence of such salts, isomers, and salts of isomers is possible within the
6	specific chemical designation:
7	(1) 5-(1,1- <u>Ddimethylheptyl</u>)-2-[(1R,3S)-3-
8	hydroxycyclohexyl]-phenol, its optical, positional, and geometric
9	isomers, salts and salts of isomers (other names: CP-47,497);
10	(2) 5-(1,1- <u>Ddimethyloctyl</u>)-2-[(1R,3S)-3-
11	hydroxycyclohexyl]-phenol, its optical, positional, and geometric
12	isomers, salts and salts of isomers (other names: cannabicyclohexanol
13	and or CP-47,497 C8-homologue);
14	(3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and
15	geometric isomers, salts and salts of isomers (other names: <u>J</u> WH-073);
16	(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1- naphthoyl) indole, its
17	optical, positional, and geometric isomers, salts and salts of isomers
18	(other names: JWH-200);
19	(5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and
20	geometric isomers, salts and salts of isomers (other names: JWH-018
21	and AM678);
22	(6) (6aR,10aR)-9-(hydroxymethyl)-6,6- dimethyl-3-
23	(2methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol-
24	(some trade or other names: HU-210) Salvia divinorum or Salvinorum
25	A; all parts of the plant presently classified botanically as Salvia
26	divinorum, whether growing or not, the seeds thereof, any extract
27	from any part of such plant, and every compound, manufacture, salts,

```
derivative, mixture, or preparation of such plant, its seeds or
 1
 2
                 extracts;
 3
                                    1-hexyl-3-(1-naphthoyl)indole (JWH-019);
                        (8)(7)
 4
                        (9) (8)1-pentyl-3-(2-methoxyphenylacetyl)indole
 5
                        (JWH-250);
                                    1-pentyl-3-[1-(4-methoxynaphthoyl)]indole
 6
                        (10)(9)
                 (JWH-081);
 7
 8
                        (11)(10)
                                    1-pentyl-3-(4-methyl-1- naphthoyl)indole (JWH–
                  122);
 9
10
                       \frac{(12)}{(11)}
                                    1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-
11
                 398);
12
                        \frac{(13)}{(12)}
                                    1-(5-fluoropentyl)-3-(1- naphthoyl)indole
13
                 (AM2201);
14
                        +(14)(13)
                                    1-(5-fluoropentyl)-3-(2- iodobenzoyl)indole
15
                 (AM694);
16
                                    1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR- and
                        \frac{(15)}{(14)}
17
                 RCS-4);
18
                        (16) (15)
                                    1-cyclohexylethyl-3-(2-
19
                 methoxyphenylacetyl)indole (SR-18 and RCS-8); and
20
                       (17)(16)
                                    1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–
21
                  203); and
                        (18) 4-methylmethcathinone (Mephedrone);
22
23
                        (19) 3,4-methylenedioxypyrovalerone (MDPV);
24
                        (20) 3,4-methylenedioxymethcathinone(methylone);
25
                        (21) Naphthylpyrovalerone (naphyrone);
26
                       (22) 4-fluoromethcathinone (flephedrone);
                        (23) 4-methoxymetheathinone (methodrone; Bk PMMA);
27
```

1	(24) Ethcathinone;
2	(25) 3,4-methylenedioxyethcathinone (ethylone);
3	(26) Beta-keto-N-methyl-3,4-benzodioxyolybutanamine
4	(butylone);
5	(27) N,N-dimethylcathinone (metamfepramone);
6	(28) Alpha-pyrrolidinopropiophenone (alpha-PPP);
7	(29) 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP);
8	(30) 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone
9	(MDPPP);
10	(31) Alpha-pyrrolidinovalerophenone (alpha-PVP);
11	(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine)
12	(MDAI);
13	(33) 3-fluorometheathinone;
14	(34) 4'-Methyl-α-pyrrolidinobutiophenone (MPBP);
15	(35) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C E);
16	(36) 2-(2,5-Dimethoxy-4- methylphenyl)ethanamine (2C D);
17	(37) 2-(4-Chloro-2,5- dimethoxyphenyl)ethanamine (2C-C);
18	(38) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
19	(39) 2-[4-(Ethylthio)-2,5- dimethoxyphenyl]ethanamine (2C
20	T-2);
21	(40) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine-
22	(2C T 4);
23	(41) 2-(2,5-Dimethoxyphenyl)ethanamine (2C H);
24	(42) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C N);
25	(43) 2-(2,5-Dimethoxy-4-(n)- propylphenyl)ethanamine (2C-
26	P); and
27	(44) (17) any synthetic cannabinoid.

1	(g) <u>Temporary listing of substances subject to emergency</u>
2	scheduling. Any material, compound, mixture or preparation which
3	contains any quantity of the following substances:
4	(1) N-(1-phenethylpiperidin-4-yl)-N- phenylpentanamide, its
5	isomers, esters, ethers, salts and salts of isomers, esters and ethers
6	(other name: valeryl fentanyl);
7	(2) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
8	yl)butyramide, its isomers, esters, ethers, salts and salts of isomers,
9	esters and ethers (other name: para-methoxybutyryl fentanyl);
10	(3) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
11	yl)isobutyramide, its isomers, esters, ethers, salts and salts of isomers,
12	esters and ethers (other name: para-chloroisobutyryl fentanyl);
13	(4) N-(1-phenethylpiperidin-4-yl)-N- phenylisobutyramide,
14	its isomers, esters, ethers, salts and salts of isomers, esters and ethers
15	(other name: isobutyryl fentanyl);
16	(5) N-(1-phenethylpiperidin-4-yl)-N-
17	phenylcyclopentanecarboxamide, its isomers, esters, ethers, salts and
18	salts of isomers, esters and ethers (other name: cyclopentyl fentanyl);
19	(6) Naphthalen-1-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole- 3-carboxylate,
20	its optical, positional, and geometric isomers, salts and salts of isomers (other
21	names: NM2201; CBL2201);
22	(7) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5- fluoropentyl)-1H-
23	indazole-3-carboxamide, its optical, positional, and geometric isomers, salts
24	and salts of isomers (other names: 5F-AB- PINACA);
25	(8) 1-(4-cyanobutyl)- <i>N</i> -(2-phenylpropan-2-yl)- 1 <i>H</i> -indazole-3-
26	carboximide, its optical, positional, and geometric isomers, salts and salts of
27	isomers (other names: 4-CN-CUMYL-BUTINACA; 4- cyano-CUMYL-

1	BUTINACA; 4-CN-CUMYL BINACA; CUMYL-4CN-BINACA; SG1-/8);
2	(9) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-3- carboxamido)-3-
3	methylbutanoate, its optical, positional, and geometric isomers, salts and salts
4	of isomers (other names: MMB-CHMICA, AMB- CHMICA);
5	(10) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)- 1H-pyrrolo[2,3-
6	b]pyridine-3-carboxamide, its optical, positional, and geometric isomers,
7	salts and salts of isomers (other names: 5F-CUMYL- P7AICA);
8	(11) N-Ethylpentylone, its optical, positional, and geometric isomers,
9	salts and salts of isomers (other names: ephylone, 1-(1,3-benzodioxol-5-yl)-
10	2-(ethylamino)-pentan-1-one);
11	(12) ethyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamido)-3,3-
12	dimethylbutanoate, its optical, positional, and geometric isomers, salts and
13	salts of isomers (trivial name:5F-EDMB-PINACA);
14	(13) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indole-3-carboxamido)-3,3-
15	dimethylbutanoate, its optical, positional, and geometric isomers, salts and
16	salts of isomers (trivial name: 5F-MDMB-PICA);
17	(14) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H- indazole-3-
18	carboxamide, its optical, positional, and geometric isomers, salts and salts of
19	isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-
20	FLUOROBENZYL));
21	(15) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-
22	carboxamide, its optical, positional, and geometric isomers, salts and salts of
23	isomers (trivial names: 5F-CUMYL-PINACA; SGT-25);
24	(16) (1-(4-fluorobenzyl)-1 <i>H</i> -indol-3-yl)(2,2,3,3-
25	tetramethylcyclopropyl) methanone, its optical, positional, and geometric
26	isomers, salts and salts of isomers (trivial name: FUB-144);
27	(17) N-Ethylhexedrone, its optical, positional, and geometric isomers,

l	salts and salts of isomers (Other name: 2-(ethylamino)-1-phenylhexan-1- one;
2	(18) alpha-Pyrrolidinohexanophenone, its optical, positional, and
3	geometric isomers, salts and salts of isomers (Other names: -PHP; alpha-
4	pyrrolidinohexiophenone; 1-phenyl-2- (pyrrolidine-1-yl)hexan-1-one);
5	(19) 4-Methyl-alpha-ethylaminopentiophenone, its optical,
6	positional, and geometric isomers, salts and salts of isomers (Other names:
7	4-MEAP; 2- (ethylamino)-1-(4-methylphenyl)pentan-1-one);
8	(20) 4 -Methyl-alpha-pyrrolidinohexiophenone, its read:
9	optical, positional, and geometric isomers, salts and salts of isomers
10	(Other names: MPHP; 4 - methyl-alpha-pyrrolidinohexanophenone; 1-(4-
11	methylphenyl)-2-(pyrrolidine-1-yl)hexan-1-one);
12	(21) alpha-Pyrrolidinoheptaphenone, its optical, positional, and
13	geometric isomers, salts and salts of isomers (Other names: PV8; 1-phenyl-2-
14	(pyrrolidine-1-yl)heptan-1-one); and
15	(22) 4'-Chloro-alpha-pyrrolidinovalerophenone, its optical,
16	positional, and geometric isomers, salts and salts of isomers (Other names:
17	4-chloro- '- PVP; 4'-chloro-alpha-pyrrolidinopentiophenone; 1-(4-
18	chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1- one).
19	Section 3. Appendix B of Chapter 67, Title 9, Guam Code Annotated, is
20	amended to
21	"(a) Substances, vegetable origin or chemical synthesis. Any of the
22	following substances, however manufactured whether produced directly or
23	indirectly by extraction from substances of vegetable origin, or independently
24	by means of chemical synthesis, or by a combination of extraction and
25	chemical synthesis:
26 27	(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-

1	derived butorphanol, dextrorphan, nalbuphine, <u>naldemedine</u> ,
2 3	nalmefene, <u>naloxegol</u> , naloxone, <u>6β- naltrexol</u> and naltrexone, and their respective salts, but including the following:
4	(A) <u>raw opiumcodeine</u> ;
5	(B) -opium extracts dihydroetorphine;
6	(C) (C) opium fluidethylmorphine;
7	(D) <u>powdered opiumetorphine hydrochloride</u> ;
8	(E) granulated opium; tincture of opiumhydrocodone;
9	(G)—codeinehydromorphone;
10	(H) ethylmorphinemetopon;
11	(I) <u>etorphinehydrochloridemorphine</u> ;
12	(J) hydrocodonenoroxymorphone;
13	(K) hydromorphoneopium extracts;
14	(L) metoponopium fluid;
15	(M) morphine oripavine;
16	(N) oxycodone;
17	(O) oxymorphone;
18	(P) thebainepowdered opium;
19	(Q) dihydroetorphineraw opium; and
20	(R) <u>oripavine.thebaine; and</u>
21	(S) <u>tincture of opium.</u>
22	(2) Any salt, compound, derivative, or preparation thereof
23	whichthat is chemically equivalent or identical with any of the
24	substances listed in Subparagraph (1)paragraph
25	(a)(1) of this section, except that these
26	substances shallbut not include the isoquinoline
27	alkaloids of opium;
28	(3) Opium poppy and poppy straw;

1	(4) Coca leaves and any salt, compound, derivative, or
2	preparation of coca leaves, (including cocaine and ecgonine and their
3	salts, isomers, derivatives, and salts of isomers and derivatives), and
4	any salt, compound, derivative, or preparation that is thereof which is
5	chemically equivalent or identical with any of these substances listed
6	in this subparagraph, but not including decocainized coca leaves or
7	extractions of coca leaves which do not contain cocaine or ecgonine;
8	and, except that the substances shall not include:
9	(A) decocainized coca leaves or extraction of
10	coca leaves, which extractions do not contain cocaine or
11	ecgonine; or
12	(B) ioflupane; and 38
13	(5) Concentrate of poppy straw (the crude extract of poppy
14	straw in either liquid, solid, or powder form which contains the
15	phenanthrene alkaloids of the opium poppy).
16	(b) <u>Opiates</u> . Any of the following synthetic opiates, including any its
17	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers
18	whenever the existence of such isomers, esters, esters, and salts is of them that
19	are theoretically possible within the specific chemical designation,
20	dextrorphan and levopropoxyphene excepted:
21	(1) alfentanil;
22	(2) alphaprodine;
23	(3) anileridine;
24	(4) bezitramide;
25	(5) <u>carfentanil</u> <u>bulk dextropropoxyphene (non-dosage forms)</u> ;
26	(6) bulk dextropropoxyphene (non-dosage forms) carfentanil;
27	(7) dihydrocodeine;

l	(8) diphenoxylate;
2	(9) fentanyl;
3	(10) isomethadone;
4	(11) levomethorphanlevo-alphacetylmethadol [some other
5	names: levo-alpha-acetylmethadol, levomethadyl acetate, LAAM];
6	(12) levorphanollevomethorphan;
7	(13) metazocinelevorphanol;
8	(14) methadonemetazocine;
9	(15) methadone-intermediate,4-cyano- 2- dimethylamino-4,4-
10	diphenyl butanemethadone;
11	(16) morāmide-intermediate,2-methyl-3- morpholino- 1,1-
12	diphenylpropane-carboxylic acidmethadone-intermediate, 4-cyano-2-
13	dimethylamino-4,4-diphenyl butane;
14	(17) pethidine (meperidine)moramide-intermediate, 2-methyl-
15	3- morpholino-1, 1-diphenylpropane-carboxylic acid;
16	(18) pethidine-intermediate-A,4-cyano-l- methyl-4-
17	phenylpiperidinepethidine (meperidine);
18	(19) pethidine-intermediate-B,ethyl- 4-phenylpiperidine-4-
19	earboxylatepethidine-intermediate-A, 4-cyano-1-methyl-4-
20	phenylpiperidine;
21	(20) pethidine-intermediate-C,1-methyl- 4- phenylpiperidine-
22	4-carboxylic acidpethidine-intermediate-B, ethyl-4- phenylpiperidine-
23	4-carboxylate;
24	(21) phenazocinepethidine-intermediate-C, 1-methyl-4-
25	phenylpiperidine-4-carboxylic acid;
26	(22) piminodinephenazocine;
27	(23) racemethorphanpiminodine;

1	(24)	racemorphanracemethorphan;
2	(25)	remifentanilracemorphan;
3	(26)	sufentanilremifentanil;
4	(27)	levo-alphacetylmethadol (other names: levo-
5	alphaacety!	methadol, levomethadyl acetate, LAAM); and sufentanil;
6	(28)	tapentadol.; and
7	(29)	thiafentanil.
8	(c) <u>Stim</u>	ulants. Any Mmaterial, compound, mixture, or preparation
9	containing which	contains any quantity of the following substances having
10	a stimulant effect	on the central nervous system:
1	(1)	amphetamine, its salts, optical isomers, and salts of its
12	optical ison	ners;
13	(2)	methamphetamine, its salts, isomers, and salts of its
14	isomers;	
15	(3)	phenmetrazine and its salts;
16	(4)	methylphenidate; and
17	(5)	lisdexamfetamine, its salts, isomers, and salts of its
18	isomers.	
19	(d) <u>Depr</u>	ressants. Any Mmaterial, compound, mixture, or preparation
20	containing which	contains any quantity of the following substances having a
21	depressant effect	on the central nervous system, including any its salts,
22	isomers, and sale	ts of isomers of them that are theoreticallywhenever the
23	existence of such	salts, isomers, and salts of isomers is possible within the
24	specific chemical	designation:
25	(1)	amobarbital;
26	(2)	pentobarbital;
27	(3)	phencyclidine; and

1	(4) secobarbital; <u>and</u>
2	(5) glutethimide;
3	(e) Hallucinogenic substances.
4	(1) Nabilone (other <u>names for nabilone</u> : (+/-)-trans-3-(1,1-
5	dimethylheptyl)-6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6- dimethyl-
6	9H-dibenzo[b,d] pyran-9-one).
7	(f) <u>Immediate precursors</u> . Any <u>Mmaterial</u> , compound, mixture, or
8	preparation containing any quantity of the following substances:
9	(1) Immediate precursor to amphetamine and
10	methamphetamine: phenylacetone (other names: phenyl-2-propanone;
11	P2P; benzyl methyl ketone; methyl benzyl ketone);
12	(2) Immediate precursors to phencyclidine (PCP):
13	(A) 1-phenylcyclohexylamine; and
14	(B) 1-piperidinocyclohexanecarbonnitrile (PCC).
15	(3) Immediate precursor to fentanyl:
16	(A) 4-anilino-N-phenethylpiperidine (ANPP).
17	(g) <u>Material</u> , compound, mixture, or preparation containing any
18	quantity of the following substances: (1) Immediate precursor to amphetamine
19	and methamphetamine: phenylacetone (other names: phenyl-2- propanone;
20	P2P; benzyl methyl ketone; methyl benzyl ketone); (2) Immediate precursors
21	to phencyclidine (PCP): (A) 1-p,henylcyclohexylamine; and (B) I-
22	piperidinocyclohexanecarbonnitrile (PCC).
23	Section 4. Appendix C of Chapter 67, Title 9, Guam Code Annotated, is
24	amended to read:
25	"(a) Stimulants. Any material, compound, mixture, or preparation
26	which containsing any quantity of the following substances having a stimulant
27	effect on the central nervous system, including anyits salts, isomers (whether

1	optical, positional, or geometric), and salts of such isomers whenever the
2	existence of such salts, isomers, and salts of isomers is of them that are
3	theoretically possible within the specific chemical designation:
4	(1) <u>Those A compounds</u> , mixtures, or preparations in dosage
5	unit form containing any stimulant substance included in Schedule II
6	and which compounds, mixtures, or preparations were was listed
7	as an excepted compound on August 25, 1971, pursuant to the federal
8	Controlled Substances Act, and any other drug of the quantitative
9	composition shown in that list for those drugs or which is the same
10	except for containing a lesser quantity of controlled substances;
11	(2) benzphetamine;
12	(3) chlorphentermine;
13	(4) clortermine; and
14	(5) phendimetrazine.
15	(b) <u>Depressants</u> . A <u>Any</u> material, compound, mixture, or preparation
16	containing any quantity of the following substances having a depressant effect
17	on the central nervous system:
18	(1) A <u>any</u> compound, mixture, or preparation containing: any
19	of the following drugs or their salts and one or more other active
20	medicinal ingredients not included in any schedule:
21	(A) amobarbital;
22	(B) secobarbital; and
23	(C) pentobarbital; or any salt thereof and one or more
24	other active medicinal ingredients which are not listed in any
25	schedule.
26	(2) any of the following drugs, or their salts, in suppository
27	dosage form, approved by the Federal Food and Drug Administration

1	for marketing only as a suppository:
2	(A) amobarbital;
3	(B) secobarbital, and
4	(C) pentobarbital.
5	(3) a substance containing any quantity of a derivative of
6	barbituric acid or any salt of a derivative of barbituric acid;
7	(4) chlorhexadol;
8	(5) embutramide;
9	(6) any drug product containing gamma hydroxybutyric acid,
10	including its salts, isomers, and salts of isomers, for which an
1	application is approved under Section 505 of the Federal Food, Drug,
12	and Cosmetic Act;
13	(7) ketamine, its salts, isomers, and salts of isomers (other
14	names: (±)-2-(2-chlorophenyl)-2- (methylamino)-cyclohexanone);
15	(8) lysergic acid;
16	(9) lysergic acid amide;
17	(10) methyprylon;
18	(11) sulfondiethylmethane; perampanel, and its salts, isomers
19	and salts of isomers.
20	(12) sulfonethylmethane; sulfondiethylmethane;
21	(13) sulfonmethane; sulfonethylmethane;
22	(14) tiletamine and zolazepam, or any salt_thereof (other names
23	for a tiletamine-zolazepam combination product: Telazol; other
24	names for tiletamine: 2- (ethylamino)-2-(2-thienyl)-cyclohexanone;
25	other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
26	trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon;
27	sulfonmethane;

1	(15) tiletamine and zolazepam, or any salt the reof (Some trade
2	or other names for a tiletamine-zolazepam combination product:
3	Telazol;. Some trade or other names fortiletamine: 2- (ethylamino)-
4	2-(2-thienyl)-cyclohexanone;. Some trade or other ames for
5	zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8- trimethylpyrazolo-
6	[3,4-ee] [1,4]-diazepin-7(1HH)-one, flupyrazapon;
7	(c) Nalorphine.
8	(d) Narcotic Drugs.
9	(1) A Any material, compound, mixture, or preparation
10	containing any of the following narcotic drugs, or their salts calculated
11	as the free anhydrous base or alkaloid, in limited quantities as set forth
12	below:
13	(A) not more than 1.8 grams of codeine
14	per 100 milliliters or not more than 90 milligrams per
15	dosage unit, with an equal or greater quantity of an isoquinoline
16	alkaloid of opium;
17	(B) not more than 1.8 grams of codeine per 100
18	milliliters or not more than 90 milligrams per dosage unit, with
19	one or more active, nonnarcotic ingredients in recognized
20	therapeutic amounts;
21	(C) not more than 300 milligrams of dihydrocodeine
22	(hydrocodone) per 100 milliliters or not more than 15 milligrams
23	per dosage unit, with one or more active-nonnarcotic ingredients
24	in recognized therapeutic amounts;
25	(D) not more than 300 milligrams 1.8 grams of
26	Dihydrocodeine (hydrocodone) per 100 milliliters or not more
27	than 15-90 milligrams per dosage unit, with one or more active-

1	nonnarcotic ingredients in recognized therapeutic amounts;
2	(E) not more than 1.8 grams of dihydrocodeine per 100
3	milliliters or not more than 90 milligrams per dosage unit, with
4	one or more active, nonnarcotic ingredients in recognized
5	therapeutic amounts not more than 300 milligrams of
6	ethylmorphine per 100 milliliters or not more than 15 milligrams
7	per dosage unit, with one or more active, nonnarcotic ingredients
8	in recognized therapeutic amounts;
9	(F) <u>not more than 300 milligrams of ethylmorphine per</u>
10	100 milliliters or not more than 15 milligrams per dosage unit,
11	with one or more active, nonnarcotic ingredients in recognized
12	therapeutic amounts not more than 500 milligrams of
13	opium per 100 milliliters or per 100 grams, or not more
14	than 25 milligrams per dosage unit, with one or more active,
15	nonnarcotic ingredients in recognized therapeutic amounts; and
16	(F) not more than 500 milligrams of opium per 100
17	milliliters or per 100 grams, or not more than 25 milligrams per
18	dosage unit, with one or more active,
19	nonnarcotic ingredients in recognized therapeutic
20	amounts; and not more than 50 milligrams of morphine per 100
21	milliliters or per 100 grams with one or more active, nonnarcotic
22	ingredients in recognized therapeutic amounts.
23	(G) not more than 500 milligrams of opium per 100
24	milliliters or per 100 grams, or not more than 25 milligrams per
25	dosage unit with one or more active nonnarcotic ingredients in
26	recognized therapeutic amounts; and not more than 50
27	milligrams of morphine per 100 milliliters or per 100 grams with

1		one	or more active, nonnarcotic ingredients in recognized
2		thera	peutic amounts.
3			(H) not more than 50 milligrams of morphine per 100
4		<u>millil</u>	liters or per 100 grams with one or more active nonnarcotic
5		<u>ingre</u>	ediants in recognized therapeutic amounts.
6		(2)	A Any material, compound, mixture, or preparation
7	conta	ining a	any of the following narcotic drugs and or its their salts as
8	set be		
9			(A) buprenorphine;
10	(e)	Anab	polic Steroids.
1	()	Any	drug or hormonal substance chemically and
12	nharmacolo	•	y related to testosterone (other than estrogens, progestins,
	•		,
13	corticostero	ids, an	nd dehydroepiandrosterone), and includes:
4		(1)	$3\underline{\beta}$ [beta],17-dihydroxy-5a-androstane;
15		(2)	$3\underline{\alpha}$ [alpha],17 $\underline{\beta}$ [beta]-dihydroxy-5a-androstane;
16		(3)	5 <u>α[alpha]</u> -androstan-3,17-dione;
17		(4)	1-androstenediol $(3\underline{\beta} - \{beta\}, 17\underline{\beta} \{beta\} - dihydroxy - 5\underline{\alpha})$
18		[alph	a] -androst-1-ene);
19		(5)	1-androstenediol (3 α -[alpha],17 β [beta]- dihydroxy-
20		5 <u>[a</u>	llpha] -androst-1-ene);
21		(6)	4-androstenediol $(3\underline{\beta} - \{beta\}, 17\underline{\beta} \{beta\} - dihydroxy - \{beta\}, 17\underline{\beta} \{beta\} - \{beta\}, 17\underline{\beta} \{b$
22		andro	ost-4-ene;
23		(7)	5-androstenediol ($\underline{\beta}$ -{beta},17 $\underline{\beta}$ -{beta}- dihydroxy-androst-
24	5-ene);	
25		(8)	1-androstenedione ([5 α [alpha]]-androst-1-en-3,17- dione;
26		(9)	4-androstenedione (androst-4-en-3,17-dione);
27		(10)	5-androstenedione (androst-5-en-3,17-dione);
28		(11)	bolasterone (7 $\underline{\alpha}$ -[alpha],17 $\underline{\alpha}$ -[alpha]- dimethyl-17 $\underline{\beta}$ [beta]-
29		hydro	oxyandrost-4-en-3_one); (12) boldenone $(17\underline{\beta}[\text{beta}]-$
30		hydro	oxyandrost-1,4-

1	diene-3-one);
2	(13) boldione (androsta-1,4-diene-3,17-dione);
3	(14) calusterone $(7\underline{\beta}\{beta\}, 17\underline{\alpha}\{alpha\}\}$ -dimethyl- $\underline{\beta}\{beta\}$ -
4	hydroxyandrost-4-en-3-one);
5	(15) chlorotestosterone (4 chlortestosterone),
6	(16) (15) clostebol (4-chloro- $17\underline{\beta}$ [beta]-hydroxyandrost-4-en-
7	3- one);
8	(17) (16) dehydrochloromethyltestosterone (4- chloro-
9	17 <u>β[beta]</u> -hydroxy- 17 <u>α [alpha]</u> -methyl- androst-1,4-dien-3-
10	one);
11 12	$\frac{(18)(17)}{(18)(17)}$ desoxymethyltestosterone $\frac{(17\alpha - \{alpha\} - methyl - 5\alpha - \{alpha\} - androst - 2 - en - 17\alpha \{beta\} - ol)$ (a.k.a 'madol')
13	$\frac{(19)(18)}{(19)(18)}$ Delta $\Delta 1$ -dihydrotestosterone (a.k.a. "1-
14	testosterone") $(17\underline{\beta}$ [beta]- hydroxy-5 $\underline{\alpha}$ [alpha]-androst-1-en-3-
15	one);
16	(20) (19) 4-dihydrotestosterone (17 <u>\beta</u> -hydroxy-
17	androstan-3-one);
18	(21) (20) drostanolone (17 <u>β[beta]-hydroxy-2α[alpha]-</u>
19	methyl-5 α [alpha]- androstan-3-one);
20	$\frac{(22)(21)}{(21)}$ ethylestrenol $\frac{(17\alpha \text{[alpha]} - \text{ethyl} - 17\beta \text{[beta]} - \text{ethyl}}{(21)}$
21	hydroxyestr-4-ene);
22	(23) (22) fluoxymesterone (9-fluoro-17 α [alpha]- methyl-
23	11 <u>β</u>
24	[beta],17 <u>B[beta]</u> -dihydroxyandrost- 4-en-3-one);
25	(24) (23) formebolone (2-formyl-17 α [alpha]- methyl-
26	11 <u>α[alpha]</u> ,17 <u>β[beta]</u> - dihydroxyandrost-1,4-dien-3-one);
27	(25) (24) furazabol $(17\alpha = 17\beta = 17\beta$
28	hydroxyandrostano[2,3-c]- furazan);
29	(26) (25) 13β [beta]-ethyl- 17β [beta]-hydroxygon-4-en-3-
30	one;
31	(27) (26) 4-hydroxytestosterone $(4,17\beta[beta]$ - dihydroxy-
32	androst-4-en-3-one);
33	(28) (27) 4-hydroxy-19-nortestosterone $(4,17\underline{\beta}[\text{beta}]$ -
34	dihydroxy-estr-4-en-3- one);
35	(29) desoxymethyltestosterone (17α[alpha]- methyl-
36	$5\underline{\alpha}$ [alpha]-androst-2- <u>en</u> -17 $\underline{\beta}$ 0[beta]-ol) (a.k.a 'madol')
37	(30) (28) mestanolone (17 <u>α[alpha]</u> -methyl-17 <u>β[beta]</u> -

1 2 3 4 5 6 7 8 9	hydroxy-5-androstan-3-one); (31) (29) mesterolone ($1\alpha[alpha]$ methyl- $17\beta[beta]$ -hydroxy- $[5\alpha[alpha]]$ -androstan-3-one); (32) (30) methandienone ($17\alpha[alpha]$ - methyl- $17\beta[beta]$ -hydroxyandrost-1,4-dien- 3-one); (33) (31) methandriol ($17\alpha[alpha]$ -methyl- 3β - $[beta]$, $17\beta[beta]$ -dihydroxyandrost-5-ene); (34) (32) methasteroneandranone ($2\alpha[alpha]$, $17\alpha[alpha]$ -dimethyl- $5\alpha[alpha]$ -androstan- $17\beta[beta]$ -ol-3-one); (35) methandrostenolone;
11	(36) (33) methenolone (1-methyl-17 β [beta]-hydroxy-
12	$5\underline{\alpha}$ [alpha]-androst-1-en-3-one);
13	(37) (34) 17α [alpha]-methyl- 3β [beta], 17β [beta]- dihydroxy-5a-
14	androstane;
15	(38) (35) $17\underline{\alpha}[alpha]$ -methyl- $3\underline{\alpha}[alpha]$, $17\underline{\beta}[beta]$ -
16	dihydroxy-5a-androstane;
17	(39) (36) $17\alpha[alpha]$ -methyl- $3\beta[beta]$, $17\beta[beta]$ -
18	dihydroxyandrost-4-ene;
19	$\frac{(40) (37)}{(37)} 17\underline{\alpha} = \frac{17}{\alpha} = \frac$
20	hydroxynandrolone($17\underline{\alpha}[alpha]$ -methyl- 4-hydroxy- $17\underline{\beta}[beta]$ -
21	hydroxyestr-4-en- 3-one);
22	$\frac{(41) (38)}{(38)} \text{methyldienolone } (17 \frac{\alpha \text{[alpha]}}{\alpha \text{[alpha]}} - \frac{1}{\alpha [alph$
23	methyl- $17\underline{\beta}$ [beta]-hydroxyestra-4,9(10)-dien-3-one);
24	(42) (39) methyltrienolone ($17\underline{\alpha}[alpha]$ - methyl- $17\underline{\beta}[beta]$ -
25	hydroxyestra-4,9-11-trien-3-one);
26	(43) (40) methyltestosterone (17α[alpha]- methyl-17β[beta]-
27	hydroxyandrost-4-en-3-one);
28	(44) (41) mibolerone $(7\alpha \frac{\text{alpha}}{17000}, 17\alpha \frac{\text{alpha}}{17000})$ -dimethyl-
29	17 <u>β[beta]</u> -hydroxyestr-4-en-3-one);
30	(45) (42) 17α [alpha]-methyl-[Delta] Δ 1 - dihydrotestosterone
31	$(17\underline{\beta}[\text{beta}]-\text{hydroxy-}17\underline{\alpha}[\text{alpha}]-\text{methyl-}5\underline{\alpha}[\text{alpha}]-\text{androst-}1-$
32	en-3- one) (a.k.a. '17- α [alpha]-methyl-1- testosterone");
33	(46) (43) nandrolone (17 <u>β[beta]</u> -hydroxyestr-4-en-3-one);
34	(47) (44) 19-nor-4-androstenediol $(3\underline{\beta}[\text{beta}], 17\underline{\beta}[\text{beta}]$
35	dihydroxyestr-4-ene);
36 37	(48) (45) 19-nor-4-androstenediol (3α-{alpha},17β-{beta}-dihydroxyestr-4-ene);
JI	umyuroxyesu-4-enej,

1	(49) (46) 19-nor-5-androstenediol $(3\underline{\beta} \text{ [beta]}, 17\underline{\beta}$ -
2	[beta]dihydroxyestr-5-ene);
3	(50) (47) 19-nor-5-androstenediol $(3\alpha - \{alpha\}, 17\beta \}$
4	dihydroxyestr-5-ene);
5	(51) (48) 19-nor-4,9(10)- androstadienedione(estra-4,9(10)-
6	diene-3,17- dione);
7	(52)(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
8	(53)(50) 19-nor-5-androstenedione(estr-5-en-3,17-dione);
9	(54) (51) norbolethone $(13\underline{\beta}-\{beta\},17\underline{\alpha}-\{alpha\}-diethyl-$
10	17 <u>β[beta]</u> - hydroxygon-4-en-3-one);
11	(55) (52) norclostebol (4-chloro-17 β [beta]- hydroxyestr-4-
12	en-3-one);
13	(56) (53) norethandrolone $(17\alpha - \text{[alpha]-})$ ethyl- $17\beta - \text{[beta]-}$
14	hydroxyestr-4-en-3-one);
15	(57) (54) normethandrolone $(17\alpha - [alpha] - methyl - 17\beta [beta] - methyl - 17\beta [beta$
16	hydroxyestr-4-en-3-one);
17	(58) (55) oxandrolone $(17\alpha - [alpha] - methyl-$
18	17 <u>β[beta]</u> -hydroxy-2-oxa-[5 <u>α [alpha]]</u> -androstan- 3-one);
19	(59) (56) oxymesterone $(17\alpha - [alpha] - methyl - 4, 17\beta - [beta] -$
20	dihydroxyandrost-4-en-3-one;
21	(60) (57) oxymetholone $(17\alpha - \frac{\text{alpha}}{\text{alpha}})$ -methyl-2-
22	hydroxymethylene- $17\underline{\beta}$ [beta]-hydroxy- [5 $\underline{\alpha}$ -[alpha]]-androstan-
23	3-one); (61) stanolone;
24	$\frac{(62)}{(58)}$ prostanozol (17β-hydroxy-5αandrostano[3,2-
25	c]pyrazole);
26	(63) (59) stanozolol $(17\alpha \frac{\text{alpha}}{\text{methyl}} - 17\beta \frac{\text{beta}}{\text{methyl}}$
27	hydroxy- $[5\underline{\alpha}$ [alpha]]-androst-2- eno[3,2-c]-pyrazole);
28	(64) (60) stenbolone $(17\underline{\beta}[\text{beta}]-\text{hydroxy- }2-\text{methyl-}$
29	$[5\underline{\alpha}[alpha]]$ -androst-1-en-3- one);
30	(65) (61) testolactone (13-hydroxy-3-oxo- 13,17
31	secoandrosta-1,4-dien-17-oic acid lactone);
32	(66) (62) testosterone $(17\underline{\beta}[beta]$ - hydroxyandrost-4-en-3-
33	one);
34	(67) (63) tetrahydrogestrinone $(13\underline{\beta}[\text{beta}], 17\underline{\alpha}[\text{alpha}]$ -
35	diethyl-17 <u>β[beta]</u> - hydroxygon-4,9,11-trien-3-one);
36	(68) (64) trenbolone (17 β [beta]-hydroxyestr- 4,9,11-trien-3-
37	one); and

Any salt, ester, or ether of a drug or substance (69) (65)described or listed in (1) through (66) above, if that salt, ester, or ether promotes muscle growth. in this paragraph. Except such term does not include an anabolic steroid which that is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph. DPHSS may exempt by rule a compound, mixture, or preparation containing a stimulant or depressant substance listed in subsections A and B from the application of all or part of this Act, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a stimulant or depressant effect on the central nervous system.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

(f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product (Some other names for dronabinol: (6a*R*-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6*H*- ibenzo[*b*,*d*]pyran-1-ol])

Section 5. Appendix D of Chapter 67, Title 9, Guam Code Annotated, is *amended* to read:

<u>"(a) Narcotic drugs.</u> A <u>Any</u> material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts

1	calculated as the free anhydrous base or alkaloid, in limited quantities as set		
2	forth below:		
3	(1) not more than 1 milligram of difenoxin and not less than		
4	25 micrograms of atropine sulfate per dosage unit;		
5	(2) dextropropoxyphene (dosage forms); and		
6	dextropropoxyphene (alpha-(+)-4-dimethylamino-		
7	1,2- diphenyl-3-methyl-2-propionoxybutane); and		
8	(3) <u>dextropropoxyphene</u> (alpha-(+)-4-dimethylamino-1,2-		
9	diphenyl-3-methyl-2-propionoxybutane)2-[(dimethylamino)methyl]-		
10	1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric		
11	isomers and salts of these isomers (including tramadol).		
12	(b) <u>Depressants</u> . A Any material, compound, mixture, or preparation		
13	which contains any quantity of the following substances having a depressant		
14	effect on the central nervous system, including any salts, isomers, and salts of		
15	isomers whenever the existence of such salts, isomers, and salts of		
16	isomers is of them that are theoretically possible within the specific		
17	chemical designation:		
18	(1) alfaxalone alprazolam;		
19	(2) alprazolam barbital;		
20	(3) <u>barbital</u> bromazepam ;		
21	(4) <u>brexanolone camazepam;</u>		
22	(5) <u>bromazepam carisoprodol</u> ;		
23	(6) <u>camazepam</u> ehloral betaine;		
24	(7) carisoprodol chloral hydrate;		
25	(8) <u>chloral betaine</u> chlordiazepoxide ;		
26	(9) <u>clobazam</u> <u>chloral hydrate</u> ;		
27	(10) clonazepam <u>chlordiazepoxide</u> ;		

1	(11)	clorazepate <u>clobazam</u> ;
2	(12)	clotiazepam <u>clonazepam</u> ;
3	(13)	cloxazolam <u>clorazepate</u> ;
4	(14)	delorazepam clotiazepam;
5	(15)	diazepam <u>cloxazolam</u> ;
6	(16)	dichloraphenazone delorazepam;
7	(17)	estazolam diazepam;
8	(18)	ethchlorvynol dichloraphenazone;
9	(19)	ethinamate estazolam;
10	(20)	ethyl loflazepate ethchlorvynol;
11	(21)	fludiazepam ethinamate;
12	(22)	flunitrazepam ethyl loflazepate;
13	(23)	flurazepam fludiazepam;
14	(24)	fospropofol flunitrazepam;
15	(25)	halazepam flurazepam;
16	(26)	haloxazolam fospropofol;
17	(27)	ketazolam halazepam;
18	(28)	loprazolam <u>haloxazolam</u> ;
19	(29)	lorazepam <u>ketazolam</u> ;
20	(30)	lormetazepam <u>loprazolam</u> ;
21	(31)	mebutamate lorazepam;
22	(32)	medazepam lormetazepam;
23	(33)	meprobamate mebutamate;
24	(34)	methohexital medazepam;
25	(35)	methylphenobarbital (mephobarbital) meprobamate;
26	(36)	midazolam methohexital;
27	(37)	nimetazepam methylphenobarbital (mephobarbital);

1	(38) nitrazepam midazolam;	
2	(39) nordiazepam nimetazepam;	
3	(40) oxazepam <u>nitrazepam</u> ;	
4	(41) <u>oxazolam nordiazepam;</u>	
5	(42) paraldehyde <u>oxazepam</u> ;	
6	(43) petrichloral oxazolam;	
7	(44) <u>phenobarbital petrichloral;</u>	
8	(45) pinazepam petrichloral;	
9	(46) prazepam phenobarbital;	
10	(47) quazepam <u>pinazepam</u> ;	
11	(48) temazepam prazepam;	
12	(49) tetrazepam quazepam;	
13	(50) triazolam suvorexant;	
14	(51) zaleplon temazepam;	
15	(52) zolpidem tetrazepam; and	
16	(53) zopiclone triazolam.;	
17	(54) zaleplon;	
18	(55) zolpidem; and	
19	(56) zopiclone.	
20	(c) Fenfluramine. Any material, compound, mi	xture, or preparation
21	which contains any quantity of the following substances	s, including its salts,
22	isomers (whether optical, position, or geometric), and sa	alts of such isomers,
23	whenever the existence of such salts, isomers, and salts o	f isomers is possible:
24	(1) fenfluramine.	
25	(d) Lorcaserin. Any material, compound, mix	ture, or preparation
26	which contains any quantity of the following substance	es, including its salts
27	isomers and salts of such isomers, whenever the exist	stence of such salts,

1	isomers, and salts of isomers is possible.		
2	(1) lorcaserin.		
3	(d) (e)Stimulants. AAny material, compound, mixture, or preparation		
4	containing any quantity of the following substances having a stimulant effect		
5	on the central nervous system, including their salts, isomers, and salts of		
6	isomers:		
7	(1) cathine ((+)-norpseudoephedrine);		
8	(2) diethylpropion;		
9	(3) fencamfamin;		
10	(4) fenproporex;		
11	(5) mazindol;		
12	(6) mefenorex;		
13	(7) modafinil;		
14	(8) pemoline (including organometallic complexes and		
15	chelates thereof);		
16	(9) phentermine;		
17	(10) pipradrol;		
18	(11) sibutramine;		
19	(12) solriamfetol (2-amino-3-phenylpropyl carbamate;		
20	benzenepropanol, beta-amino-carbamate (ester)); and		
21	(12)(13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).		
22	(e)(f) Other substances. A Any material, compound, mixture, or		
23	preparation containing any quantity of the following substance, including its		
24	salts:		
25	(1) pentazocine;		
26	(2) butorphanol (including its optical isomers); and		
27	(3) eluxadoline $(5-[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-$		

1	$\underline{\text{dimethylphenyl}}_{-1}-\underline{\text{oxopropyl}}_{[(IS)-1-4-\text{phenyl}-1H-\text{imidazol}-2-\text{phenyl}-2-phenyl$			
2	yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical			
3	isomers) and salts of isomers.			
4	(f) (g) DPHSS may exempt by rule any compound, mixture, or			
5	preparation containing a depressant substance listed in subsection B from the			
6	application of all or part of this Act, if the compound, mixture, or preparation			
7	contains one or more active medicinal ingredients not having a depressant			
8	effect on the central nervous system and the admixtures are in combinations,			
9	quantity, proportion, or concentration that vitiate the potential for abuse of the			
10	substances having a depressant effect on the central nervous system.			
11	Section 6. Appendix E of Chapter 67, Title 9, Guam Code Annotated, is			
12	amended to read:			
13	"(a) Narcotic drugs. Unless specifically excepted or unless listed in			
14	another schedule, any material, compound, mixture, or preparation containing			
15	any of the following narcotic drugs and their salts, as set forth below:			
16	(b) Narcotic drugs containing non-narcotic active medicinal			
17	ingredients. A Any compound, mixture, or preparation containing any of the			
18	following narcotic drugs, or their salts calculated as the free anhydrous base			
19	or alkaloid, in limited quantities as set forth below, which shall include also			
20	contains one or more non-narcotic active medicinal ingredients in sufficient			
21	proportion to confer upon the compound, mixture, or preparation, valuable			
22	medicinal qualities other than those possessed by the narcotic drugalone:			
23	(1) not more than 200 milligrams of codeine per 100			
24	milliliters or per 100 grams;			
25	(2) not more than 100 milligrams of dihydrocodeine per 100			
26	milliliters or per 100 grams;			
27	(3) not more than 100 milligrams of ethylmorphine per 100			

1	milliliters or per 100 grams;	
2	(4) not more than 2.5 milligrams of diphenoxylate and not less	
3	than 25 micrograms of atropine sulfate per dosage unit;	
4	(5) not more than 100 milligrams of opium	
5	per 100 milliliters or per 100 grams; and	
6	(6) not more than 0.5 milligram of difenoxin and not less	
7	than 25 micrograms of atropine sulfate per dosage unit.	
8	(c) <u>Stimulants</u> . <u>A Any</u> material, compound, mixture, or preparation	
9	containing any quantity of the following substances having a stimulant effect	
0	on the central nervous system, including their salts, isomers and salts of	
1	isomers:	
12	(1) pyrovalerone.	
13	(d) <u>Depressants</u> . A <u>Any</u> material, compound, mixture, or preparation	
4	which containsing any quantity of the following substances having a	
15	depressant stimulant effect on the central nervous system, including their its	
16	salts:, isomers and salts or isomers:	
17	(1) lacosamide $[(R)$ -2-acetoamido- N -benzyl-	
18	3- methoxy-propionamide] brivaracetam ((S)-2-[(4R)-2-oxo-4-	
19	propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714;	
20	Briviact) (including its salts);	
21	(2) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]-	
22	cenobamate ([(1R)-1-(2-chlorophenyl)-2- (tetrazol-2-	
23	yl)ethyl]carbamate; 2H-tetrazole-2- ethanol, alpha-(2-chlorophenyl)-,	
24	carbamate(ester), (alphaR)-; carbamic acid (R)- (+)-1-(2-	
25	<u>chlorophenyl)-2-(2<i>H</i>-tetrazol-2-yl)ethyl</u> <u>ester);</u>	
26	(3) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-	
27	phenyl]-carbamic acid ethyl ester];	

1	<u>(4)</u>	lacosamide $[(R)$ -2-acetoamido- N -benzyl- 3- methoxy-
2	propionami	de];
3	(5)	lasmiditan [2,4,6-trifluoro-N-(6-(1- methylpiperidine-4-
1	carbonyl)py	yridine-2-yl- benz-amide]; and
5	<u>(6)</u>	pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].
6	Section 7.	Severability. If a provision of this act or its application
7	to any person or circumstance is held invalid, the invalidity does not affect ot	
3	provisions or applicatio	ns of the act that can be given effect without the invalid
)	provision or application,	, and to this end the provisions of this act are severable.

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS) I MINA'TRENTAI SAIS NA LIHESLATURAN GUÂHAN 2021 (FIRST) Regular Session

Bill No. 169-36 (LS) As Amended by the Committee on Health, Land, Justice and Culture

Introduced by:

1 2

Telena Cruz Nelson

AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT.

Deleted: 26

Deleted: OF

BE IT ENACTED BY THE PEOPLE OF GUAM:

- Section 1. Legislative Intent.
- 3 I Liheslaturan Guåhan finds that the continued health and public
- 4 safety of the People of Guam necessitates a unified legal framework that regulates
- 5 the use, dispensation, and categorization of controlled substances. The purpose of
- 6 this bill is to update Schedule I through Schedule V of controlled substances based
- 7 on their medical utility and potential for dependence or abuse.
- 8 I Liheslaturan Guåhan further finds that the Department of Public health and
- 9 Social Services has the authority to administer this Act and to add, delete, or
- 10 otherwise update Appendices A, B, C, D, and E in accordance with §67.201 under
- 11 Chapter 67, Title 9 of GCA. The following updated lists of controlled substances
- 12 are in accordance with DPHSS's findings and research.

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)

1	It is therefore the intent of I Liheslaturan Guåhan and DPHSS to properly		
2	update the list of scheduled drugs to reflect with federal regulations provided by		
3	§1308.11, §1308.12, §1308.13, §1308.14, and §1308.15 of Title 21, Code of		
4	Federal Regulations, relative to schedules of controlled substances.		
5	Section 2. Appendix A of <u>Chapter 67.</u> Title 9, Guam Code Annotated, is <i>amended</i> to		
6	read:		
7	(a) Opiates. Any of the following synthetic opiates,	Formatted: Font: Not Italic	
8	including any their isomers, esters, ethers, salts, and		
9	salts of isomers, esters, and ethers, whenever the		
10	existence of such isomers, esters, ethers and salts is		
11	others of them that are theoretically possible within the		
12	specific chemical designation (for purposes of 3-		
13	methylthiofentanyl only, the term isomer includes the		
14	optical and geometric isomers):		
15	(1) acetyl-alpha-methylfentanyl (N-[1-(l-		
16	methyl-2-phenethyl)-4-piperidinyl]-N-		
17	phenylacetamide);		
18	(2) acetylmethadol;		
19	(3) acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-		
20	N-phenylacetamide);		
21	(4) acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-		
22	N-phenylacrylamide; other name:		
23	acryloylfentanyl);		
24	(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)		
25	cyclohexylmethyl]benzamide:		
26	(3) (6) allylprodine;		
27	(4) (7) alphacetylmethadol (except levoalphacetylmethadol	Deleted: -	
28	also known as levo-alpha- acetylmethadol, levomethadyl		
29	acetate, or LAAM);		
30	(5) (8) alphameprodine;		
31	(6) (9) alphamethadol;		
32	(7) (10) alpha-methylfentanyl (N-[1-(alpha-		
33	methyl-beta-phenyl)_ethyl-4-piperidyl]		
34	propionanilide; 1-(l-methyl-2-phenylethyl)-4-(N-	Deleted:	
35	propanilido) piperidine);		
36	$\frac{(8)}{(11)}$ alpha-methylthiofentanyl (N-[1-methyl-2-		
	2		

(2-thienyl)ethyl-4-piperidinyl]-N-

37

1 2	phenylpropanamide); (9) (12) benzethidine;	Formatted: Left: 0.49 , Right: 0.92 , Top: 0.96 , Bottom: 0.67 , Footer distance from edge: 0.53
3	(10) (13) betacetylmethadol;	
4	$\frac{(11)}{(14)}$ beta-hydroxyfentanyl (N-[1-(2-hydroxy-	
5	2- phenethyl)-4-piperidinyl]-N-phenylpropamide);	
6	(12) (15) beta-hydroxy-3-methylfentanyl (other	
7	name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-	Deleted:
8	piperidinyl]-N-phenylpropanamide);	
9	(13) (16) N-[1-[2-hydroxy-2-(thiophen-2-	
10	yl)ethyl]piperidin-4-yl]-N-phenylpropionamide	
11	(other name: beta-Hydroxythiofentanyl);	
12	(14) (17) betameprodine;	
13	$\frac{(15)}{(18)}$ betamethadol;	
14	(16) (19) betaprodine;	
15	(17) (20) butyryl fentanyl (N-(1-	
16	phenethylpiperidin-4-yl)-N-phenylbutyramide);	
17	(18) (21) clonitazene;	
18	(19) (22) cyclopropyl fentanyl (N-(1-	
19	phenethylpiperidin-4-yl)-N-	
20	phenylcyclopropanecarboxamide):	
21	(20) (23) dextromoramide;	
22	(21) (24) diampromide;	
23	(22) (25) diethylthiambutene;	
24	(23) (26) difenoxin;	
25	(24) (27) dimenoxadol;	
26	(25) (28) dimepheptanol;	
27	(26) (29) dimethylthiambutene;	
28	(27) (30) dioxaphetyl butyrate;	
29	(28) (31) dipipanone;	
30	(29) (32) ethylmethylthiambutene;	
31	(30) (33) etonitazene;	
32	(31) (34) etoxeridine;	
33	(32) (35) 4-Fluoroisobutyryl fentanyl (N-(4-	
34	fluorophenyl)-N-(1-phenethylpiperidin-4-	
35	yl)isobutyramide; other name: para-	
36	fluoroisobutyryl fentanyl):	

1	(33) (36) furanyl fentanyl (N-(1-		
2	phenethylpiperidin-4-yl)-N-phenylfuran-2-		
3	carboxamide);		
4	(34) (37) furethidine;		
5	(35) (38) hydroxypethidine;		
6	(36) (39) ketobemidone;		
7	(37) (40) levomoramide;		
8	(38) (41) levophenacylmorphan;		
9	(39) (42) methoxyacetyl fentanyl (2-methoxy-N-		
10	(1-phenethylpiperidin-4-yl)-N-phenylacetamide):		
11	(40) (43) 3-methylfentanyl (N-[3-methyl-l-(2-		
12	phenylethyl)-4-piperidyl]-N-		
13	phenylpropanamide);		
14	(41) (44) 3-methylthiofentanyl (N-[(3-methyl-1-(2-		
15	thienyl)ethyl-4-piperidinyl]-N-		
16	phenylpropanamide);		
17	(42) (45) morpheridine;		
18	(43) (46) MPPP (1-methyl-4-phenyl-4-		
19	propionoxypiperidine);		
20	(44) (47) MT-45 (1-cyclohexyl-4-(1.2-		
21	diphenylethyl)piperazine);		
22	(45) (48) noracymethadol;		
23	$\frac{(46)}{(49)}$ norlevorphanol;		
24	(47) (50) normethadone;		
25	(48) (51) norpipanone;		
26	(49) (52) ocfentanil (N-(2-fluorophenyl)-2-		
27	methoxy-N-(1-phenethylpiperidin-4-		
28	yl)acetamide);		
29	(50)(53) ortho-Fluorofentanyl (N-(2-		
30	fluorophenyl)-N-(1-phenethylpiperidin-4-		
31	yl)propionamide); other name: 2-fluorofentanyl;		
32	(51)(54) para-Fluorobutyryl fentanyl (N-(4-		
33	fluorophenyl)-N-(1-phenethylpiperidin-4-		
34	yl)butyramide);		
35	(52) (55) para-fluorofentanyl (N-(4-fluorophenyl)-		
36	N-[1-(2-phenethyl)-4-piperidinyl] propanamide;	Deleted:	
37	(53) (56) PEPAP (1-(-2-phenethyl)-4-phenyl-4-		

1 2	acetoxypiperidine); (54) (57) phenadoxone;	
3	(55) (58) phenampromide;	
4	(56) (59) phenomorphan;	
5	(57) <u>(60)</u> phenoperidine;	
6	(58) (61) piritramide;	
7	(59) (62) proheptazine;	
8	(60) (63) properidine;	
9	(61) (64) propiram;	
10	(62) <u>(65)</u> racemoramide;	
11	(63) (66) tetrahydrofuranyl fentanyl (N-(1-	
12	phenethylpiperidin-4-yl)-N-	
13	phenyltetrahydrofuran-2-carboxamide):	
14	(64) (67) thiofentanyl (N-phenyl-N-[1-(2-	
15	thienyl)ethyl-4- piperidinyl]-propanamide);	
16	(65) (68) tilidine; and	
17	(66) (69) trimeperidine; and	
18	(67) (70) U-47700(3,4-Dichloro-N-[2-	
19	(dimethylamino)cyclohexyl]-N-	
20	methylbenzamide).	
21	(b) Opium derivatives. Any of the following opium	Formatted: Font: Not Italic
22	derivatives, including any its salts, isomers and salts of	
23	isomers whenever the existence of such salts, isomers.	
24	and salts of isomers is of them that are theoretically	
25 26	possible within the specific chemical designation: (1) acetorphine;	
27	(2) acetyldihydrocodeine;	
28	(3) benzylmorphine;	
29	(4) codeine methylbromide;	
30	(5) codeine-N-Oxide;	
31	(6) cyprenorphine;	
32	(7) desomorphine; (8) dihydromorphine;	
33		
34	(9) drotebanol;(10) etorphine (except hydrochloride salt);	
35	(10) atornhina (avcent hydrochloride calt):	
26		
36	(11) heroin;	

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS) 1 (12) hydromorphinol; 2 (13) methyldesorphine; 3 (14) methyldihydromorphine; 4 (15) morphine methylbromide; 5 (16) morphine methylsulfonate; 6 (17) morphine-N-oxide; Deleted: O 7 (18) myrophine; 8 (19) nicocodeine; 9 (20) nicomorphine; (21) normorphine; 10 (22) pholcodine; and 11 12 (23) thebacon. 13 14 (c) Hallucinogenic substances, Any Mmaterial, Formatted: Underline 15 compound, mixture, or preparation which containsing Formatted: Font: Not Italic 16 any quantity of the following hallucinogenic Formatted: Underline 17 substances, or which contains including any of its salts, Formatted: Strikethrough 18 isomers, and salts of isomers whenever the existence of Formatted: Underline 19 such salts, isomers, and salts of isomers is of them that Formatted: No underline are theoretically possible within the specific chemical 20 designation (for purposes of this paragraph only, the term 21 "isomer" includes the optical, position and geometric 22 23 24 (1) Alpha-ethyltryptamine (some trade or other 25 names: etryptamine; Monase; alphaα-ethyl-lHindole-3-ethanamine; 3-(2-aminobutyl) indole; 26 27 alphaα-ET; and AET); 28 (2) 4-bromo-2,5-dimethoxy-amphetamine 29 (some trade or other names: 4-bromo-2,5dimethoxy-alphaα-methylphenethylamine; 4-30 31 bromo-2,5-DMA); (3) 4-bBromo-2,5-dimethoxyphenethylamine 32 33 (some trade or other names: 2-(4-bromo-2,5-34 dimethoxyphenyl)-1-aminoethane; alphadesmethyl DOB; 2C-B, Nexus); 35 36 (4) 2,5-dimethoxyamphetamine (some trade or

1 2	other names: 2,5-dimethoxy- alpha <u>\alpha</u> -methylphenethylamine; 2,5-DMA);		
3	(5) 2,5-dimethoxy-4-ethylamphet-amine		
4	(some trade or other name; DOET);	Deleted: s	
5 6 7 8 9	 (6) 2,5-dimethoxy-4-(n)- propylthiophenethylamine (other name: 2C-T- 7); (7) 4-methoxyamphetamine (some trade or other names: 4-methoxy-alphaα- methylphenethylamine;paramethoxyamphe 		
11	tamine, PMA);		
12 13 14 15 16	(8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alphaα-methylphenethylamine; "DOM"; and "STP"); (10) 3,4-methylenedioxy amphetamine;		
18 19 20 21 22	(11) 3,4-methylenedioxymethamphetamine (MDMA); (12) 3,4-methylenedioxy-N-ethylamphetamine (other names also known as: N-ethyl-alpha-methyl- 3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);		
23 24 25 26 27	(13) N-hydroxy-3,4- methylenedioxyamphetamine (othernames also known as: N-hydroxy-alpha-methyl- 3,4(methylenedioxy)-phenethylamine, and N- hydroxy MDA);		
28 29 30 31 32	(14) 3,4,5-trimethoxy amphetamine; (15) 5-methoxy-N,N-dimethyltryptamine (some trade or other names: 5-methoxy-3-[2- (dimethylamino)ethyl]indole; 5-MeO-DMT; (16) Alpha-methyltryptamine (other name: AMT);		
33 34 35 36 37	(17) bufotenine (<u>some trade or</u> other names: 3- (<u>betaβ</u> -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N- dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine);		

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS) 1 (18) diethyltryptamine (some trade or 2 other names: N,N- Diethyltryptamine; 3 (19) dimethyltryptamine (some trade or other name: DMT); 4 5 (20) 5-methoxy-N,N-diisopropyltryptamine 6 (other name: 5-MeO-DIPT); 7 (21) ibogaine (some trade or other names: 7-8 Ethyl-6,6Betaβ.7,8,9,10,12,13-octahydro-2-9 methoxy-6,9-methano-5H-pyrido [12/22/1,2] 10 azepino [5,4-b] indole; Tabernanthe iboga); 11 (22) lysergic acid diethylamide; 12 (23) [Repealed]; 13 (24) mescaline; (25) parahexyl (some trade or other names: 3-14 15 Hexyl-l-hydroxy-7,8,9,10- tetrahydro-6,6,9-16 trimethyl-6H-dibenzo[b,d]pyran; Synhexyl); 17 (26) peyote (meaning all parts of the plant presently classified botanically as Lophophora 18 Formatted: Font: Not Italic williamsii Lemaire, whether growing or not, it's 19 20 the seeds thereof, any extract from any part of 21 the such plant, and every compound, 22 manufacture, salts, derivative, mixture, or 23 preparation of such plant, its seeds or extracts); 24 (27) N-ethyl-3-piperidyl benzilate; (28) N-methyl-3-piperidyl benzilate; 25 26 (29) psilocybin; 27 (30) psilocyn: 28 (31) [Repealed]; (32) ethylamine analog of phencyclidine (some 29 trade or other names: N-ethyl-1-30 31 phenylcyclohexylamine, (1-phenylcyclohexy-32 1)ethylamine, N-(1-phenylcyclohexy-Formatted: Underline 33 1)ethylamine, cyclohexamine, PCE); Formatted: Underline 34 (33) pyrrolidine analog of phencyclidine (some 35 trade or other names: 1-(1-phenylcyclohexyl)pyrrolidine, PCPy, PHP); 36

1 2 3 4	(34) thiophene analog of phencyclidine (some trade or other names: 1-[l-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP); and
5	(35) TCPy (other name: 1-[1-(2-thieny-1)cyclohexyl]pyrrolidine) Formatted: Underline
6	(36) 4-methylmethcathinone (Mephedrone);
7	(37) 3,4-methylenedioxypyrovalerone (MDPV);
8 10	(38) 2-(2.5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E):
11 12	(39) 2-(2.5-Dimethoxy-4- methylphenyl) ethanamine (2C-D):
13 14	(40) 2-(4-Chloro-2,5- dimethoxyphenyl) ethanamine (2C-C):
15 16	(41) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C-I):
17 18	(42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-2);
19 20	(43) 2-[4-(Isopropylthio)-2.5- dimethoxyphenyl] ethanamine (2C-T-4):
21 22	(44) 2-(2.5-Dimethoxypheny-1) ethanamine (2C- H):
23 24	(45) 2-(2.5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
25 26	(46) 2-(2.5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P):
27 28	(47) 3.4-Methylenedioxy-N-methylcathinone (Methylone):
29 30	(48) (1-pentyl-1 <i>H</i> -indol-3-yl) (2,2,3,3- tetramethylcyclopropy-1) methanone (UR-144):
31 32 33	(49) [1-(5-fluoro-pentyl)-1 <i>H</i> -indol-3-yl](2,2,3,3-tetramethylcyclopropy-1) methanone (5-fluoro-UR-144, XLR11);
34	(50) N-(1-adamantyl)-1-pentyl-1H-indazole-3-

1	carboxamide (APINACA, AKB48);
2	(51) quinolin-8-yl 1-pentyl-1 <i>H</i> -indole-3-
3	carboxylate (PB-22; QUPIC);
4	(52) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-
5	3-carboxylate (5-fluoro-PB-22; 5F-PB-22);
6	(53) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
7 8	<u>fluorobenzyl</u>)-1 <i>H</i> -indazole-3-carboxamide (AB-FUBINACA);
9	(54) <i>N</i> -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
10	1-pentyl-1 <i>H</i> -indazole-3-carboxamide (ADB-
11	PINACA);
12	(55) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
13	methoxybenzyl)ethanamine (25I-NBOMe, 2C-I-
14	NBOMe);
15	(56) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
16	methoxybenzyl)ethanamine (25C-NBOMe, 2C-C-
17	NBOMe);
18	(57) 2-(4-bromo-2,5-dimethoxyphenyl)- <i>N</i> -(2-
19	methoxybenzyl)ethanamine (25B-NBOMe, 2C-B-NBOMe, 2C-B-NBOMe)
20	NBOMe);
21	(58) 4-methyl-N-ethylcathinone (4-MEC);
22	(59) 4-methyl-alpha-pyrrolidinopropiophenone
23	<u>(4-MePPP);</u>
24	(60) <i>alpha</i> -pyrrolidinopentiophenone (α-PVP);
25	(61) 1-(1,3-benzodioxol-5-yl)-2-
26	(methylamino)butan-1-one (butylone, bk-MBDB);
27	(62) 2-(methylamino)-1-phenylpentan-1-one
28	(pentedrone);
29	(63) 1-(1,3-benzodioxol-5-yl)-2-
30	(methylamino)pentan-1-one (pentylone, bk-
31	MBDP);
32	(64) 4-fluoro- <i>N</i> -methylcathinone (4-FMC;
33	flephedrone);
34	(65) 3-fluoro-N-methylcathinone (3-FMC):

1 2	(66) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone);
3	(67) alpha-pyrrolidinobutiophenone (α-PBP);
4 5 6	(68) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA);
7 8 9	(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA);
10 11	(70) [1-(5-fluoropentyl)-1 <i>H</i> -indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201);
12 13 14 15	(71) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA; ADB-CHMINACA);
16 17 18	(72) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-MDMB-PINACA);
19 20 21	(73) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-carboxamido)-3-methylbutanoate (Other names: 5F-AMB);
22 23 24	(74) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H- indazole-3-carboxamide (Other names: 5F- APINACA, 5F-AKB48);
25 26 27	(75) <i>N</i> -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-carboxamide (Other names: ADB-FUBINACA);
28 29 30	(76) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA);
31 32 33	(77) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-FUBINACA); and
34 35	(78) methyl 2-(1-(4-fluorobenzyl)-1 <i>H</i> -indazole-3-carboxamido)-3-methylbutanoate, (FUB-AMB,

1	MMB-FUBINACA, AMB-FUBINACA).	
2	(d) Depressants. Any Mmaterial, compound,	Formatted: Font: Not Italic
3	mixture or preparation which containsing any quantity	
4	of the following substances having a depressant effect	
5	on the central nervous system, including any its salts,	
6	isomers and salts of isomers whenever the existence of	
7	such salts, isomers, and salts of isomers is of them that	
8	are theoretically possible within the specific chemical	
9	designation:	
10	(1) gamma-hydroxybutyric acid (some other	Formatted: Underline
11	names include GHB; gamma-hydroxybutyrate; 4-	
12	hydroxybutyrate; 4-hydroxybutanoic acid; sodium	
13	oxybate; sodium oxybutyrate);	
14	(2) mecloqualone; and	
15	(3) methaqualone.	
16	(e) Stimulants. Any Mmaterial, compound,	
17	mixture, or preparation which containsing any quantity	Formatted: Underline
18	of the following substances having a stimulant effect on	
19	the central nervous system, including its their salts,	
20	isomers and salts of isomers:	
21	(1) Aminorex (other names: aminoxaphen; 2-	
22	amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-	Deleted:
23	phenyl-2-oxazolamine);	Deleted:
24	(2) N-Benzylpiperazine (other names: BZP,	
25	1-benzylpiperazine);	Deleted:
26	(3) Cathinone (other names: 2-amino-1-	
27	phenyl-1- propanone; alpha-aminopropiophenone; 2-	Deleted: ¶
28	aminopropiophenone; and norephedrone);	Formatted: Font: 14 pt
29	(4) Fenethylline;	
30	(5) Methcathinone (other names: 2-(methylamino)- propiophenone; alpha-	Formatted: Left, Indent: Hanging: 1.94 , Line spacing: Exactly 16.1 pt
31	(methylamino)propiophenone; 2-(methylamino)-	Deleted: ¶
32	1-phenylpropan-l-one; alpha-N-	Formatted: Font: 14 pt
33	methylaminopropiophenone; monomethylpropion;	1
34	ephedrone; N-methylcathinone; methylcathinone;	
37	AL-464; AL-422; AL-463 and UR1432), its salts.	
38	optical isomers and salts of optical isomers);	

1 2 3 4 5 6 7 8 9 10 11 12 13	(6) (±/±)cis-4-methylaminorex (other name: (±/±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); (7) N-ethylamphetamine; and (8) N,N-dimethylamphetamine (other names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine). (f) Cannabimimetic agents. Any material, compound, mixture or preparation which contains any quantity of the following substances or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) 5-(1,1-Ddimethylheptyl)-2-[(1R,3S)-3-	Deleted: Deleted:
8 9 10 11 12	(f) <u>Cannabimimetic agents</u> . Any material, compound, mixture or preparation which contains any quantity of the following substances <u>or which contains</u> their salts, isomers, and salts of isomers whenever the <u>existence of such salts</u> , isomers, and salts of isomers is possible within the specific chemical designation:	
	(1) 5-(1.1- D dimethylheptyl)-2-[(1R.3S)-3-	
14 15 16 17	hydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers (other names: CP-47,497);	
18 19 20	(2) 5-(1,1- <u>Dd</u> imethyloctyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol, its optical, positional, and geometric isomers, salts and salts of isomers	Deleted: -
21 22 23 24 25	(other names: cannabicyclohexanol and or CP-47,497 C8-homologue); (3) 1-Butyl-3-(1-naphthoyl)indole, its optical, positional, and geometric isomers, salts and salts of isomers (other names: JWH-073);	Formatted: Strikethrough Formatted: Underline Formatted: Underline
26 27 28 29	(4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)_indole, its optical, positional, and geometric isomers, salts and salts of isomers (other names: JWH-200);	Deleted:
30 31 32 33 34 35	(5) 1-Pentyl-3-(1-naphthoyl)indole, its optical, positional, and geometric isomers, salts and salts of isomers (other names: JWH-018 and AM678); (6) (6aR,10aR) 9 (hydroxymethyl) 6,6-dimethyl 3 (2methyloctan 2 yl) 6a,7,10,10a-tetrahydrobenzo[e]ehromen 1 ol (some trade or	Deleted: ; Deleted: -
36 37	other names: HU 210) Salvia divinorum or Salvinorum A; all parts of	

	COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)	
1 2 3 4 5	the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts;	
7	(8) (7) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);	
8	(9) (8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250);	Deleted:
10	(10) (9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole	Deleted: ¶
12 13 14 15 16 17 18 19	(JWH-081); (11) (10) 1-pentyl-3-(4-methyl-1- naphthoyl)indole (JWH-122); (12) (11) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH- 398); (13) (12) 1-(5-fluoropentyl)-3-(1- naphthoyl)indole (AM2201); (14) (13) 1-(5-fluoropentyl)-3-(2- iodobenzoyl)indole (AM694);	Formatted: Space Before: 6 pt Deleted: end
20 21	(15) (14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19 and RCS–4);	
22 23 24	(16) (15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8); and	
25 26 27	(17) (16) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–203); and (18) 4 methylmetheathinone (Mephedrone);	Deleted:
28 29	(19) 3,4 methylenedioxypyrovalerone (MDPV); (20)3,4 methylenedioxymethcathinone(methylone);	
30 31 32 33 34 35 36 37	(21) Naphthylpyrovalerone (naphyrone); (22) 4 fluorometheathinone (flephedrone); (23) 4 methoxymetheathinone (methedrone; Bk PMMA); (24) Etheathinone; (25) 3,4 methylenedioxyetheathinone (ethylone); (26) Beta keto N methyl 3,4- benzodioxyolybutanamine (butylone);	
	1:	5

1 2	(27) N,N dimethyleathinone (metamfepramone); (28) Alpha pyrrolidinopropiophenone (alpha PPP);	
3	(29) 4 methoxy alpha	
4	pyrrolidinopropiophenone (MOPPP);	
5	(30) 3,4 methylenedioxy alpha	
6	pyrrolidinopropiophenone (MDPPP);	
7	(31) Alpha pyrrolidinovalerophenone (alpha PVP);	
8	(32) 6,7 dihydro 5H indeno (5,6 d) 1,3 dioxol 6	
9	amine) (MDAI);	
10	(33) 3 fluorometheathinone;	
11	(34) 4' Methyl α pyrrolidinobutiophenone (MPBP);	
12	(35) 2 (2,5 Dimethoxy 4 ethylphenyl)ethanamine	
13	(2C E);	
14	(36) 2 (2.5 Dimethoxy 4	
15	methylphenyl)ethanamine (2C D);	
16	(37) 2 (4 Chloro 2,5-	
17	dimethoxyphenyl)ethanamine (2C-C);	
18	(38) 2 (4 Iodo 2,5 dimethoxyphenyl)ethanamine	
19	(2C I);	
20	(39) 2 [4 (Ethylthio) 2,5-	
21	dimethoxyphenyl]ethanamine (2C T 2);	
22	(40) 2 [4 (Isopropylthio) 2,5	
23	dimethoxyphenyl]ethanamine (2C T 4);	
24	(41) 2 (2,5 Dimethoxyphenyl)ethanamine (2C H);	
25	(42) 2 (2,5 Dimethoxy 4 nitrophenyl)ethanamine	4
26	(2C N);	Deleted:-
27	(43) 2 (2,5 Dimethoxy 4 (n)	
28	propylphenyl)ethanamine (2C P); and	
29	(44) (17) any synthetic cannabinoid.	
30	(g) Temporary listing of substances subject to	Formatted: Font: Not Italic
31	emergency scheduling. Any material, compound, mixture	
32	or preparation which contains any quantity of the	
33	following substances:	
34	(1) N-(1-phenethylpiperidin-4-yl)-N-	
35	phenylpentanamide, its isomers, esters, ethers,	
36	salts and salts of isomers, esters and ethers (other	
37	name: valeryl fentanyl);	
38	(2) N-(4-methoxyphenyl)-N-(1-	

1	phenethylpiperidin-4-yl)butyramide, its isomers,
2	esters, ethers, salts and salts of isomers, esters and
3	ethers (other name: para-methoxybutyryl
4	fentanyl);
5	(3) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4
6	yl)isobutyramide, its isomers, esters, ethers, salts
7	and salts of isomers, esters and ethers (other name
8	para-chloroisobutyryl fentanyl);
9	(4) N-(1-phenethylpiperidin-4-yl)-N-
10	phenylisobutyramide, its isomers, esters, ethers,
11	salts and salts of isomers, esters and ethers (other
12	name: isobutyryl fentanyl);
13	(5) <i>N</i> -(1-phenethylpiperidin-4-yl)- <i>N</i> -
14	phenylcyclopentanecarboxamide, its isomers,
15	esters, ethers, salts and salts of isomers, esters and
16	
17	ethers (other name: cyclopentyl fentanyl); (6) Namhthalan 1 yl 1 (5 flyaronatyl) 1 U indola
	(6) Naphthalen-1-yl 1-(5-fluoropentyl)-1 <i>H</i> -indole-
18	3-carboxylate, its optical, positional, and
19	geometric isomers, salts and salts of isomers
20	(other names: NM2201; CBL2201);
21	(7) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
22	fluoropentyl)-1 <i>H</i> -indazole-3-carboxamide, its
23	optical, positional, and geometric isomers, salts
24 25	and salts of isomers (other names: 5F-AB-
25	<u>PINACA);</u>
26	(8) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-
27	1H-indazole-3-carboximide, its optical, positional,
28	and geometric isomers, salts and salts of isomers
29	(other names: 4-CN-CUMYL-BUTINACA; 4-
30	cyano-CUMYL-BUTINACA; 4-CN-CUMYL
31	BINACA; CUMYL-4CN-BINACA; SGT-78);
32	(9) methyl 2-(1-(cyclohexylmethyl)-1 <i>H</i> -indole-3-
33	carboxamido)-3-methylbutanoate, its optical,
34	positional, and geometric isomers, salts and salts
35	of isomers (other names: MMB-CHMICA, AMB-
36	CHMICA);
37	(10) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
38	1 <i>H</i> -pyrrolo[2,3-b]pyridine-3-carboxamide, its
39	optical, positional, and geometric isomers, salts
40	and salts of isomers (other names: 5F-CUMYL-

1	<u>P7AICA);</u>
2	(11) N-Ethylpentylone, its optical, positional, and
3	geometric isomers, salts and salts of isomers
4	(other names: ephylone, 1-(1,3-benzodioxol-5-yl)-
5	2-(ethylamino)-pentan-1-one);
6	(12) ethyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indazole-3-
7	carboxamido)-3,3-dimethylbutanoate, its optical,
8	positional, and geometric isomers, salts and salts
9	of isomers (trivial name:5F-EDMB-PINACA);
10	(13) methyl 2-(1-(5-fluoropentyl)-1 <i>H</i> -indole-3-
11	carboxamido)-3,3-dimethylbutanoate, its optical,
12	positional, and geometric isomers, salts and salts
13	of isomers (trivial name: 5F-MDMB-PICA);
14	(14) <i>N</i> -(adamantan-1-yl)-1-(4-fluorobenzyl)-1 <i>H</i> -
15	indazole-3-carboxamide, its optical, positional,
16	and geometric isomers, salts and salts of isomers
17	(trivial names: FUB-AKB48; FUB-APINACA;
18	AKB48 N-(4-FLUOROBENZYL));
19	(15) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
20	1H-indazole-3-carboxamide, its optical, positional,
21	and geometric isomers, salts and salts of isomers
22	(trivial names: 5F-CUMYL-PINACA; SGT-25);
23	(16) (1-(4-fluorobenzyl)-1 <i>H</i> -indol-3-yl)(2,2,3,3-
23 24	tetramethylcyclopropyl) methanone, its optical,
25	positional, and geometric isomers, salts and salts
25 26	of isomers (trivial name: FUB-144);
27	(17) <i>N</i> -Ethylhexedrone, its optical, positional, and
28	geometric isomers, salts and salts of isomers
29	(Other name: 2-(ethylamino)-1-phenylhexan-1-
30	one;
31	(18) alpha-Pyrrolidinohexanophenone, its optical,
32	positional, and geometric isomers, salts and salts
33	of isomers (Other names: α -PHP; <i>alpha</i> -
34	pyrrolidinohexiophenone; 1-phenyl-2-
35 35	<u>(pyrrolidine-1-yl)hexan-1-one);</u>
36	(19) 4-Methyl- <i>alpha</i> -ethylaminopentiophenone, its
37	
38	optical, positional, and geometric isomers, salts
38 39	and salts of isomers (Other names: 4-MEAP; 2-
	(ethylamino)-1-(4-methylphenyl)pentan-1-one);
40	(20) 4'-Methyl-alpha-pyrrolidinohexiophenone, its

1	optical, positional, and geometric isomers, salts	
2	and salts of isomers (Other names: MPHP; 4'-	
3	methyl-alpha-pyrrolidinohexanophenone: 1-(4-	
4	methylphenyl)-2-(pyrrolidine-1-yl)hexan-1-one);	
5	(21) alpha-Pyrrolidinoheptaphenone, its optical.	
6	positional, and geometric isomers, salts and salts	
7	of isomers (Other names: PV8; 1-phenyl-2-	
8	(pyrrolidine-1-yl)heptan-1-one); and	
9	(22) 4'-Chloro-alpha-pyrrolidinovalerophenone,	
10	its optical, positional, and geometric isomers, salts	
11	and salts of isomers (Other names: 4-chloro-α-	
12	PVP: 4'-chloro-alpha-pyrrolidinopentiophenone;	
13	1-(4-chlorophenyl)-2-(pyrrolidine-1-yl)pentan-1-	
14	one).	
15		
10	Section 3. Appendix B of Chapter 67. Title 9, Guam Code Annotated, is	
16	amended to	
17	read:	
18	() 01	
19	(a) <u>Substances, vegetable origin or chemical</u> Formatted: Font: Not Italic	
19 20	(a) <u>Substances, vegetable origin or chemical</u> <u>Formatted: Font: Not Italic</u> <u>synthesis.</u> Any of the following substances, <u>however</u>	
19 20 21	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by	
19 20 21 22	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or	
19 20 21	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a	
19 20 21 22	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:	
19 20 21 22 23	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound,	
19 20 21 22 23 24	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate	
19 20 21 22 23 24 25	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived	
19 20 21 22 23 24 25 26	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine,	
19 20 21 22 23 24 25 26 27	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β-	
19 20 21 22 23 24 25 26 27 28	(a) <u>Substances, vegetable origin or chemical</u> <u>synthesis.</u> Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective	
19 20 21 22 23 24 25 26 27 28 29	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however- manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following:	
19 20 21 22 23 24 25 26 27 28 29 30 31	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) row anitum codeine:	
19 20 21 22 23 24 25 26 27 28 29 30 31 32	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) -raw opium-codeine;	
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however- manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) -raw opiumcodeine; (B) -opium extracted dihydroetorphine;	
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) raw opiumcodeine; (B) opium extracts dihydroetorphine; (C) opium fluidethylmorphine; (D) powdered opiumetorphine hydrochloride;	
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however- manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) -raw opium extracts dihydroetorphine; (C) -opium fluidethylmorphine; (D) -powdered opiumetorphine hydrochloride;	
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	(a) Substances, vegetable origin or chemical synthesis. Any of the following substances, however- manufactured whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β- naltrexol and naltrexone, and their respective salts, but including the following: (A) -raw opium extracts dihydroetorphine; (C) -opium fluidethylmorphine; (D) -powdered opiumetorphine hydrochloride;	

1 (G) eodeine hydromorphone: 2 (H) ethylmorphinemetopon; 3 (I) etorphinehydrochloridemorphine; 4 (J) hydrocodonenoroxymorphone; 5 (K) hydromorphoneopium extracts; 6 (L) metoponopium fluid; 7 (M) morphineoripavine: 8 (N) oxycodone; 9 (O) oxymorphone; 10 (P) thebainepowdered opium; (Q) dihydroeterphineraw opium; and 11 12 (R) oripavine.thebaine; and (S) tincture of opium. 13 14 (2) Any salt, compound, derivative, or Formatted: No underline 15 preparation thereof whichthat is chemically equivalent or identical with any of the 16 17 substances listed in Subparagraph (1)paragraph 18 (a) (1) of this section, except that these 19 substances shallbut not include the isoquinoline 20 alkaloids of opium; 21 Opium poppy and poppy straw; 22 (4) Coca leaves and any salt, compound, 23 derivative, or preparation of coca leaves,-24 (including cocaine and ecgonine and their salts, 25 isomers, derivatives, and salts of isomers and 26 derivatives), and any salt, compound, 27 derivative, or preparation that is thereof which 28 is chemically equivalent or identical with any of 29 these substances listed in this subparagraph, but Formatted: No underline 30 not including decocninized coen leaves or Formatted: No underline 31 extractions of coca leaves which do not contain 32 eocaine or eegonine; and, except that the 33 substances shall not include: (A) decocainized coca leaves or extraction 34 35 of coca leaves, which extractions do not 36 contain cocaine or ecgonine; or 37 (B) ioflupane; and

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)

38

	COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)	
1 2 3 4	(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).	
5	(b) Opiates. Any of the following synthetie	Formatted: Font: Not Italic
6	opiates, including any its isomers, esters, ethers, salts,	
7	and salts of isomers, esters, and ethers whenever the	
8	existence of such isomers, esters, esters, and salts isof	
9	them that are theoretically possible within the specific	
10	chemical designation, <u>dextrorphan and</u>	Formatted: Underline
11 12	levopropoxyphene excepted: (1) alfentanil;	
13	(2) alphaprodine;	
14	(3) anileridine;	
15	(4) bezitramide:	
16	(5) <u>earfentanil</u> bulk dextropropoxyphene (non-dosage forms):	
17	(6) bulk dextropropoxyphene (non dosage forms) carfentanil;	Formatted: Not Strikethrough
18	(7) dihydrocodeine;	
19	(8) diphenoxylate;	
20	(9) fentanyl;	
21	(10) isomethadone;	
22	(11) levomethorphanlevo-alphacetylmethadol [some other	
23	names: levo-alpha-acetylmethadol, levomethadyl acetate.	
24	LAAM];	
25	(12) levorphanol levomethorphan;	
26	(13) metazoeinelevorphanol;	
27	(14) methadonemetazocine;	
28	(15) methadone intermediate,4 eyano-	
29	2 dimethylamino 4,4 diphenyl	
30	butanemethadone;	
31	(16) moramide intermediate, 2 methyl 3	
32	morpholinō 1,1 diphenylpropane earboxylie	
33	neidmethadone-intermediate, 4-cyano-2-	
34	dimethylamino-4.4-diphenyl butane;	
35	(17) pethidine (meperidine)moramide-intermediate, 2-methyl-3-	
36	morpholino-1, 1-diphenylpropane-carboxylic acid;	
37	(18) pethidine intermediate A,4 eyano 1-	

1	methyl 4 phenylpiperidinepethidine		
2	(meperidine);		
3	(19) pethidine intermediate Bethyl-		
4	4 phenylpiperidine 4		
5	earboxylatepethidine-intermediate-A,		
6	4-cyano-1-methyl-4-		
7	phenylpiperidine;		
8	(20) pethidine intermediate C,1 methyl-		
9	4 phenylpiperidine 4 carboxylie		
10	acidpethidine-intermediate-B, ethyl-4-		
11	phenylpiperidine-4-carboxylate;		
12	(21) phenazoeinepethidine-intermediate-C. 1-methyl-4-		
13	phenylpiperidine-4-carboxylic acid;		
14	(22) piminodinephenazocine:		
15	(23) racemethorphanpiminodine;		
16	(24) racemorphanracemethorphan;		
17	(25) remifentanil racemorphan;		
18	(26) sufentanilremifentanil;		
19	(27) levo alphaeetylmethadol (other names:		
20	levo-alphaacetylmethadol, levomethadyl		
21	acetate,		
22	LAAM); and sufentanil;		
23	(28) tapentadol.: and		
24	(29) thiafentanil.		
25	(c) Stimulants. Any Mmaterial, compound,	Formatted: Font: Not Italic	
26	mixture, or preparation eontaining which contains any		
27	quantity of the following substances having a		
28	stimulant effect on the central nervous system:		
29	(1) amphetamine, its salts, optical isomers, and		
30	salts of its optical isomers;		
31	(2) methamphetamine, its salts, isomers, and salts		
32	of its isomers;		
33	(3) phenmetrazine and its salts;		
34	(4) methylphenidate; and		
35	(5) lisdexamfetamine, its salts, isomers, and salts		
36	of its isomers.		
37	(d) <u>Depressants. Any Mmaterial</u> , compound,	Formatted: Font: Not Italic	

mixture, or preparation eontainingwhich contains any 1 quantity of the following substances having a depressant 2 effect on the central nervous system, including any its 3 salts, isomers, and salts of isomers of them that are-4 theoreticallywhenever the existence of such salts, 5 isomers, and salts of isomers is possible within the 6 specific chemical designation: 7 (1) amobarbital; 8 (2) pentobarbital; 9 (3) phencyclidine; and 10 (4) secobarbital; and 11 (5) glutethimide; 12 (e) Hallucinogenic substances. Formatted: Font: Not Italic 13 (1) Nabilone (other names for nabilone: (+/-)-Deleted: name 14 trans-3-(1,1-dimethylheptyl)-6,6a,7,8, 10,10a-15 Formatted: Not Strikethrough hexahydro-1-hydroxy-6,6- dimethyl-9H-Deleted: eAnother 16 dibenzo[b,d] pyran-9-one). 17 Formatted: Not Strikethrough (f) Immediate precursors. Any Mmaterial, compound, 18 Deleted: trans mixture, or preparation containing any quantity of the Deleted: 19 following substances: 20 (1) Immediate precursor to amphetamine and Formatted: Indent: First line: 0 , Right: 1.49 , Line 21 spacing: Multiple 1.01 li, Tab stops: 1.35 , Left + Not at methamphetamine: phenylacetone (other 22 names: phenyl-2-propanone; P2P; benzyl 23 Deleted: ¶ methyl ketone; methyl benzyl ketone); 24 Formatted: Font: 14 pt 25 (2) Immediate precursors to phencyclidine (PCP): Deleted: 26 (A) 1-phenylcyclohexylamine; and 27 (B) 1-piperidinocyclohexanecarbonnitrile (PCC). 28 (3) Immediate precursor to fentanyl: 29 (A) 4-anilino-N-phenethylpiperidine (ANPP). 30 (g) Material, compound, mixture, or preparation containing any quantity of the 31 following substances: (1) Immediate precursor to amphetamine and methamphetamine: phenylacetone (other names: phenyl-2- propanone; 32 P2P; benzyl methyl ketone; methyl benzyl ketone); (2) Immediate 33 precursors to phencyclidine (PCP): (A) 1-p,henylcyclohexylamine; and (B) 34 I-piperidinocyclohexanecarbonnitrile (PCC). 35 Deleted: 36 Section 4. Appendix C of Chapter 67, Title 9, Guam Code Annotated, is amended to read: 37

	(a) Stimulants. Any material, compound, mixture, or	Formatted: Font: Not Italic	
1	preparation which containsing any quantity of the	Deleted: A	
2	following substances having a stimulant effect on the	Formatted: No underline	
3	central nervous system, including anyits salts, isomers	Formatted: Top: 0.81	
4	(whether optical, positional, or geometric), and salts of	Formatted: Underline	
5	such isomers whenever the existence of such salts,	Formatted: Underline	
6	isomers, and salts of isomers is of them that are	Deleted: s	
7	theoretically possible within the specific chemical		
8	designation:		
9	(1) Those A compounds, mixtures, or preparations in		
10	dosage unit form containing any stimulant		
11	substance included in Schedule II and which		
12	compounds, mixtures, or preparations were		
13	was-listed as an excepted compound on August 25,		
14	1971, pursuant to the federal Controlled		
15	Substances Act, and any other drug of the		
16	quantitative composition shown in that list for		
17	those drugs or which is the same except for	Deleted:	
18	containing a lesser quantity of controlled		
19	substances;		
20	(2) benzphetamine;		
21	(3) chlorphentermine;		
22	(4) clortermine; and		
23	(5) phendimetrazine.		
24	(b) Depressants. A Any material, compound,	Formatted: Font: Not Italic	
25	mixture, or preparation containing any quantity of the	Deleted:	
26	following substances having a depressant effect on the		
27	central nervous system:		
28	(1) A any compound, mixture, or preparation containing:		
29	any of the following drugs or their salts and one		
30	or more other active medicinal ingredients not		
31	included in any schedule:		
32	(A) amobarbital;		
33	(B) secobarbital; and		
34	(C) pentobarbital;		
35	or any salt thereof and one or more other active medicinal		
36	ingredients which are not listed in any schedule.		
37	(2) any of the following drugs, or their salts, in		
38	suppository dosage form, approved by the Federal		
38	suppository dosage form, approved by the Federal		

1 Food and Drug Administration for marketing only 2 as a suppository: 3 (A) amobarbital: 4 (B) secobarbital, and (C) pentobarbital. 5 6 (3) a substance containing any quantity of a 7 derivative of barbituric acid or any salt of a derivative of barbituric acid; 8 9 (4) chlorhexadol; 10 (5) embutramide; 11 (6) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, 12 and salts of isomers, for which an application is 13 approved under Section 505 of the Federal Food. 14 15 Drug, and Cosmetic Act; 16 (7) ketamine, its salts, isomers, and salts of isomers (other names: (±)-2-(2-chlorophenyl)-2-Deleted: [17 18 (methylamino)-cyclohexanone); Formatted: Not Strikethrough Deleted: (8) lysergic acid; 19 Formatted: Not Strikethrough 20 (9) lysergic acid amide; Deleted: 1 21 (10) methyprylon; (11) sulfondiethylmethane; perampanel, and its salts, isomers 22 23 and salts of isomers. 24 (12) sulfonethylmethane; sulfondiethylmethane; 25 (13) sulfonmethane; sulfonethylmethane; 26 (14) tiletamine and zolazepam, or any salt thereof 27 (other names for a tiletamine zolazepam combination product: 28 Telazol; other names for tiletamine: 2-29 (ethylamino) 2 (2 thienyl) eyelohexanone; other names for zolazepam: 4 (2 fluorophenyl) 6,8 dihydro 1,3,8 30

trimethylpyrazolo [3,4 e] [1,4] diazepin 7(1H) one,

(15) tiletamine and zolazepam, or any salt thereof

(Some trade or other names for a tiletamine-

Some trade or other names fortiletamine: 2-

flupyrazapon: sulfonmethane:

zolazepam combination product:

31

32

33 34

35

36

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)

Formatted: Indent: Left: 2.02, No bullets or numbering

Deleted: g

Deleted: H

1 2 3	(ethylamino)-2-(2-thienyl)-cyclohexanone; Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-ee] [1,4]-diazepin-7(1HH)-one,	
4	flupyrazapon;	
5	(c) Nalorphine.	
6	(d) Narcotic Drugs.	Formatted: Font: Not Italic
7	(1) A Any material, compound, mixture, or preparation containing any	
8	of the following narcotic drugs, or their salts calculated as the free	
9	anhydrous base or alkaloid, in limited quantities as set forth below:	
10	(A) not more than 1.8 grams of codeine	
11	per 100 milliliters or not more than 90 milligrams per dosage	
12	unit, with an equalor greater quantity of an isoquinoline alkaloid	
13	of opium:	
14	(B) not more than 1.8 grams of codeine per	
15	100 milliliters or not more than 90 milligrams per	
16	dosage unit, with one or more active, nonnarcotic	
17	ingredients in recognized therapeutic amounts;	Deleted: <#>(C) not more than 300 milligrams of dihydrocodeine (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit.
18	(C) not more than 300 milligrams of dihydrocodeine (hydrocodone) per 100 milliliters	with one or more active nonnarcotic ingredients in recognized therapeutic amounts;
19	or not more than 15 milligrams per dosage unit,	Deleted: (E)
20	with one or more active-nonnarcotic ingredients in	Formatted: No underline
21	recognized therapeutic amounts;	Formatted: No underline
22	(D) not more than 300 milligrams 1.8 grams of	Formatted: Strikethrough
23	Dihydrocodeine (hydrocodone) per 100 milliliters or not more	Formatted: No underline
24	than 15_90 milligrams per dosage unit, with one or	Formatted: No underline
25	more active-nonnarcotic ingredients in recognized	Formatted: No underline
26	therapeutic amounts;	Formatted: Strikethrough
27	(E) not more than 1.8 grams of dihydrocodeine	Formatted: No underline
28	per 100 milliliters or not more than 90 milligrams per	Formatted: Indent: Left: 0.19 , Hanging: 1.88
29	dosage unit, with one or more active, nonnarcotic	Deleted: ,
30	ingredients in recognized therapeutic amounts	Deleted: (F)
		Formatted: No underline
31	not more than 300 milligrams of	Formatted: Strikethrough
32	ethylmorphine per 100 milliliters or not more than	Formatted: Underline
33	15 milligrams per dosage unit, with one or more	Formatted: Indent: Left: 0.19 , Hanging: 1.88
34	active, nonnarcotic ingredients in recognized	Deleted: (G)
35	therapeutic amounts;	Formatted: No underline
36	(F) not more than 300 milligrams of	Formatted: Strikethrough

37	ethylmorphine per 100 milliliters or not more than	
38	15 milligrams per dosage unit, with one or more	
39	active, nonnarcotic ingredients in recognized	
40	therapeutic amounts not more than 500 milligrams of	Formatted: Underline
1	opium per 100 milliliters or per 100 grams, or not	
2	more than 25 milligrams per dosage unit, with one	
3	or more active, nonnarcotic ingredients in	
4	recognized therapeutic amounts; and	Formatted: Underline
5	(G) not more than 500 milligrams of opium per	Deleted: (##)
6	100 milliliters or per 100 grams, or not more than 25	Formatted: Indent: Hanging: 2.96
7	milligrams per dosage unit, with one or more active.	Formatted: No underline
1		Formatted: Strikethrough
8	nonnarcotic ingredients in recognized therapeutic	Formatted: Strikethrough
9	amounts; and not more than 50 milligrams of	Formatted: Strikethrough
10	morphine per 100 milliliters or per 100 grams	Formatted: Strikethrough
11	with one or more active, nonnarcotic ingredients	Formatted: Strikethrough
12	in recognized therapeutic amounts	Formatted: Strikethrough
13	(H) not more than 50 milligrams of morphine per	Formatted: Underline
14	100 milliliters or per 100 grams with one or more active,	Deleted:
15	nonnarcotic ingredients in recognized therapeutic	Formatted: No underline, Strikethrough
16	amounts.	Formatted: Strikethrough
17		Formatted: Indent: Hanging: 2.96
18	(2) A Any material, compound, mixture, or	Formatted: Strikethrough
19	preparation containing any of the following narcotic	Formatted: Strikethrough
20	drugs and or its their salts as set below:	Formatted: Strikethrough
21	(A) <u>buprenorphine</u> ;	Formatted: Strikethrough
22	(e) Anabolic Steroids.	
23	Any drug or hormonal substance chemically and	Formatted: Strikethrough Deleted: or their
24	pharmacologically related to testosterone (other than	Deleted: B
25	estrogens, progestins, corticosteroids, and	
26	dehydroepiandrosterone), and includes:	Formatted: Font: Not Italic
27	(1) 3 β[beta] ,17-dihydroxy-5a-androstane;	
28	(2) 3α [alpha], 17β [beta]-dihydroxy-5a-androstane;	
29	(3) 5α [alpha]-androstan-3,17-dione;	
30	(4) 1-androstenediol (3 <u>B[beta]</u> ,17 <u>B[beta]</u> -	
31	dihydroxy-5 <u>α[alpha]</u> -androst-1-ene);	
32	(5) 1-androstenediol ($3\alpha \frac{\text{falpha}}{\text{log}}$, $17\beta \frac{\text{fbeta}}{\text{log}}$	
33	dihydroxy-5 α [alpha]-androst-1-ene);	
55	omy aroxy - 3 according - and ost-1-enc),	
	27	

34	(6) 4-androstenediol (3β [beta] ,17β [beta]-
35	dihydroxy-androst-4-ene;
36	(7) 5-androstenediol (3 \(\beta \) [beta \] .
37	dihydroxy-androst-5-ene);
38	(8) 1-androstenedione ($[5\alpha \frac{\text{[alpha]}}{\text{]}}$)-androst-1-en-3,17-
39	dione;
40	(9)4-androstenedione (androst-4-en-3,17-dione);
41	(10)5-androstenedione(androst-5-en-3,17-dione);
42	(11) bolasterone (7 α[alpha] ,17 α[alpha] -
43	dimethyl-17 <u>β[beta]</u> -hydroxyandrost-4-en-3-one);
44	(12) boldenone (17 β [beta]-hydroxyandrost-1,4-
45	diene-3-one);
46	(13) boldione (androsta-1,4-diene-3,17-dione);
47	(14) calusterone (7β [beta] ,17α [alpha] -dimethyl-

1	17 β[beta] -hydroxyandrost-4-en-3-one);	
2	(15) ehlorotestosterone (4 ehlortestosterone),	
3	(16) (15) clostebol (4-chloro-17β[beta]-hydroxyandrost-4-en-3-	
4	one);	
5	(17) (16) dehydrochloromethyltestosterone (4-	
6	chloro- 17 <u>β</u> [beta] -hydroxy-17 <u>α[alpha]-methyl-</u>	
7	androst-1,4-dien-3-one);	
8	(18) (17) desoxymethyltestosterone	
9	(17 <u>α[alpha]-</u> methyl-5 <u>α[alpha]-androst-2-<u>e</u>n-</u>	
10	17 <u>β[beta]</u> -ol) (a.k.a 'madol <u>'</u>)	
11	$\frac{(19)}{(18)}$ Delta Δ 1-dihydrotestosterone	
12	(a.k.a. "1- testosterone") (17β [beta]	Deleted: '
13	hydroxy-5 <u>α[alpha]</u> -androst-1-en-3-one);	Deleted: <u>'</u>
14	(20) (19) 4-dihydrotestosterone	
15	(17 <u>β{beta}</u> hydroxy-androstan-3-one);	
16	(21) (20) drostanolone (17β[beta]-hydroxy-	
17	2 <u>α[alpha]</u> -methyl-5 <u>α[alpha]</u> -androstan-3-one);	
18	$\frac{(22)}{(21)}$ ethylestrenol $(17\alpha \frac{\text{[alpha]}}{}$	
19	ethyl-17β [beta]- hydroxyestr-4-ene);	
20	(23) (22) fluoxymesterone (9-fluoro-17α [alpha] -	
21	methyl- 11 <u>B[beta]</u> ,17 <u>B[beta]</u> -dihydroxyandrost-	
22	4-en-3-one);	
23	(24) (23) formebolone (2-formyl-17\(\alpha\)[alpha]-	
24	methyl- 11 <u>α[alpha]</u> ,17 <u>β[beta]</u>	
25	dihydroxyandrost-1,4-dien-3-one);	
26	$\frac{(25)}{(24)}$ furazabol $(17\alpha \frac{\text{falpha}}{\text{methyl}}$ -methyl-	
27	17 <u>β[beta]</u> -hydroxyandrostano[2,3-c]-	
28	furazan);	
29	(26) (25) 13β[beta]-ethyl-17β[beta]-hydroxygon-4-en-3-one;	
30	$\frac{(27)}{(26)}$ 4-hydroxytestosterone (4,17 $\frac{\beta \text{[beta]}}{(26)}$	
31	dihydroxy-androst-4-en-3-one);	
32	(28) (27) 4-hydroxy-19-nortestosterone	
33	(4,17 β[beta] -dihydroxy-estr-4-en-3-	
34	one);	Deleted: mestanolone (17α [alpha] methyl-
35	(29) desoxymethyltestosterone (17α[alpha]-	17 <u>B[beta]</u> hydroxy-5-androstan-3-one);
36	methyl 5α[alpha] androst 2 en 17β[beta] ol)	Formatted: Space Before: 0 pt, Line spacing: Exactly

```
1
                              (a.k.a 'madol')
 2
                              (30) (28) mestanolone (17 \alpha [alpha]-methyl-17
 3
                              \beta[beta]-hydroxy-5-androstan-3-one);
 4
                              (31) (29) mesterolone (1\alpha \frac{\text{[alpha]}}{\text{methyl}})
 5
                              17\underline{\beta}[beta]-hydroxy-[5\underline{\alpha}[alpha]]-androstan-3-
 6
                              one);
                              (32) (30) methandienone (17\alpha \text{ [alpha]})
 7
 8
                              methyl-17<u>β[beta]</u>-hydroxyandrost-1,4-dien-
 9
                              3-one);
10
                              (33) (31) methandriol (17\alpha[alpha]-methyl-
                              3\underline{\beta}[beta], 17\underline{\beta}[beta]-dihydroxyandrost-5-ene);
11
12
                              (34) (32) methasteroneandranone (2\alpha[alpha], 17\alpha[alpha]
13
                              dimethyl-5\alpha[alpha]-androstan-17\beta[beta]-ol-3-one);
14
                              (35) methandrostenolone;
                              (36) (33) methenolone (1-methyl-17<u>B[beta]</u>-hydroxy-
15
                              5\alpha [alpha]-androst-1-en-3-one);
16
17
                              (37) (34) 17\alpha[alpha]-methyl-3\beta[beta], 17\beta[beta]-
18
                              dihydroxy-5a-androstane;
19
                              (38) (35) 17\alpha[alpha]-methyl-
20
                              3\alpha[alpha], 17\beta[beta]-dihydroxy-5a-androstane;
                              (39) (36) 17\alpha [alpha]-methyl-
21
                              3\underline{\beta}[beta],17\underline{\beta}[beta]-
22
23
                              dihydroxyandrost-4-ene;
24
                              (40) (37) 17\alpha[alpha]-methyl-4-
                              hydroxynandrolone(17\alpha[alpha]-methyl-
25
                              4-hydroxy-17<u>β</u><del>[beta]</del>-hydroxyestr-4-en-
26
27
                              3-one);
28
                              (41) (38) methyldienolone (17\alpha[alpha]-
29
                              methyl-17β[beta]-hydroxyestra-4,9(10)-dien-
30
31
                              (42) (39) methyltrienolone (17\alpha[alpha]-
                              methyl-17<u>B[beta]</u>-hydroxyestra-4,9-11-trien-
32
33
                              3-one);
34
                              (43) (40) methyltestosterone (17\alpha[alpha]-
35
                              methyl-17<u>β[beta]</u>-hydroxyandrost-4-en-3-one);
36
                              (44) (41) mibolerone
```

```
(7\alpha[alpha], 17\alpha[alpha]-dimethyl-
 1
 2
                                 17β[beta]-hydroxyestr-4-en-3-one);
 3
                                (45) (42) 17\alpha[alpha]-methyl-[Delta]\Delta1-
                                dihydrotestosterone (17<u>β</u><del>[beta]</del>-hydroxy-
 4
 5
                                 17\underline{\alpha}[alpha]-methyl-5\underline{\alpha}[alpha]-androst-1-en-3-
 6
                                one) (a k.a. '17-\alpha[alpha]-methyl-1-
 7
                                testosterone"');
 8
                                (46) (43) nandrolone (17<u>\beta</u>]-hydroxyestr-4-en-3-one);
 9
                                (47) (44) 19-nor-4-androstenediol
10
                                (3\underline{\beta}[\text{beta}], 17\underline{\beta}[\text{beta}] - \text{dihydroxyestr-4-ene});
                                (48) (45) 19-nor-4-androstenediol
11
12
                                (3\alpha \frac{\text{[alpha]}}{17\beta \text{[beta]}} - \text{dihydroxyestr-4-ene)};
                                (49) (46) 19-nor-5-androstenediol (3\beta \text{[beta]},
13
                                 17β<del>[beta]</del>-dihydroxyestr-5-ene);
14
                                (50) (47) 19-nor-5-androstenediol
15
                                (3\alpha \frac{\text{[alpha]}}{17\beta \text{[beta]}} - \text{dihydroxyestr-5-ene)};
16
17
                                (51) (48) 19-nor-4,9(10)-
18
                                androstadienedione(estra-4,9(10)-diene-3,17-
19
                                dione);
20
                                (52)(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
                                (53)(50)19-nor-5-androstenedione(estr-5-en-3,17-dione);
21
22
                                (54) (51) norbolethone
                                (13\underline{\beta}[\text{beta}], 17\underline{\alpha}[\text{alpha}] - \text{diethyl} - 17\underline{\beta}[\text{beta}] -
23
                                hydroxygon-4-en-3-one);
24
25
                                (55) (52) norclostebol (4-chloro-17\underline{\beta}[beta]-
                                hydroxyestr-4-en-3-one);
26
27
                                (56) (53) norethandrolone (17\alpha[alpha]-
                                ethyl-17β<del>[beta]</del>-hydroxyestr-4-en-3-one);
28
29
                                (57) (54) normethandrolone (17\alpha \text{[alpha]}-
30
                                methyl-17<u>β[beta]</u>-hydroxyestr-4-en-3-one);
                                (58) (55) oxandrolone (17\alpha \text{ [alpha]}\text{-methyl-}
31
32
                                 17\underline{\beta}[beta]-hydroxy-2-oxa-[5\underline{\alpha}[alpha]]-androstan-
33
                                3-one);
34
                                (59) (56) oxymesterone (17\alpha[alpha]-methyl-4,17\beta[beta]-
35
                                dihydroxyandrost-4-en-3-one;
```

1	(60) (57) oxymetholone (17 α alpha) methyl-2-	
2	hydroxymethylene-17 β[beta]- hydroxy-	
3	$[5\alpha \frac{\text{alpha}}{\text{alpha}}]$ -androstan-3-one);	
4	(61) stanolone;	
5	$\frac{(62)}{(58)}$ prostanozol $(17\beta-hydroxy-5\alpha)$	Deleted: £
6	androstano[3,2-c]pyrazole);	Deleted: betal
7	$\frac{(63)}{(59)}$ stanozolol $(17\alpha \frac{\text{alpha}}{\text{methyl}})$ -methyl-	Deleted: [alpha]
8	17 <u>β{beta}</u> hydroxy-[5 <u>α{alpha}]</u> -androst-2-	
9	eno[3,2-c]-pyrazole);	
10	(64) (60) stenbolone (17 <u>Bfbeta</u>]-hydroxy-	
11	2-methyl-[5 <u>αfalpha]</u>]-androst-1-en-3-	
12	one);	
13	(65) (61) testolactone (13-hydroxy-3-oxo-	
14	13,17- secoandrosta-1,4-dien-17-oic acid	
15	lactone);	
16	$\frac{(66)}{(62)}$ testosterone $(17\underline{\beta}$ [beta]-	
17	hydroxyandrost-4-en-3-one);	
18	(67) (63) tetrahydrogestrinone	
19	$(13\underline{\beta}[\text{beta}], 17\underline{\alpha}[\text{alpha}] - \text{diethyl} - 17\underline{\beta}[\text{beta}]$	
20	hydroxygon-4,9,11-trien-3-one);	
21	$\frac{(68)}{(64)}$ trenbolone $(17\underline{\beta}$ [beta] hydroxyestr-	
22	4,9,11-trien-3-one); and	
23	(69) (65) Any salt, ester, or ether of a drug or	
24	substance described or listed in (1) through (66)	Formatted: Not Strikethrough
25	above, if that salt, ester, or ether promotes muscle	
26	growth. in this paragraph. Except such term does	
27	not include an anabolic steroid which that is	
28	expressly intended for administration through	
29	implants to cattle or other nonhuman species	
30	and which has been approved by the Secretary	
31	of Health and Human Services for such	
32	administration. If any person prescribes,	
33	dispenses, or distributes such steroid for human	
34	use, such person shall be considered to have	
35	prescribed, dispensed, or distributed an anabolic	
36	steroid within the meaning of this paragraph.	
37		

DPHSS may exempt by rule a compound, mixture, or preparation containing a stimulant or depressant substance listed in subsections A and B from the application of all or part of this Act, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a stimulant or depressant effect on the central nervous system. (f) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product

Formatted: Font: Not Italic

(Some other names for dronabinol: (6aR-trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6Hdibenzo[b,d]pyran-1-ol])

Section 5. Appendix D of Chapter 67, Title 9, Guam Code Annotated, is amended to

read:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

38

- (a) Narcotic drugs. A Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
 - (1) not more than 1 milligram of diffenoxin and not less than 25 micrograms of atropine sulfate per dosage unit:
 - (2) dextropropoxyphene (dosage forms); and dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2- diphenyl-3-methyl-2-propionoxybutane); and
 - (3) dextropropoxyphene (alpha (+) 4 dimethylamino
 - 1.2 diphenyl 3 methyl 2 propionoxybutane)2-

[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).

(b) Depressants. A Any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including any salts,

Formatted: Font: Not Italic

Formatted: Underline

Formatted: Strikethrough

Formatted: Font: Not Italic

1	isomers, and salts of isomers whenever the existence	
2	of such salts, isomers, and salts of isomers is of	
3	them that are theoretically possible within the	//
4	specific chemical designation:	
5	(1) alfaxalone alprazolam:	
6	(2) alprazolam barbital;	
7	(3) barbital bromazepam;	
8	(4) brexanolone camazepam:	1
9	(5) bromazepam earisepredel;	
10	(6) camazepam ehloral betaine:	
11	(7) carisoprodol chloral hydrate;	
12	(8) chloral betaine ehlordiazepoxide;	
13	(9) elobazam chloral hydrate;	The state of the s
14	(10) clonazepam chlordiazepoxide:	
15	(11) clorazepate clobazam:	The same
16	(12) elotiazepam clonazepam;	
17	(13) eloxazolam clorazepate;	
18	(14) delorazepam clotiazepam;	
19	(15) diazepam cloxazolam:	
20	(16) diehloraphenazone delorazepam:	
21	(17) estazolam diazepam:	
22	(18) ethehlorvynol dichloraphenazone:	
23	(19) ethinamate estazolam;	
24	(20) ethyl loflazepate ethchlorvynol:	
25	(21) fludiazepam ethinamate;	
26	(22) flunitrazepam ethyl loflazepate;	
27	(23) flurazepam fludiazepam;	
28	(24) fospropofol flunitrazepam:	
29	(25) halazepam flurazepam:	
30	(26) haloxazolam fospropofol;	
31	(27) ketazolam halazepam:	
32	(28) loprazolam haloxazolam:	
33	(29) lorazepam ketazolam:	Annual Control
34	(30) lormetazepam loprazolam:	
35	(31) mebutamate lorazepam;	
36	(32) medazepam Jormetazepam;	

	Deleted: 5
1	Deleted: +-
1	Formatted: Strikethrough
6	Formatted: Right: 2.16 , Tab stops: 2.13 , Left + Not at 1.52 + 1.52
-	Deleted: (1)
-711	Formatted: Underline
Towns,	Formatted: Strikethrough
-	Deleted: (2)
1	Formatted: Underline
1	
1	Formatted: Strikethrough
1	Deleted: (3)
1	Formatted: Strikethrough
1	Deleted: -4)
	Formatted: Underline
	Formatted: Strikethrough
	Deleted: (5)
1	<u> </u>
	Formatted: Underline
	Formatted: Strikethrough
	Deleted: -6)
	Formatted: Underline
	Formatted: Strikethrough
1	Deleted: (7)
1	Formatted: Underline
	Formatted: Strikethrough
	Formatted: Underline
	Formatted: Underline
	————
	Formatted: Strikethrough
	Formatted: Underline
	Deleted: <# (8) (9) ehloral hydrate;
	(9) (10) chlordiazeponide;
H	16 (10) (11) clobazam; 11) 12) clobazepam;
	12) 13) clorazepate;
	(13) (14) elotiazepam;
	(14) (15) cloxazolam;
	The state of the s
	(15) (16) delorazepam;
	22 (16) (17) diazepam;
	(17) (18) dichloraphenazone;
	19) 19) estazelam;
	19) 20) ethehlersynel;
	(20) (21) ethinamate; (21) (22) ethinamate; (21)
	(21) (22) ethyl loflazepate; [1]

2	(24) 4 1 5 1 4	
	(34) methohexital medazepam;	
3	(35) methylphenobarbital (mephobarbital) meprobamate.	
4	(36) midazolam methohexital:	
5	(37) nimetazepam methylphenobarbital (mephobarbital):	
6	(38) mitrazepam midazolam:	
7	(39) nordiazepam nimetazepam;	
8	(40) oxazepam nitrazepam:	
9	(41) oxazolam nordiazepam:	
10	(42) paraldehyde oxazepam;	
11	(43) petrichloral oxazolam;	
12	(44) phenobarbital petrichloral;	
13	(45) pinazepam petrichloral;	
14	(46) prazepam phenobarbital:	
15	(47) quazepam pinazepam;	
16	(48) temazepam prazepam;	
17	(49) tetrazepam quazepam;	
18	(50) triazolam suvorexant:	
19	(51) zaleplon temazepam;	
20	(52) zolpidem tetrazepam; and	
21	(53) zopielone triazolam÷	
22	(54) zaleplon;	
23	(55)zolpidem; and	
24	(56) zopiclone.	
2.5		
25	(c) Fenfluramine. Any material, compound,	
26	mixture, or preparation which contains any quantity of	
27	the following substances, including its salts, isomers	
28	(whether optical, position, or geometric), and salts of	
29	such isomers, whenever the existence of such salts,	
30	isomers, and salts of isomers is possible;(1) fenfluramine.	

Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.17 + Indent at: 1.52 , Tab stops: 2.13 , Left + Not at 2.15 + 2.15 Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.17 + Indent at: 1.52 Formatted: No underline, Not Strikethrough Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.17 + Indent at: 1.52 Deleted: <#>(29) (30) loprazolam; Formatted: Font: 14 pt Deleted: <#>(30) (31) lorazepam; (31) (32) lormetazepam; 32) (33) mebutamate; -33) (34) medazepam; -34) (35) meprobamate; (35) (36) methohexital; (36) (37) methylphenobarbital (mephobarbital); (37) (38) midazolam; (38) (39) nimetazepam; -39) (40) nitrazepam; 40) (41) nordiazepam; 13-41) (42) oxazepam; 14-(42) (43) oxazolam; (43) (44) paraldehyde; (44) (45) petrichloral; (45) (46) phenobarbital; (46) (47) pinazepam; 19 47) (48) prazepam; 20 - 48) (49) quazepam; (49) (50) suvorexant; (50) (51) temazepam; (51) (52) tetrazepam; (52) (53) triazolam; 25 (53) (54) zaleplon; -54) (55) zolpidem; and -55) (56) zopiclone ¶ Formatted: Font: Not Italic Deleted: <#> Formatted ...[2] Deleted: Deleted: Deleted:

Deleted: 1

1	(d) Lorcaserin. Any material, compound.	Formatted: Underline
2	mixture, or preparation which contains any quantity of	Formatted: Font: Not Italic
3	the following substances, including its salts isomers and	
4	salts of such isomers, whenever the existence of such	
5	salts, isomers, and salts of isomers is possible.	
6	(1) lorcaserin.	
7	(e) Stimulants. AAny material, compound,	Formatted: Strikethrough
8	mixture, or preparation containing any quantity of the	Formatted: Font: Not Italic
9	following substances having a stimulant effect on the	
10	central nervous system, including their salts, isomers,	
11	and salts of isomers:	
12	(1) cathine ((+)-norpseudoephedrine);	
13	(2) diethylpropion;	
14	(3) fencamfamin;	
15	(4) fenproporex;	
16	(5) mazindol;	
17	(6) mefenorex;	
18	(7) modafinil;	
19	(8) pemoline (including organometallic	
20	complexes and chelates thereof);	
21	(9) phentermine;	
22	(10) pipradrol;	
23	(11) sibutramine;	
24	(12) solriamfetol (2-amino-3-phenylpropyl carbamate;	
25	benzenepropanol, beta-amino-carbamate (ester)); and	
26	(12)(13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).	
27	(e)(f) Other substances. A Any material,	Formatted: Font: Not Italic
28	compound, mixture, or preparation containing any	
29	quantity of the following substance, including its salts:	
30	(1) pentazocine;	
31	(2) butorphanol (including its optical isomers): and	
32	(3) eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-	
33	dimethylphenyl]-1-oxopropyl][(1S)-1-4-phenyl-1H-imidazol-	
34	2-yl)ethyl]amino]methyl]-2-methoxybenzoicacid)(including	
35	its optical isomers) and salts of isomers.	

(f) (g) DPHSS may exempt by rule any compound, mixture, or preparation containing a depressant substance listed in subsection B from the application of all or part of this Act, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system and the admixtures are in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances having a depressant effect on the central nervous system.

Section 6. Appendix E of <u>Chapter 67.</u> Title 9, Guam Code Annotated, is *amended* to

read:

(a) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:

(b) Narcotic drugs containing non-narcotic active

1 2

medicinal ingredients. A Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include also contains one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than

those possessed by the narcotic drugalone:

 not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(3) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(4) not more than 2.5 milligrams of

Formatted: Font: Not Italic

Formatted: Font: Not Italic

	COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)	
1	diphenoxylate and not less than 25 micrograms	
2	of atropine sulfate per dosage unit;	
3	(5) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and	
5	(6) not more than 0.5 milligram of difenoxin	
6	and not less than 25 micrograms of atropine	
7	sulfate per dosage unit.	
8	(c) Stimulants. A Any material, compound,	Formatted: Font: Not Italic
9	mixture, or preparation containing any quantity of the	
10	following substances having a stimulant effect on the	
11	central nervous system, including their salts, isomers	
12	and salts of isomers:	
13	(1) pyrovalerone	Deleted: ;
14		Formatted: Font: Not Italic
15	(d) <u>Depressants</u> . <u>A Any</u> material, compound, mixture, or preparation which contains any quantity of the	Pormattee. Polit. Not Italic
16	following substances having a depressant stimulant	
17	effect on the central nervous system, including their	
18	its salts; isomers and salts or isomers:	
18		
20	(1) lacosamide ((R) 2 acetoamido N benzyl	Deleted: 19+
	3 methoxy propionamide brivaracetam ((2S)-2-[(4R)-2-oxo-	Formatted: Font: 14 pt
	4-propylpyrrolidin-1-yl]butanamide) (also referred	Deleted:
21	to as BRV; UCB-34714; Briviact) (including its	Formatted: Strikethrough
22	salts): (2) pregabalin [(S) 3 (aminomethyl) 5 methylhexanoic acid]	Formatted: Body Text, Indent: Left: 2.15 , Space Before: 4.15 pt, Line spacing: Exactly 18.65 pt, No bullets or numbering, Tab stops: Not at 2.15
-	****	Deleted: 5
23	cenobamate ([(1R)-1-(2-chlorophenyl)-2-	Formatted: Strikethrough
24	(tetrazol-2-yl)ethyl]carbamate; 2H-tetrazole-2-	
25	ethanol, alpha-(2-chlorophenyl)-,	
26	carbamate(ester), (alphaR)-; carbamic acid (R)-	
27 28	(+)-1-(2-chlorophenyl)-2-(2 <i>H</i> -tetrazol-2-yl)ethyl	
	ester):	
29	(3) ezogabine [N-[2-amino-4-(4-	
30	fluorobenzylamino)-phenyl]-carbamic acid ethyl	
31	ester]:	
32	(4) lacosamide $[(R)$ -2-acetoamido- N -benzyl-	Deleted: -1)
33	3- methoxy-propionamide];	
2.1	(5) lasmiditan [2.4,6-trifluoro- <i>N</i> -(6-(1-	Deleted: (2)
34		Deleted, TET

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)

1	benz-amide]; and
2	(6) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid],
3	Section 7, Severability. If a provision of this act or its application to any
4	person or circumstance is held invalid, the invalidity does not affect other provisions.
5	or applications of the act that can be given effect without the invalid provision or
6	application, and to this end the provisions of this act are severable.

Formatted: No underline

Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.08 + Indent at: 0.33

Formatted: Underline

Deleted:

Formatted: No underline

Formatted: Font: 14 pt, Bold

Formatted: Font: 14 pt

Formatted: Font: 14 pt

Formatted: Underline

Formatted: Font: 14 pt

Formatted: Font: 14 pt

Formatted: Underline

Formatted: Font: 14 pt
Formatted: Underline

Formatted: Font: 14 pt

Formatted: List Paragraph, Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.08 + Indent at: 0.33 , Tab stops: 1 , Left + 2.15 , Left + 2.15 , Left

Formatted: Font: 14 pt, Underline

COMMITTEE MARK-UP VERSION OF BILL 169-36 (LS)

Deleted: #>Section 7 Severability If a provision of this act or its application to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the act that can be given effect without the invalid provision or application, and to this end the provisions of this act are severable

Page 34: [1] Deleted Therese Terlaje 3/14/22 3:53:00 PM

Page 35: [2] Formatted Therese Terlaje 3/14/22 4:08:00 PM

ı

Line spacing: Exactly 17.95 pt, Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.17" + Indent at: 1.52", Tab stops: 2.15", Left + 2.15", Left + Not at 1.52" + 1.52"



Guam Congress Building 163 Chalan Santo Papa Hagåtña, Guam 96910 Tel 671-472-2461 Cor@guamlegislature.org

August 16, 2021

MEMO

To: Rennae Meno

Clerk of the Legislature

From: Senator Amanda L. Shelton

Acting Chairperson, Committee on Rules

Re: Fiscal Note Waiver for Bill No. 169-36 (LS)

Håfa adai,

Attached, please find the fiscal note waiver for the following bill:

Bill No. 169-36 (LS)

Please forward the same to Management Information Services (MIS) for posting on our website.

If you have any questions or concerns, please feel free to contact Mary Maravilla, Committee on Rules Director at 472-2461.

Thank you for your attention to this important matter.





BUREAU OF BUDGET & MANAGEMENT RESEARCH

OFFICE OF THE GOVERNOR
Post Office Box 2950, Hagaiña Guam 96932

LOURDES A. LEON GUERRERO GOVERNOR

LESTER L. CARLSON, JR. DIRECTOR

JOSHUA F. TENORIO LIEUTENANT GOVERNOR

AUG 1 6 2021

Vice Speaker Tina Muña Barnes Chairperson, Committee on Rules I Mina'trentai Sais Na Liheslaturan Guåhan Thirty-Sixth Guam Legislature Guam Congress Building 163 Chalan Santo Papa Hagåtnå, Guam 96910

Hafa Adai Vice Speaker Barnes:

The Bureau requests that Bill No. 169-36 (LS) be granted a waiver pursuant to Public Law 12-229, as amended for the following reason(s):

BILL NO. 169-36 (LS) IS "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E OF CHAPTER 26, TITLE 9 OF GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

The proposed legislation intends to properly update the list of scheduled drugs to reflect with federal regulations provided by §1308.11, §1308.12, §1308.13, §1308.14, AND §1308.15 OF Title 21, Code of Federal Regulations, relative to schedules of controlled substances.

As such, the bill is administrative in nature and poses no fiscal impact upon any of the funds of Government of Guam.

Senseramente,

LESTER L. CARLSON, JR.



Office of the Speaker THERESE M. TERLAJE

I Mina'trentai Sais na Liheslaturan Guåhan 36th Guam Legislature Committee on Health, Land, Justice and Culture

COMMITTEE VOTE SHEET

Bill No. 169-36 (LS)- As Amended by the Committee on Health, Land, Justice and Culture- Introduced by Senator Telena Cruz Nelson- "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

	SIGNATURE	TO DO PASS	TO NOT PASS	TO REPORT OUT ONLY	TO ABSTAIN	TO PLACE IN INACTIVE FILE
Speaker Therese M. Terlaje Chairperson	There M. Talgie 3/14/22	Х				
Senator Sabina Flores Perez Vice Chairperson of Health, Land and Culture	E-Vote 3/15/22			X		
Senator Telena C. Nelson Vice Chairperson of Justice						
Vice Speaker Tina Muña Barnes Member	E-Vote 3/15/22	X				
Senator Joanne M. Brown Member	E-Vote 3/15/22	Х				
Senator Christopher M. Dueñas Member	E-Vote 3/15/22			X		
Senator Amanda L. Shelton Member	E-Vote 3/15/22	X				
Senator Telo T. Taitague, Member	E-Vote 3/15/22			X		
Senator Jose "Pedo" Terlaje Member	E-Vote 3/15/22	X				



Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

REQUEST FOR E-VOTE: BILL 169-36 (LS)- AS AMENDED

9 messages

Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com>

Mon, Mar 14, 2022 at 6:38 PM

To: Sabina Perez <sabina@senatorperez.org>, Senator Sabina Perez <office@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortcnelson@gmail.com>, Senator Telena Cruz Nelson <senatortcnelson@guamlegislature.org>, Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>, "Honorable Joanne M. Brown" <office@senatorjoannebrown.com>, Chris Duenas <senatorchrisduenas@gmail.com>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Office of Senator Shelton Guam Legislature <officeofsenatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>, Senator Jose Pedo Terlaje <senatorpedo@senatorjpterlaje.com>

Hafa Adai Committee Members,

Please see attached Committee Report on Bill No. 169-36 (LS)- As Amended by the Committee on Health, Land, Justice and Culture- Introduced by Senator Telena Cruz Nelson- "AN ACT TO AMEND APPENDIX A, APPENDIX B, APPENDIX C, APPENDIX D, AND APPENDIX E ALL OF CHAPTER 67, TITLE 9, GUAM CODE ANNOTATED, RELATIVE TO UPDATING THE LIST OF SCHEDULED CONTROLLED SUBSTANCES PROVIDED IN THE GUAM UNIFORM CONTROLLED SUBSTANCES ACT."

Please indicate your preferred action from the following;

- TO DO PASS
- TO DO NOT PASS
- _ TO REPORT OUT ONLY
- _ TO ABSTAIN;
- _ TO PLACE IN INACTIVE FILE

Should you have any questions, please do not hesitate to contact our office.

Respectfully, Charissa L. Manibusan Committee Director

Office of Speaker Therese M. Terlaje

Committee on Health, Land, Justice and Culture I Mina'trentai Sais na Liheslaturan Guåhan

36th Guam Legislature

Guam Congress Building, 163 Chalan Santo Papa, Hagåtña, Guam 96910

T: (671) 472-3586 F: (671) 989-3590 Email: senatorterlajeguam@gmail.com

website: www.senatorterlaje.com

Electronic Privacy Notice: This e-mail and any attachment(s), contains information that is, or may be, covered by electronic communications privacy laws and legal privileges, and is also confidential and proprietary in nature. If you are not the intended recipient, please be advised that you are legally prohibited from retaining, using, copying, distributing, or otherwise disclosing the information in this e-mail or any attachment in any manner. Instead, please reply to the sender that you have received this communication in error, and then immediately delete it. Thank you in advance for your cooperation.



COMMITTEE REPORT_BILL 169-36 (LS) AS AMENDED_Redacted.pdf

Senator Pedo Terlaje <senatorpedo@senatorjpterlaje.com>

Tue, Mar 15, 2022 at 9:40 AM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

Cc: Sabina Perez <sabina@senatorperez.org>, Senator Sabina Perez <office@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortcnelson@gmail.com>, Senator Telena Cruz Nelson <senatortcnelson@guamlegislature.org>, Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>, "Honorable Joanne M. Brown" <office@senatorjoannebrown.com>, Chris Duenas <senatorchrisduenas@gmail.com>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Office of Senator Shelton Guam Legislature <officeofsenatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>

To do pass.

[Quoted text hidden]

--

The Office of Senator Jose "Pedo" Terlaje

Committee on Public Safety, Emergency Response, Military and Veterans Affairs, Mayors' Council, and Public Transit

36th Guam Legislature I Mina'trentai Sais na Liheslaturan Guåhan

777 Route 4, MVP Center - Units 101/102, Sinajana, GU 96910

Tel: (671) 989-5301/3218

Email: senatorpedo@senatorjpterlaje.com

Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>

Tue, Mar 15, 2022 at 9:42 AM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

Cc: Sabina Perez <sabina@senatorperez.org>, Senator Sabina Perez <office@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortcnelson@gmail.com>, Senator Telena Cruz Nelson <senatortcnelson@guamlegislature.org>, "Honorable Joanne M. Brown" <office@senatorjoannebrown.com>, Chris Duenas <senatorchrisduenas@gmail.com>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Office of Senator Shelton Guam Legislature <officeofsenatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>, Senator Jose Pedo Terlaje <senatorpedo@senatorjpterlaje.com>

To do pass.

١



Sinseru yan Minagåhet,

Office of the Vice Speaker • Tina Rose Muña Barnes

Committee on Rules

Committee on Public Accountability, Human Resource, Guam Buildup, Hagåtña Revitalization, Regional Affairs, Public Library, Telecommunications, and Technology

36th Guam Legislature

I Mina'trentai Sais na Liheslaturan Guåhan Guam Congress Building | 163 Chalan Santo Papa | Hagåtña, GU 96910 senatormunabarnes@guamlegislature.org

This e-mail message is intended only for the use of the individual or entity named above and may contain confidential and privileged information. If you are not the intended recipient, any disclosure, copying, distribution or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please immediately notify us by replying to senatormunabarnes@guamlegislature.org and delete the message immediately. Thank you very much.

Gumai pribilehu yan konfedensia este siha na mensåhi. Solo espesiåtmente para hågu ma entensiona pat ma aturisa para unrisibi. Sen prubidu kumu ti un ma aturisa para manribisa, na'setbe, pat mandespåtcha. Yanggen lachi rinisibu-mu nu este na mensåhi, put fabot ago' guatu gi I numa'huyong gi as senatormunabarnes@guamlegislature.org yan despues destrosa todu siha I kopian mensåhi. Si Yu'os ma'åse'.

On Mon, Mar 14, 2022 at 6:39 PM Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> wrote:

Chris Duenas <senatorchrisduenas@gmail.com>

Tue, Mar 15, 2022 at 9:44 AM

To: Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>

Cc: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, Sabina Perez <sabina@senatorperez.org>, Senator Sabina Perez <office@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortcnelson@gmail.com>, Senator Telena Cruz Nelson <senatortcnelson@guamlegislature.org>, "Honorable Joanne M. Brown" <office@senatorjoannebrown.com>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Office of Senator Shelton Guam Legislature <officeofsenatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>, Senator Jose Pedo Terlaje <senatorpedo@senatorjpterlaje.com>

Hafa Adai,

To Report Out Only.

Si Yu'os Ma'åse'.



Office of Senator Christopher M. Dueñas

36th Guam Legislature I Mina'trentai Sais Na Liheslaturan Guåhan (671) 989-9554 - 116 Chalan Santo Papa, Hagatna senatorchrisduenas@gmail.com

for a senator duenas

This e-mail message is intended only for the use of the individual or entity named above and may contain confidential and privileged information. If you are not the intended recipient, any disclosure, copying, distribution or use of the information contained in this transmission is strictly PROHIBITED. If you have

received this transmission in error, please immediately notify us by replying to senatorchrisdue nas@gmail.com and delete the message immediately. Thank you very much.

[Quoted text hidden]

Sabina Perez <sabina@senatorperez.org>

Tue, Mar 15, 2022 at 9:45 AM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

To report out only.

On Mon, Mar 14, 2022 at 6:39 PM Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> wrote:

[Quoted text hidden]

--



Senator Sabina Perez

Office of Senator Sabina Perez
36th Guam Legislature • *I Mina'Trentai Sais na Liheslaturan Guåhan*Committee on Environment, Revenue and Taxation, Labor, Procurement, and Statistics, Research, and Planning

Tel: (671) 989-2968

Email: sabina@senatorperez.org Website: senatorperez.org

Office of Senator Joanne M. Brown <office@senatorjoannebrown.com>

Tue, Mar 15, 2022 at 11:14 AM

To: Chris Duenas <senatorchrisduenas@gmail.com>

Cc: Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>, "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, Sabina Perez <sabina@senatorperez.org>, Senator Sabina Perez <office@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortenelson@gmail.com>, Senator Telena Cruz Nelson <senatortenelson@guamlegislature.org>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Office of Senator Shelton Guam Legislature <officeofsenatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>, Senator Jose Pedo Terlaje <senatorpedo@senatoripterlaje.com>

Hafa Adai, To Do Pass.

Very Respectfully,

Tracey Aguerro

Office Manager

Office of Senator Joanne M. Brown | *I Mina' Trentai Sais Na Liheslaturan* Guåhan (*36th Guam Legislature*) 120 Father Dueñas Avenue

Capitol Plaza Building, Suite 103

Hagåtña, Guam 96932 Telephone: (671) 647-1409

Hafa Adai! Except with respect to public records exempt from disclosure by express provisions of the law, please be advised that, as an official office of the Legislative Branch of the Government of Guam, this electronic communication, is subject to the laws, rules and regulations governing the Sunshine Reform Act, and any other processes and procedures carried out in the spirit of an open and transparent government.

[Quoted text hidden]

Office of Senator Joanne M. Brown <office@senatorjoannebrown.com> To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

Tue, Mar 15, 2022 at 11:53 AM

Hafa Adai, To Do Pass.

Very Respectfully,

Tracey Aguerro

Office Manager
Office of Senator Joanne M. Brown | *I Mina' Trentai Sais Na Liheslaturan* Guåhan (*36th Guam Legislature*)
120 Father Dueñas Avenue
Capitol Plaza Building, Suite 103

Hagåtña, Guam 96932 Telephone: (671) 647-1409

Hafa Adai! Except with respect to public records exempt from disclosure by express provisions of the law, please be advised that, as an official office of the Legislative Branch of the Government of Guam, this electronic communication, is subject to the laws, rules and regulations governing the Sunshine Reform Act, and any other processes and procedures carried out in the spirit of an open and transparent government.

On Mon, Mar 14, 2022 at 6:39 PM Speaker Therese M. Terlaje <senatorterlajeguam@gmail.com> wrote: [Quoted text hidden]

Senator Telo Taitague <senatortelot@gmail.com>

Tue, Mar 15, 2022 at 1:05 PM

To: "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>

Hafa adai,

To report out only.

Kindest regards,

Senator Taitague

Si Yu'os Ma'åse,

Create a Great Day!

Senator Telo T. Taitague 36th Guam Legislature Suite 309 DNA Building 238 Archbishop Flores St. Hagatna, Guam 96910 Tel: (671) 989-8356

Email: senatortelot@gmail.com

[Quoted text hidden]

Office of Senator Amanda L. Shelton <officeofsenatorshelton@guamlegislature.org> Wed, Mar 16, 2022 at 12:48 PM To: "Office of Senator Joanne M. Brown" <office@senatorjoannebrown.com> Cc: Chris Duenas <senatorchrisduenas@gmail.com>, Vice Speaker Tina Rose Muña Barnes <senatormunabarnes@guamlegislature.org>, "Speaker Therese M. Terlaje" <senatorterlajeguam@gmail.com>, Sabina Perez <sabina@senatorperez.org>, "Office of Senator Telena C. Nelson" <senatortcnelson@gmail.com>, Senator Telena Cruz Nelson <senatortcnelson@guamlegislature.org>, "Amanda S. Shelton" <senatorshelton@guamlegislature.org>, Senator Telo Taitague <senatortelot@gmail.com>, Senator Jose Pedo Terlaje <senatorpedo@senatorjpterlaje.com>

To do pass.

Si Yu'os Ma'ase'.



Office of the People • Senator Amanda L. Shelton Legislative Secretary & Chairwoman, Committee on Air Transportation, Parks, Tourism, Higher Education, and the Advancement of Women, Youth, and Senior Citizens

36th Guam Legislature

163 Chalan Santo Papa, Hagåtña, Guam 96910

T+1 (671) 969-2574 • (671) 989-2572

E officeofsenatorshelton@guamlegislature.org

[Quoted text hidden]